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2Abstract
Feline leukaemia virus is a significant pathogen of domestic cats which causes a
range of proliferative and non-proliferative haematopoietic disorders. This virus
has been extensively studied in the past, however advancements in molecular
techniques now allow long-standing controversial topics to be revisited and
reanalysed. Although FeLV-A is the only transmittable form of the virus, FeLV-B
and –C may arise in infected cats if the initial virus escapes immune clearance
and establishes a chronic infection. These studies aimed to investigate
previously-unanswered questions regarding FeLV pathogenesis, specifically
pertaining to the ability of FeLV-A to evolve into the novel subgroups B and C.
These results indicate that strains of FeLV-A possessing residues D83 and D91 in
their envelope glycoprotein display increased rates of viral replication, mediated
by an enhanced interaction with their cognate receptor, THTR1. Evidence is
provided that these viral proteins are also able to bind efficiently to the FeLV-C
receptor, FLVCR1, and that these mutations represent the first in a step-wise
accumulation of mutations which eventually result in a FeLV-C viral variant
emerging within the host. Subsequent studies aimed to elucidate the respective
roles of the acquired immune response (neutralising antibodies) and receptor
availability in driving this evolutionary process; however a definitive conclusion
regarding FeLV-C selection pressures was not reached due to limitations of the
model.
These studies also describe the first isolation of novel FeLV-B field isolates which
present without a FeLV-A co-infection. Characterisation of these strains revealed
they possessed recombinant genomes, composed of exogenous LTRs and mostly
endogenously-derived env genes. Further investigations into the potential
functionality of endogenous FeLV elements within the domestic cat genome
revealed numerous intact env genes, the proviruses of which may be restricted
from exogenous transmission by their inability to form homodimeric RNA
genomes with functional secondary structures. Although this suggestion requires
experimental validation, this represents a novel mechanism of endogenous
retroviral restriction.
3This thesis is dedicated to my parents, Ian and Joy,
for their unwavering support.
4Table of Contents
Abstract...................................................................................... 2
Table of Contents .......................................................................... 4
List of Tables................................................................................ 9
List of Figures .............................................................................. 10
List of Abbreviations ...................................................................... 12
Acknowledgements........................................................................ 14
1. Introduction and Literature Review ............................................... 16
1.1 Introduction to FeLV ......................................................... 17
1.1.1. Prevalence.................................................................. 17
1.1.2. Transmission................................................................ 18
1.1.3. Detection and diagnosis .................................................. 19
1.1.4. Treatment .................................................................. 20
1.1.5. FeLV Vaccines.............................................................. 21
1.2 Genetics and proteins of FeLV.............................................. 23
1.2.1. Non-coding RNA structures............................................... 24
1.2.2. Structural proteins ........................................................ 26
1.2.3. Enzymatic proteins ........................................................ 27
1.2.4. Envelope glycoprotein .................................................... 28
1.2.4.1. Surface Unit domain ................................................ 29
1.2.4.2. Transmembrane domain ........................................... 30
1.3 The retroviral replication cycle ............................................ 31
1.4 Immune responses to FeLV infection ...................................... 34
1.5 Outcomes of FeLV infection................................................. 37
1.6 Endogenous FeLV elements ................................................. 40
1.7 The FeLV subgroups and their host ranges................................ 42
1.8 FeLV-A.......................................................................... 44
1.8.1. FeLV-A receptor: feTHTR1 ............................................... 44
1.8.2. Pathogenesis of FeLV-A infection ....................................... 45
1.9 FeLV-B.......................................................................... 47
1.9.1. Evolution of FeLV-B envelope genes.................................... 47
1.9.2. FeLV-B receptor: fePit1 .................................................. 49
1.9.3. Pathogenesis of FeLV-B infection ....................................... 49
1.10 FeLV-C.......................................................................... 51
51.10.1. Evolution of FeLV-C envelope genes.................................... 52
1.10.2. FeLV-C receptor: feFLVCR1 .............................................. 54
1.10.3. Pathogenesis of FeLV-C infection ....................................... 56
1.11 FeLV-T.......................................................................... 57
1.11.1. FeLV-T envelope, FeLIX and Pit1 binding .............................. 58
1.11.2. Pathogenesis of FeLV-T infection ....................................... 59
1.12 Other feline retroviruses .................................................... 61
1.12.1. Feline immunodeficiency virus .......................................... 61
1.12.2. Feline foamy virus......................................................... 63
1.12.3. Feline sarcoma virus ...................................................... 65
1.12.4. Endogenous retroviruses: RD114 and FcEV............................. 67
1.13 Scope and aims of this thesis ............................................... 69
2. Materials and Methods............................................................... 72
2.1 Cell culture techniques ...................................................... 72
2.1.1. Maintenance of cell lines................................................. 72
2.1.2. Transient transfection of adherent cells............................... 73
2.1.3. X-Gal staining of lacZ-expressing cells ................................. 73
2.1.4. Stable transduction of cell lines......................................... 73
2.1.5. Interference assay......................................................... 74
2.1.6. Reverse interference assay .............................................. 74
2.1.7. QN10 focus-forming assays ............................................... 75
2.2 Protein-based assays ......................................................... 75
2.2.1. Reverse transcriptase detection assay ................................. 75
2.2.2. SDS-PAGE and immunoblots.............................................. 76
2.2.3. Immunofluorescence ...................................................... 77
2.2.4. Flow cytometry ............................................................ 77
2.3 Molecular cloning techniques ............................................... 78
2.3.1. Cellular nucleic acid extraction ......................................... 78
2.3.2. Viral RNA extraction ...................................................... 78
2.3.3. cDNA synthesis ............................................................. 79
2.3.4. Plasmid constructs ........................................................ 79
2.3.5. General cloning techniques .............................................. 80
2.3.5.1. Polymerase chain reaction......................................... 80
2.3.5.2. Purification of PCR products ...................................... 80
2.3.5.3. Restriction enzyme digestion and ligation....................... 81
62.3.5.4. Transformation ...................................................... 81
2.3.6. Preparation of plasmid DNA.............................................. 81
2.3.7. Genetic sequencing ....................................................... 82
2.3.8. Site-directed mutagenesis of plasmids ................................. 82
2.4 In silico and bioinformatics techniques ................................... 83
2.4.1. RNA structural models .................................................... 83
2.4.2. Multiple sequence alignments ........................................... 84
2.4.3. Transcription factor screens ............................................. 84
2.4.4. Graphs and statistics...................................................... 84
3. Specific FeLV-A strains may be predisposed towards conversion to FeLV-C 85
3.1 Introduction ................................................................... 85
3.2 Results.......................................................................... 91
3.2.1. D83N and N91D-bearing mutants of FeLV-A (Glasgow-1) are
replication-competent.................................................................... 91
3.2.2. The N91D mutation increases viral entry through THTR1 ........... 92
3.2.3. Enhanced binding of FeLV D83:D91 SU to viral receptors ........... 98
3.3 Discussion .....................................................................100
3.3.1. The D83:D91 motif enhances viral replication .......................101
3.3.2. FeLV-A RBDs display promiscuous receptor binding .................103
3.4 Conclusions ...................................................................103
4. Investigation of potential factors which may drive FeLV-A to -C evolution 105
4.1 Introduction ..................................................................105
4.2 Results.........................................................................107
4.2.1. D83N and N91D Env mutations do not alter neutralisation
susceptibility ..............................................................................107
4.2.2. Long-term replication of FeLV in vitro under immune pressure does
not produce FeLV-C variants............................................................108
4.2.3. Evolution of non-functional FeLV Env proteins during long-term viral
replication ..............................................................................112
4.2.4. Specific FeLV Env mutations within the C-domain of SU increase
cellular entry via THTR1.................................................................113
4.2.5. FeLV-A culture within MDTF-huFLVCR1/2 cells does not produce
FeLV-C variants ...........................................................................115
4.2.6. Expansion of FeLV-A subpopulations upon MDTF-huFLVCR1/2 cells ..
..............................................................................116
74.3 Discussion .....................................................................119
4.3.1. The role of VNAs in viral evolution ....................................119
4.3.2. Analysis of mutations arising during long-term viral replication ..121
4.3.3. Cell-to-cell transmission in FeLV replication .........................122
4.3.4. Additional factors influencing viral evolution ........................123
4.3.5. In vivo models of FeLV-A to -C evolution .............................124
4.3.6. The role of receptor availability in retroviral evolution............125
4.4 Conclusions ...................................................................126
5. Are endogenous feline leukaemia viruses really endogenous? ...............128
5.1 Introduction ..................................................................128
5.2 Results.........................................................................130
5.2.1. The field isolates FeLV-2518 and -4314 are phenotypically subgroup
B ..............................................................................130
5.2.2. FeLV-2518-infected cells downregulate both THTR1 and Pit1 .....132
5.2.3. FeLV-4314 and -2518 are not encoded by single enFeLV transcripts .
..............................................................................135
5.2.4. A defective exogenous FeLV env gene is present within FeLV-2518 ..
..............................................................................136
5.2.5. FeLV-4314 and -2518 contain exogenous LTRs .......................137
5.2.6. Non-FeLV retroelements are not present in either isolate .........138
5.2.7. FeLV-4314 and -2518 possess recombinant genomes................139
5.2.8. Alteration of the LTRs may alter the pathogenic potential of enFeLV
..............................................................................143
5.2.9. The RNA structure of the RBD displays increased propensity for
recombination ............................................................................147
5.3 Discussion .....................................................................149
5.3.1. FeLV-4314 and -2518 represent distinct recombination events ...150
5.3.2. RNA recombination in gammaretroviruses ............................151
5.3.3. Exogenous LTRs may alter the properties of enFeLV viral strains.153
5.3.4. The potential roles of the defective FeLV-2518(A) genome .......154
5.4 Conclusions ...................................................................155
6. The functionality of endogenous FeLV elements...............................157
6.1 Introduction ..................................................................157
6.2 Results.........................................................................159
86.2.1. Multiple intact enFeLV env genes are present in the feline genome .
..............................................................................159
6.2.2. The majority of intact enFeLV env genes are non-functional .....162
6.2.3. EnFeLV env transcripts are not detectable in feline tissues .......166
6.2.4. In silico modelling of MLV RNA structural elements.................168
6.2.5. RNA structural elements are intact in FeLV-A RNA homodimers ..171
6.2.6. EnFeLV RNA homodimers may be non-functional ....................173
6.2.7. Heterodimeric RNA genomes have regained functionality .........175
6.3 Discussion .....................................................................177
6.3.1. The majority of intact enFeLV Env proteins are non-functional ..177
6.3.2. Non-functional packaging signals may prevent horizontal
transmission of enFeLV ..................................................................180
6.4 Conclusions ...................................................................182
7. Concluding Remarks ................................................................184
8. Appendices...........................................................................191
8.1 Buffers and solutions ........................................................191
8.2 List of Primers................................................................192
8.3 Nucleotide mutations arising in long-term FeLV cultures .............193
8.4 Genome sequences of FeLV-2518 and -4314.............................198
8.5 Predicted secondary structures within FeLV env RNA..................211
8.6 Predicted secondary structures within FeLV leader sequences.......212
8.7 Publications arising from this work .......................................215
9. References ...........................................................................216
9List of Tables
Table 3.1: Primary FeLV isolates........................................................ 87
Table 3.2: Receptors expressed in MDTF and 104C1 cells. .......................... 95
Table 4.1: Mutations arising within the PRR and Cdom during long-term viral
replication. ................................................................................112
Table 5.1: The U3 regions of endogenous and exogenous LTRs contain
differential TF binding sites. ...........................................................144
10
List of Figures
Figure 1.1: The genes and proteins of FeLV. .......................................... 24
Figure 1.2: The FeLV RNA genome...................................................... 24
Figure 1.3: The FeLV virion. ............................................................. 27
Figure 1.4: The FeLV Envelope protein. ............................................... 29
Figure 3.1: RBDs from the envs of anaemogenic strains of FeLV. .................. 89
Figure 3.2: Mutants of the FeLV-A(Glasgow-1) molecular clone produce
replication-competent virus. ............................................................ 91
Figure 3.3: The DD mutant of FeLV-A(Glasgow-1) displays a higher viral titre. . 93
Figure 3.4: The DD Env supports more efficient infection of HEK293T cells. .... 94
Figure 3.5: Stably transduced cells express a range of retroviral receptors. .... 96
Figure 3.6: The DD Env confers enhanced utilisation of THTR1 homologues. .... 97
Figure 3.7: Expression of soluble Fc-tagged FeLV SUs. .............................. 98
Figure 3.8: The DD mutations confer enhanced binding to multiple receptors. 100
Figure 4.1: Neutralisation of FeLV by either pooled serum from FeLV-recovered
cats or anti-gp70 monoclonal antibody. ..............................................108
Figure 4.2: Replication of FeLV in the presence of sub-neutralising
concentrations of anti-FeLV antibodies. ..............................................109
Figure 4.3: Acquisition of non-synonymous mutations in the Envs of FeLV-A
mutants following long-term culture. .................................................111
Figure 4.4: Mutant FeLV Env proteins display inconsistent levels of incorporation
into MLV(FeLV) pseudotypes. ...........................................................113
Figure 4.5: Specific Env mutants which arise through genetic drift increase
cellular entry via THTR1 homologues. ................................................114
Figure 4.6: A 1:103 dilution (vol/vol) of FeLV-C within a FeLV-A population is
detectable by RT detection assay after 50 days in culture upon MDTF-huFLVCR1
cells. .......................................................................................118
Figure 5.1: FeLV-2518 and -4314 can infect both FEA and HEK293T cells. ......131
Figure 5.2: FeLV-2518 and -4314 Env proteins mediate cellular entry through the
Pit1 receptor. .............................................................................132
Figure 5.3: Receptor downregulation by novel FeLV-B isolates. ..................133
Figure 5.4: FEA cells infected with FeLV-2518 are resistant to both FeLV-A and –
B; FeLV-4314 infected cells are resistant solely to FeLV-B superinfection. .....134
11
Figure 5.5: EnFeLV transcripts are not present in FeLV-2518 and -4314. ........135
Figure 5.6: Exogenous Env PCR reveals a truncated FeLV-A env transcript within
FeLV-2518 virions, termed FeLV-2518(A). ............................................136
Figure 5.7: Exogenous LTRs are present in FeLV-2518 and -4314. ................137
Figure 5.8: The endogenous virus RD114 is not present in FeLV-2518 or -4314. 138
Figure 5.9: FcEV transcripts are not present in FeLV-2518 and -4314............139
Figure 5.10: Both FeLV-4314 and -2518 contain recombinant env genes. .......140
Figure 5.11: The genomes of FeLV-2518 and -4314 .................................142
Figure 5.12: The U3 regions of endogenous and exogenous FeLV proviruses
display differential TF binding motifs .................................................146
Figure 5.13: The predicted RNA secondary structures in FeLV env ...............148
Figure 6.1: The feline genome contains multiple intact enFeLV env genes .....161
Figure 6.2: The majority of putatively-functional enFeLV Env proteins are not
incorporated into viral pseudotype particles.........................................162
Figure 6.3: enFeLV Env-5 utilises hPit1 for cellular entry..........................163
Figure 6.4: Non-functional enFeLV Env-2, -3, -6 and -7 are translated ..........165
Figure 6.5: enFeLV env transcripts are not expressed in domestic cat tissues..167
Figure 6.6: The Alifold program accurately reproduces the known structural
elements within the MLV leader sequence ...........................................170
Figure 6.7: The leader sequence of FeLV-A RNA homodimers is predicted to form
the required structural elements for viral replication..............................172
Figure 6.8: The enFeLV RNA leader sequence is not predicted to form the
structures required for viral packaging ...............................................174
Figure 6.9: Heterodimeric RNA genomes are predicted to contain the structural
elements required for packaging.......................................................176
12
List of Abbreviations
AIDS Acquired Immunodeficiency Syndrome
BFU-E Burst Forming Units - Erythroid
bp base pairs
CA Capsid Protein
cDNA complementary deoxyribonucleic acid
CFU-E Colony Forming Units – Erythroid
CFU-GM Colony Forming Units – Granulocyte-Macrophage
CPE Cytopathic Effect
CTL Cytotoxic T-lymphocytes
DMEM Dulbecco’s Modified Eagle’s Medium
DNA Deoxyribonucleic Acid
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-Linked Immunosorbent Assay
enFeLV endogenous feline leukaemia virus
env Envelope-encoding gene
Env Envelope glycoprotein
ER Endoplasmic Reticulum
ERV Endogenous Retrovirus
FcEV Felis catus endogenous virus
FeFV Feline foamy virus
FeLV Feline leukaemia virus
FeLV-A Feline leukaemia virus, subgroup A
FeLV-B Feline leukaemia virus, subgroup B
FeLV-C Feline leukaemia virus, subgroup C
FeLV-FAIDS Feline leukaemia virus-Feline AIDS
FeLV-T Feline leukaemia virus, subgroup T
FeLIX Feline leukaemia virus Infectivity Accessory Protein
FeSV Feline Sarcoma Virus
FIV Feline Immunodeficiency Virus
FLVCR Feline Leukaemia Virus Subgroup C Receptor protein
FOCMA Feline Oncornavirus-Associated Cell Membrane Antigen
gag Group-specific antigen-encoding gene
13
Gag Group-specific antigen protein
HA Haemagluttinin
HIV Human Immunodeficiency Virus
IgG Immunoglobulin class G
IN Integrase
kB kilobases
kDa kilodaltons
LTR Long Terminal Repeat
MA Matrix Protein
MAb Monoclonal Antibody
mRNA Messenger Ribonucleic Acid
MLV Murine Leukaemia Virus
NC Nucleocapsid Protein
ORF Open Reading Frame
PBS Primer Binding Site
PBS Phosphate buffered saline
PCR Polymerase Chain Reaction
Pit Sodium-Phosphate Symporter
PRCA Pure Red Cell Aplasia
Pro Protease
pro-pol Protease-integrase-polymerase- encoding gene
PRR Proline Rich Region
RNA Ribonucleic Acid
RT Reverse Transcriptase
SU Surface Unit domain
THTR1 Thiamine Transporter
TM Transmembrane domain
USA United States of America
VNA Virus Neutralising Antibodies
14
Acknowledgements
I would firstly like to thank my supervisors, Prof. Brian Willett and Prof.
Margaret Hosie, for taking me on all those years ago and providing guidance,
advice and countless opportunities during my PhD. A lab as good as theirs is hard
to find and I have been extremely lucky to have had such great mentors over the
last four years. I also would like to thank my fellow scientists and friends from
the Retrovirus Research Group, especially Isabelle, Chi, Linda and Nicola for
providing so much laughter and friendship.
There are many additional people outside our lab group who have helped me and
deserve recognition: Prof. Massimo Palmarini, for his advice over the past four
years; Dr Claudio Murgia, for help with RNA extractions and immuno-
fluorescence; Matt Golder, for performing the original 300-odd interference
assays which led to this research (and his immeasurable help and guidance);
Michael McDonald and the Companion Animal Diagnostics Unit for catering to my
ridiculous requests when it came to reagents; Dorothy Montgomery and the
Leukaemia Research Laboratory for the use of their flow cytometry equipment
and helping with the data interpretation. A special thank you is definitely due to
Dr Andrew Shaw, Dr Filipe Nunes and Dr Mariana Varela for their incredible
patience whilst reading innumerable drafts of papers and chapters.
I would like to thank the University of Glasgow for funding my PhD program and
allowing this research to take place. I would also like to acknowledge Prof.
Andrew Lever and Dr Julia Kenyon at the University of Cambridge, for their
invaluable help with the RNA in silico modelling work, and for giving me desk
space and a lot of their time when I was in their lab.
Finally, a PhD is a long and arduous journey, made a lot easier by the support of
your friends and family. A huge thank you is due to my friends (both in Glasgow
and back home in Brisbane) especially Christine. Finally but most importantly my
parents, who never doubted that I could do it.
15
Authors Declaration
I declare that, except where explicit reference is made to the contribution of
others, this dissertation is the result of my own work and has not been submitted
for any other degree at the University of Glasgow or any other institution.
Signature:
Printed name: Hazel Stewart
16
1. Introduction and Literature Review
Retroviruses are enveloped, single-stranded RNA viruses which, upon infection of
the host cell, use a virally-encoded RNA-dependent DNA polymerase to produce
a double-stranded DNA copy of their genome. This is integrated into the host
DNA, forming the provirus. The provirus is then transcribed and translated as a
standard host gene, producing both viral proteins and genomic RNA for viral
replication.
Early evidence of retroviral associations with cancer led to their description as
RNA tumour viruses or oncoviruses, however the majority of retroviruses are not
oncogenic and this nomenclature is no longer commonly used. Retroviruses were
also classified according to their morphology, which led to the A-, B-, C- and D-
type particle descriptions found in early studies (Bernhard, 1960). The members
of the Retroviridae family are now classified into two subfamilies, the
orthoretrovirinae and the spumaretrovirinae. The latter subfamily contains a
single genus; the spumaretroviruses (see Section 1.11.2). However there are six
genera within the orthoretrovirinae, including the alpha-, beta-, gamma-, delta-
and epsilon-retroviruses and lentiviruses. Most of the orthoretroviruses are
termed “simple” retroviruses as their genomes contain only essential genes
required for viral replication. By contrast, lentiviruses and spumaretroviruses are
“complex” retroviruses which contain accessory genes that may allow avoidance
of the host innate immune system.
Gammaretroviruses are able to infect an unusually broad range of vertebrates
(Gifford & Tristem, 2003) and are associated with leukaemia and lymphoma in
cats, pigs, mice, and marsupials. These pathogenic viruses, especially the
prototype murine leukaemia virus (MLV), have been widely utilised as models of
human retroviral infection and have contributed to the understanding of
numerous diseases, including the events leading to cancer progression. The
gammaretrovirus feline leukaemia virus (FeLV) was the first feline retrovirus to
be described (W. F. Jarrett, Crawford, Martin, & Davie, 1964) and was quickly
recognised to be an important pathogen of both domestic and wild cats.
Discovered in 1964, it was initially described as C-type viral particles, isolated
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from the plasma of cats with both spontaneous and experimentally-transmitted
leukaemia (W. F. Jarrett, et al., 1964). It is now known to consist of three major
subgroups, FeLV-A, -B, and -C and a fourth, rare variant FeLV–T which differ in
their in vitro behaviour and pathogenic consequences for the host. Almost fifty
years after its discovery, FeLV research has produced both vaccines and
treatment for infected cats; it has also been a useful model for human disease
research. However there are still many questions regarding FeLV infection,
replication and pathogenesis that remain unanswered. This introductory chapter
will provide an overview of the current understanding of FeLV infection and
disease manifestation, and highlight the areas in which further research is
required.
1.1 Introduction to FeLV
1.1.1. Prevalence
FeLV displays a worldwide distribution, although its prevalence varies
significantly across geographical regions. On a local scale the rate of infection
depends highly upon the size of the feral cat population and the degree of
interaction between domestic and feral cats; for example recent studies found
9% of cats in central Italy are infected (Bandecchi, Dell'Omodarme, Magi,
Palamidessi, & Prati, 2006) compared to 4% in Germany where the cats studied
were mainly indoor pets in urban areas (Gleich, Krieger, & Hartmann, 2009).
Early epidemiological studies found 5% of healthy cats and 18% of sick cats
within the UK were FeLV-positive (Hosie, Robertson, & Jarrett, 1989), which
were similar statistics to those determined in the USA (J. K. Levy, Scott,
Lachtara, & Crawford, 2006; Shelton, Waltier, Connor, & Grant, 1989). In
Australia 25% of clinically ill domestic cats were found to be FeLV-positive, a
proportion which has not been observed elsewhere (Sabine, Michelsen, Thomas,
& Zheng, 1988). In mainland Europe infection rates ranged between 1 to 10%
(Moraillon, 1990; Sukura, Salminen, & Lindberg, 1992; Ueland & Lutz, 1992).
Recent studies from both Canada (Little, Sears, Lachtara, & Bienzle, 2009) and
Central America (Guatemala and Costa Rica) (Blanco, Prendas, Cortes, Jimenez,
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& Dolz, 2009; Coelho et al., 2008; Lickey, Kennedy, Patton, & Ramsay, 2005)
indicate this rate of infection has remained constant in some areas. However its
European prevalence has drastically decreased in recent years as a result of
wide-spread vaccination and pet-owner awareness schemes (J. Levy et al.,
2008), decreasing to as low as 1% of healthy cats in some regions (Juvet,
Brennan, & Mooney, 2011). The positive effects these programs have are
apparent when comparing these infection rates to countries where vaccines are
not commercially available; for example Iran where 15% of cats remain positive
for FeLV (Akhtardanesh, Ziaali, Sharifi, & Rezaei, 2010).
FeLV is also a major threat to both the highly endangered Iberian lynx (Lynx
pardinus) and Florida panthers (Puma concolor coryi), as it causes severe clinical
symptoms and high mortality in these felids (M. A. Brown et al., 2008; Meli et
al., 2010; Meli et al., 2009). Infection has also been found in ocelot (Leopardus
pardalis), puma (Puma concolor) and oncilla (Leopardus tigrinus) in Brazil
although clinical symptoms were not observed in these species (Guimaraes et
al., 2009). Within the UK, approximately 10% of Scottish wildcats (a threatened
species) are infected with FeLV (Daniels, Golder, Jarrett, & MacDonald, 1999).
Therefore FeLV remains a significant threat to both domestic and wild cats
despite the decrease in prevalence since its initial discovery.
1.1.2. Transmission
Initial FeLV infection occurs in the oropharynx, with viral replication occurring
mainly in the local lymph nodes and circulating lymphocytes and monocytes
(Hofmann-Lehmann et al., 2008; Rojko, Hoover, Mathes, Olsen, & Schaller,
1979). This initial systemic lymphatic viraemia may be successfully cleared in a
minority of cases; more commonly a successful infection of the bone marrow
follows (Lutz, Pedersen, & Theilen, 1983). This is the major site of viral
replication. A secondary viraemia is then observed during which the virus
spreads via the peripheral vasculature system to peripheral organs and epithelial
tissues. This cycle generally occurs over 3 weeks and viral RNA is detectable in
plasma approximately one week after FeLV exposure. Infectious virus is shed in
the saliva approximately four weeks after the initial infection (O. Jarrett, 1999).
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The main FeLV transmission route is oronasal, therefore both fighting and
mutual grooming are high risk activities between infected and naïve cats.
Infectious virus is shed through saliva, nasal secretions, milk, faeces and urine
(Gomes-Keller et al., 2009; W. D. Hardy, Jr. et al., 1976; Pacitti, Jarrett, & Hay,
1986), although saliva represents the highest potential for virus transmission. As
FeLV does not survive outside the host for extended periods of time (Francis,
Essex, & Gayzagian, 1979) the risk factor presented by faeces and urine was
presumed to be negligible, however recent evidence indicates transmission may
occur through these routes (Gomes-Keller, et al., 2009). There is also
preliminary evidence that fleas may be able to transmit infectious virus between
hosts through their saliva and faeces (Vobis, D'Haese, Mehlhorn, & Mencke,
2005). FeLV is transmissible trans-placentally (Rojko, Hoover, Quackenbush, &
Olsen, 1982), although usually viraemic queens are unable to sustain pregnancy
(Lutz et al., 2009). Transmission has also been observed through blood
transfusions between latently infected and naïve cats; although reactivation of
latently infected cells is rare (Chen et al., 1998).
1.1.3. Detection and diagnosis
FeLV infection is often suspected following assessment of clinical signs and
haematology. The initial diagnosis is then confirmed by screening for either viral
proteins or genetic material. As vaccinated and infected cats are often
serologically indistinguishable, antibody detection is not indicative of a current
infection. Historically, virus culture (the isolation of infectious virus from clinical
samples) was the gold standard for the diagnosis of FeLV (O. Jarrett, 1980),
however due to the time and level of scientific equipment required, this was not
a feasible option for most diagnostic clinics.
Enzyme Linked Immunosorbent Assays (ELISAs) for the detection of the core
capsid protein (CA, or p27) in whole blood is the most common method of
diagnosis in veterinary clinics worldwide (Lutz, Pedersen, Durbin, & Theilen,
1983) and displays very high sensitivity and specificity against all other methods
tested to date (Hartmann, Werner, Egberink, & Jarrett, 2001; Hofmann-Lehmann
et al., 2001). Although tears and saliva may also be used in some ELISAs, whole
blood is the most accurate predictor of clinical status (Hawkins, 1991; Hawkins,
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Johnson, Pedersen, & Winston, 1986). Currently the leading ELISA-based
diagnostic in veterinary clinics is the SNAP FIV/FeLV Combo kit (Idexx
Laboratories), which detects simultaneously FeLV antigen and feline
immunodeficiency virus (FIV) antibodies in serum samples.
Immunochromatography diagnosis kits have also been developed and display
similar sensitivity and specificity parameters to ELISAs, however these are less
economical and more laborious for commercial clinics (Hartmann et al., 2007;
Robinson et al., 1998). Immunofluorescence-based tests, although available, are
not commonly conducted due to their irreproducibility and ambiguity in the
interpretation of results (Floyd, Suter, & Lutz, 1983). A Polymerase Chain
Reaction (PCR) to detect proviral DNA in either whole blood or saliva has also
been developed (Gomes-Keller, Gonczi, et al., 2006; Gomes-Keller, Tandon, et
al., 2006). This method is more sensitive than ELISAs and allows detection at an
earlier stage of infection, as the initial presence of infectious virus in plasma
coincides with the detection of proviral DNA in PCR assays (Hofmann-Lehmann et
al., 2006). However detection of provirus will not distinguish between active
infection and recovered cats and thus confirmatory testing is usually required.
Real-time PCR may be conducted to detect and/or quantify the presence of low
levels of viral RNA or proviral DNA within a sample.
1.1.4. Treatment
Due to the range of clinical symptoms associated with FeLV infection, there are
multiple options for treatment of the infected cat. However these are merely
therapeutic; there is no known method of clearing infection and most
treatments will only relieve symptoms for a short duration.
Although initial studies were not encouraging (Hartmann et al., 1998),
immunomodulators are now used to relieve the immunosuppression caused by
FeLV infection and allow the immune system to attempt to clear the infection
(McCaw et al., 2001). The antiviral recombinant protein feline interferon-ω 
(Virbac Animal Health) is used widely, as this is naturally produced from
leukocytes during FeLV infection. This treatment correlates to a moderate
increase in survival rates (de Mari, Maynard, Sanquer, Lebreux, & Eun, 2004),
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although it does not decrease viraemia. Human interferon-α (Alfa Wasserman, 
Italy) has been used to treat cats infected simultaneously with both FeLV and
FIV; however this is administered infrequently (Pedretti et al., 2006).
Alternatively anti-retroviral drugs may be used; however the only compound
commercially available for treatment of cats is the nucleoside analogue
zidovudine. This reduces plasma viral load and improves clinical status, however
significant side effects may develop at higher dosage concentrations (Hartmann
et al., 1992). Retroviral integrase inhibitors have also displayed promising results
in in vitro assays but are not commercially available as treatment (Cattori et al.,
2011). Treatment of FeLV-C-infected anaemic cats with reverse transcriptase-
inhibitors allows the recurrence of erythropoiesis (Abkowitz, 1991), but must be
continued through the cats life to prevent viral reactivation. Similarly,
leukopaenia may be temporarily relieved by administration of granulocyte
colony-stimulating factor to stimulate haematopoiesis (Fulton, Gasper, Ogilvie,
Boone, & Dornsife, 1991). FeLV-induced lymphomas may be treated with
chemotherapy, although this will not prevent future viraemia (Ettinger, 2003).
It is obvious, therefore, that despite the decrease in FeLV prevalence suitable
treatments remain unavailable for those cats presenting with active infections.
This highlights the necessity of further research into the pathogenic mechanisms
of FeLV infection and the subsequent identification of potential drug targets.
1.1.5. FeLV Vaccines
FeLV was the first retrovirus for which a vaccine was successfully developed,
which at the time was viewed as a promising indication that it was possible to
induce protection against other retroviruses including HIV. Early studies tried
various antigenic preparations, however whole killed virus and envelope-based
subunit vaccines were found to be ineffective (Hunsmann, Pedersen, Theilen, &
Bayer, 1983; R. G. Olsen, Hoover, Schaller, Mathes, & Wolff, 1977; Salerno,
Lehman, Larson, & Hilleman, 1978; Yohn et al., 1976). There were also reports
of enhanced infection occurring during challenge of cats vaccinated with the
early whole inactivated virus preparations (N. C. Pedersen, Johnson, Birch, &
Theilen, 1986).The first commercially available FeLV vaccine was introduced in
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the USA in 1984, and was prepared from purified FeLV antigens (Lewis, Mathes,
& Olsen, 1981). However this vaccine has now been withdrawn from the market
due to poor efficacy (Hoover, Mullins, Chu, & Wasmoen, 1995; Legendre,
Mitchener, & Potgieter, 1990; Lutz, et al., 2009; N. C. Pedersen, et al., 1986).
There were also subsequent investigations into the utilisation of a canarypox-
based virus vector, which expresses retroviral proteins in the host cell upon
infection (Tartaglia, Jarrett, Neil, Desmettre, & Paoletti, 1993). This vaccine is
currently licenced in Europe (Purevax, Merial) but not USA. However this method
does not induce virus-neutralising antibodies (VNA) and the acquired immunity is
mediated through the priming and stimulation of B and T lymphocytes. This is in
direct conflict to the commonly-held view that the vaccination event must
induce VNA to ensure protective immunity (Sparkes, 2003). Currently there are
conflicting opinions as to whether VNAs and/or CTL responses are required for a
protective response against FeLV.
Numerous vaccines are currently available (Sparkes, 2003). The most commonly
used formulation is FeL-O-Vax (Fort Dodge Animal Health), a multivalent vaccine
with a preparation containing antigens from feline herpes virus, calicivirus,
parvovirus and chlamydia. A monovalent vaccine consisting of whole inactivated
FeLV is also available from Fort Dodge Animal Health; this induces high titres of
VNAs associated with high levels of protection (Hoover, et al., 1995). Other
currently available vaccines include Fevaxyn FeLV, a whole inactivated vaccine
available from Schering-Plough Animal Health, and Leukocell, a preparation of
subunit proteins from Pfizer Animal Health. Current recommendations for kittens
are an initial vaccination at 8 weeks of age followed by a booster inoculation 3 –
4 weeks later (J. Levy, et al., 2008). All vaccines are recommended to be re-
administered annually, as the duration of immunity has not been precisely
defined (Harbour et al., 2002; Hoover, Mullins, Chu, & Wasmoen, 1996).
Multiple studies of vaccine efficacy have been conducted and there is no
correlation between any one vaccine and the induction of protective, sterilising
immunity (Sparkes, 2003). Therefore, although vaccination provides a degree of
protection, initial infection may still occur. Indeed, cats displaying low level RNA
viraemia and persistent detection of proviral DNA, without any development of
clinical signs, are often regarded as protected (Lutz, et al., 2009). Recent
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investigations into the viral DNA and RNA loads in vaccinated cats has revealed
that some may possess circulating viral RNA at levels detectable by qPCR,
despite not being antigenaemic (Torres, Mathiason, & Hoover, 2005; Torres,
O'Halloran, Larson, Schultz, & Hoover, 2010). It is possible that these nucleic
acids correlate to non-infectious virions. It was also found that those cats which
successfully controlled infection upon challenge did not always contain high VNA
titres, in direct contrast to the commonly-held assumption that these were
essential for FeLV protection (Torres, et al., 2010). This had been suggested
previously (Haffer, Koertje, Derr, & Beckenhauer, 1990; Hofmann-Lehmann, et
al., 2006).
In recent years attempts at developing more efficient or safer FeLV vaccines
have been rare, however there has been promising research towards utilisation
of the TM of Env as an immunogen (Langhammer, Fiebig, Kurth, & Denner, 2011;
Langhammer, Hubner, Jarrett, Kurth, & Denner, 2011). Despite the initial
promise FeLV vaccines offered for retroviral immunology, the induction of
sterilising immunity has still not been achieved and continues to be regarded as
the ultimate aim of a retroviral vaccine.
1.2 Genetics and proteins of FeLV
The members of the gammaretroviridae genus have a highly conserved genomic
structure, containing three open reading frames (ORFs); gag (group-specific
antigen), pro-pol (protease-polymerase) and env (envelope glycoprotein). The
ORFs encode numerous structural and enzymatic proteins (Figure 1.1). Within
the provirus, the ORFs are bracketed by long terminal repeats (LTRs). All
proteins are translated from the genomic mRNA; however a subgenomic
transcript is also produced via splicing of whole transcripts. The majority of Env
proteins are produced from this RNA.
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Figure 1.1: The genes and proteins of FeLV.
1.2.1. Non-coding RNA structures
The LTRs of retroviral genomes are non-coding regions at the termini of the
provirus. Each proviral LTR consists of three regions, being U3 (unique 3’
region), R (repeat region) and U5 (unique 5’ region) (5’ to 3’, respectively).
Comparatively, viral genomic RNA contains the R and U5 regions at the 5’
terminus, and the U3 and R regions at the 3’ terminus (Figure 1.2). Duplication
of the U3 and U5 regions occurs during reverse transcription of the viral genome
(see Section 1.3). Although the R and U5 regions are highly conserved, the U3
region differs significantly between endogenous FeLV elements (see Section 1.5)
and exogenous FeLV genomes (Berry, Ghosh, Kumar, Spodick, & Roy-Burman,
1988; Casey et al., 1981; Okabe, DuBuy, Gilden, & Gardner, 1978). For this
reason LTR analysis is often utilised to determine the proviral origin of FeLV
strains (Tandon, Cattori, Willi, Lutz, & Hofmann-Lehmann, 2008).
Figure 1.2: The FeLV RNA genome.
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The 3’ LTR often contributes significantly to the virulence and pathogenic
potential of retroviruses, including FeLV. As promoter and enhancer-like
elements including the CCAAT (Grosschedl & Birnstiel, 1980) and Goldberg-
Hogness boxes (Corden et al., 1980; Proudfoot, 1979) are located within the U3
region, the binding of transcription factors to these elements may activate
proto-oncogenes downstream of the site of insertion (Fan, 1997; L. S. Levy,
Lobelle-Rich, & Overbaugh, 1993; Uren, Kool, Berns, & van Lohuizen, 2005). The
availability of these transcription factors will vary between cell types; therefore
the 3’ LTR affects the pathogenic potential of the virus across various tissue
types (Short, Okenquist, & Lenz, 1987). This insertional activation may also have
long range effects if the U3 enhancer elements increase transcription from host
promoters further downstream from the site of integration.
In addition to the activation of oncogenes, gammaretroviruses may interrupt
host tumour-suppressor genes during proviral integration, thereby leading to
transformation of the host cell. Collectively, these two oncogenic mechanisms
were assumed to be the only two available to gammaretroviruses, as they do not
encode any viral oncogenes which may directly induce transformation. However
there is recent evidence that antisense transcription may occur in MLV, initiated
from multiple positions within the 5’ LTR. This produces chimaeric host-virus
transcripts and therefore contributes to enhanced expression of host oncogenic
proteins (M. H. Rasmussen et al., 2010). Thus the oncogenic mechanisms of
gammaretroviruses may not be as fully explored as previously thought. Whether
this occurs in FeLV infection has not been investigated.
In addition to the LTRs, the non-coding RNA regions of importance in the FeLV
genome are the primer binding site (PBS) and the packaging signal (Ψ). These 
motifs are located across the 3’ region of the 5’ LTR and the initiation codon of
the gag gene, and are both utilised during the retroviral replication cycle (see
Section 1.3). The packaging signal also contains the splice donor site for the
generation of the subgenomic env mRNA transcript. The packaging signal is a
section of cis-acting RNA which forms complex secondary structures including
multiple hairpin regions (Burns, Moser, Banks, Alderete, & Overbaugh, 1996;
Konings, Nash, Maizel, & Arlinghaus, 1992). These structures allow RNA
dimerisation and recognition of such dimers by the structural proteins, resulting
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in packaging of the viral genome by core proteins. Both matrix and nucleocapsid
domains of the Gag precursor protein recognise sections of FeLV-ψ (Linial & 
Miller, 1990; Wang, Norris, & Mansky, 2003). As MLV and FeLV are able to cross-
package in vitro (Burns, et al., 1996) it is assumed that high structural
conservation exists between FeLV-ψ and MLV-ψ, however the primary sequences 
of these genomic regions display low identity. The secondary structures required
for FeLV RNA dimerisation and packaging have therefore not been extensively
investigated. Such studies would allow comparisons between FeLV and other
retroviruses and the identification of essential structures required for retroviral
replication.
1.2.2. Structural proteins
The structural proteins which form the core of the FeLV virion do not contribute
to pathogenicity, nor do they vary to a large degree between subgroups or
strains of FeLV. Therefore they are not as thoroughly studied as the Env proteins
or LTR sequences. The gag (Group-specific antigen) gene encodes a polyprotein,
Pr65, which is translated from the gag ORF within the genomic mRNA transcript.
This polyprotein is cleaved into four mature structural proteins, being the matrix
(MA, or p15), capsid (CA, or p27), nucleocapsid (NC, or p10) and a small protein
of unknown function termed p12.
The FeLV virion structure (Figure 1.3) is similar to that of other retroviruses. The
outermost protein layer of the viral core (i.e., those which face the lipid bilayer)
is composed of MA proteins. The association between these proteins and the
membrane is essential for viral budding and maturation and is often aided by the
presence of myristic acid groups on the protein (Copeland et al., 1988). The CA
protein (p27) forms the inner core of the virion and is the most easily detectable
antigen in FeLV-infected cells. Within the virion core are NC proteins, which
bind to the genomic RNA dimer during production of the virion and remain
associated with the RNA during subsequent cellular entry (Prats et al., 1990). NC
proteins tend to be highly basic and often contain the zinc-finger structures
characteristic of nucleic-acid binding proteins (Katz & Jentoft, 1989).
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Figure 1.3: The FeLV virion.
1.2.3. Enzymatic proteins
The pro-pol gene is in-frame with the gag ORF and encodes the viral enzymes,
which are packaged within immature virions. The precursor polyprotein
(Pr180gag-pol) is translated from genomic mRNA and cleaved and processed into
the individual proteins, being protease, reverse transcriptase and integrase.
The viral protease (Pro) displays many similarities to cellular aspartyl proteases
(Jaskolski, Miller, Rao, Leis, & Wlodawer, 1990). Prior to budding, the protease
is inactive and activity is triggered once the virion has budded. It catalyses the
condensation of the viral core by cleaving structural precursor proteins, leading
to maturation of the virion.
The Reverse Transcriptase (RT) enzyme mediates RNA-dependent-DNA synthesis,
and transcribes the initial nascent DNA strand from the viral genomic RNA. This
enzyme contains an additional RNase H function, which removes the RNA
component of the DNA-RNA heteroduplex to allow cellular DNA polymerase to
synthesise the complementary DNA strand (reviewed in Goff, et al. 1990 (Goff,
1990b)). The RNase H domain (an RNA-DNA hybrid specific ribonuclease) is
located at the C terminus of the protein and is separate to the RT domain.
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The integrase enzyme (IN) has multiple functions, including trimming of the
dsDNA complex prior to integration and cleavage of the host DNA at the
integration site. Integrase also possesses a ligation function to covalently fuse
the viral and host DNA following integration (Bushman & Craigie, 1991).
1.2.4. Envelope glycoprotein
The overall structure of the env gene is highly conserved amongst the
gammaretroviridae (Figure 1.4); as this protein mediates cellular entry there are
numerous structural constraints which limit possible sequence variation. The
production of functional Env glycoproteins is therefore a highly conserved
process within retroviruses (Einfeld, 1996; Hunter & Swanstrom, 1990).The viral
envelope itself is a host-originating phospholipid bilayer, from which the virally-
encoded Env glycoproteins, in their native trimeric form, extend as “spikes”.
After translation from the subgenomic mRNA, the Env precursor protein, gp85, is
cleaved by cellular proteases into the two constitutive proteins, being the
Surface Unit (SU, or gp70) and the transmembrane (TM, or p15E) domains. The
two domains remain associated through disulphide bridges and non-covalent
bonds (Pinter, Lieman-Hurwitz, & Fleissner, 1978). Each domain of Env plays an
essential role in the retroviral life cycle. SU mediates receptor binding and host
cell entry, whilst the TM anchors the Env complex within the viral membrane.
During the processing of gp85, the N terminal signal sequence is recognised by
the cellular transport machinery and directs the polyprotein into the
endoplasmic reticulum (ER). The N terminal regions are translocated across the
ER membrane; however the hydrophobic C terminal membrane anchor halts
translocation at this point. Thus the N terminal region of gp85, the SU domain, is
within the ER lumen whereas the C terminal TM domain remains within the
cytoplasm. Within the lumen, the signal peptide is removed by host proteases,
N-linked glycosylation occurs and disulphide bonds are formed. As a result the SU
domain of mature retroviral virions is significantly more highly glycosylated than
the TM domain. Correct glycosylation is required for future processing of the
domains; additionally, although the sugar chains themselves may not be involved
in receptor-Env binding, incorrectly glycosylated proteins reduce the infectivity
of the virus (Knoper, Ferrarone, Yan, Lafont, & Kozak, 2009; Schultz, Rabin, &
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Oroszlan, 1979). The oligomerisation of Env trimer complexes also occurs in the
ER.
Env complexes are then transported to the Golgi apparatus where N-linked
oligosaccharides are modified and O-linked oligosaccharides may be added to
the SU domain. Cleavage of the SU and TM domains by cellular proteases also
occurs in the Golgi. The Env proteins are then transported to the cellular
membrane where they are incorporated into budding virions through interactions
with viral core MA proteins.
Figure 1.4: The FeLV Envelope protein.
1.2.4.1. Surface Unit domain
As the SU protein (gp70) is the major determinant of both cell tropism and
disease outcome in FeLV, it has been studied intensively for many years (see
Sections 1.8.1 and 1.9.1 for further details). However many aspects of this
protein, including the genetic determinants of disease prognosis and interactions
with host proteins, remain not fully understood. The SU domain of
gammaretroviral envelope proteins is responsible for receptor recognition and
hence entry into host cells. It is this protein which varies significantly between
the FeLV subgroups, through alterations in its receptor usage. The main
determinants of receptor binding are found in the N terminal region. There are
two regions in this area (termed VRA and VRB) that are highly divergent between
the gammaretroviridae, separated by a conserved region approximately 38
amino acids in length. Collectively these motifs constitute the receptor-binding
domain (RBD) (Bae, Kingsman, & Kingsman, 1997; Battini, Danos, & Heard, 1998;
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Battini, Heard, & Danos, 1992; Gray & Roth, 1993; Hoover & Mullins, 1991; Rigby
et al., 1992).
Between the RBD and the C-terminal region of SU is a proline-rich region (PRR),
which also varies significantly between the gammaretroviridae. The PRR is
thought to act as a hinge between the N-terminal globular RBD and the C-
terminal region (Barnett, Davey, & Cunningham, 2001; Fass et al., 1997). It is
essential for viral infectivity as it allows conformational changes within the Env
complexes (Lavillette, Ruggieri, Boson, Maurice, & Cosset, 2002) but does not
appear to contribute to receptor recognition (Gray & Roth, 1993).
Another region of importance within the SU domain is the N terminal fusion
motif (consisting of four sequential amino acids, SPHQ). This is distinct from the
fusion peptide within the TM domain, which is protected by SU prior to the
membrane fusion event. Mutations in the SU fusion motif disrupt the membrane
fusion process although both incorporation of Env into virions and subsequent
receptor binding may still occur (Bae, et al., 1997; Lavillette, Boson, Russell, &
Cosset, 2001; Lavillette & Kabat, 2004). Mutations of the histidine are especially
disruptive; this residue is involved in the formation and disruption of the
disulphide bridges which link SU and TM. The isomerisation of these bridges is
required for exposure of the fusion peptide and its subsequent insertion into the
cellular membrane.
1.2.4.2. Transmembrane domain
In contrast to the SU domain, the TM domain (p15E) of the envelope glycoprotein
is highly conserved between both the FeLV subgroups (Riedel, Hoover, Gasper,
Nicolson, & Mullins, 1986) and retroviruses as a whole (Kobe, Center, Kemp, &
Poumbourios, 1999; Patarca & Haseltine, 1984). Structurally, the TM domain
forms a trimeric coiled complex (Fass, Harrison, & Kim, 1996). The TM domain
consists of a short C-terminal cytoplasmic peptide, followed by a hydrophobic
membrane spanning domain which anchors the protein within the viral
membrane, and finally an N terminal ectodomain.
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The cytoplasmic tail of TM is cleaved by the viral protease shortly before cellular
infection, shortening it from p15E to p12E. The presence of this peptide (termed
the R peptide) prevents membrane fusion until receptor binding has occurred.
The R peptide was initially thought to be dispensable for viral infectivity (Perez,
Davis, & Hunter, 1987), however it is now known that the cleavage of p15E to
p12E is required to allow fusion and subsequent entry of the target cell
(Bobkova, Stitz, Engelstadter, Cichutek, & Buchholz, 2002; Loving, Li, Wallin,
Sjoberg, & Garoff, 2008; Song, Micoli, Bauerova, Pichova, & Hunter, 2005).
N-terminal to the R peptide is the so-called membrane anchor; this highly
hydrophobic region prevents further translocation of the protein through the
cellular membrane, ensuring the final Env trimer is a transmembrane complex.
Between this region and the SU/TM cleavage site is the short TM ectodomain,
which includes a hydrophobic peptide required for mediating host-viral
membrane fusion essential for subsequent viral entry (Einfeld, 1996; Gallaher,
1987). This fusion peptide is buried within the trimer complex during virion
maturation. Fusion is induced once the mature virion encounters a host cell
membrane. SU-receptor binding and isomerisation of the disulphide bridges,
aided by the SU fusion motif, may then occur. The TM ectodomain also contains
a central highly conserved region associated with immunosuppression of the
host, although a mechanism for this has not been established (Cianciolo, Bogerd,
& Snyderman, 1988; Ogasawara et al., 1988). There is also evidence that
particular residues in the FeLV ectodomain are essential for correct Env
precursor processing within the ER and Golgi (Burns, Poss, Thomas, &
Overbaugh, 1995). Thus both the SU and TM domains of Env are required for
successful completion of the retroviral lifecycle.
1.3 The retroviral replication cycle
The retroviral replication cycle is a highly conserved process throughout the
Retroviridae family, reflecting the conserved structure of these viral particles.
When retroviral virions bind to their cognate receptor through non-convalent
binding of the SU glycoprotein, a conformational change is triggered which
exposes the hydrophobic fusion peptide within the TM region (Lavillette, et al.,
2002). This catalyses membrane fusion and entry into the host cell.
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Entry and Un-coating: Gammaretroviral cell entry is pH-independent, although
pH levels within the virion may affect the kinetics of fusion peptide exposure.
Following membrane fusion, the virion core is effectively uncoated of the lipid
envelope and released into the cytoplasm where reverse transcription will occur.
The virion core particle contains the dimeric RNA genome and the virally-
encoded enzymes. Cellular tRNA molecules are also found within mature
retroviral virions, as retroviruses utilise a specific tRNA during reverse
transcription. FeLV utilises the tRNA(Pro) molecule (Laprevotte, Hampe, Sherr,
& Galibert, 1984).
Reverse Transcription: Reverse transcription is a highly complex process which
is still not fully understood, despite being heavily researched for many years (for
an early review, see Gilboa, et al. 1979)(Gilboa, Mitra, Goff, & Baltimore, 1979).
Importantly, the RT enzyme does not possess proof-reading or exonuclease
activity. Mutations through misincorporation are therefore relatively common,
leading to the high evolutionary rate observed in retroviral genomes (10-4 to 10-5
substitutions/site/cycle) (Overbaugh & Bangham, 2001).
The first step in FeLV reverse transcription is binding of the tRNA(Pro) to the
primer-binding site (PBS[-]), an 18 bp sequence complementary to that of the
tRNA, adjacent to the U5 region within the 5’ LTR (Joshi, Van Brunschot,
Robson, & Bernstein, 1990). Thus the tRNA acts as a primer to allow initiation of
reverse transcription. The RT enzyme then extends the complementary region
from the 3’ end of the tRNA to the 5’ end of the viral genome, by synthesising a
singular DNA strand until it reaches the end of the R region. This is termed the
“strong-stop” antisense DNA and is a short single-stranded segment. The RNase H
function of RT allows degradation of the 5’ R region of RNA, leaving this area of
the strong-stop DNA available for complementary base-pairing.
The first strand transfer event now occurs, where the R region of the strong-stop
DNA can bind to the 3’ R region of the viral genome. It then acts as a secondary
primer for RT, allowing reverse transcription of the remainder of the viral
genome producing the full length nascent (antisense) DNA strand. This strand
now contains the entire 3’ LTR of the DNA due to the transfer of R and U5
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domains in the strong-stop DNA. The RNase H motif of RT digests the RNA
component of the heteroduplex, producing single stranded nascent DNA.
A RNase H-resistant area is located between the 3’ U3 and the polypurine tract
(PPR). This remaining RNA is now utilised as a third primer binding site
(commonly called PBS[+]), initiating the positive sense DNA strand synthesis from
the 3’ terminus of the RNA to the end of the viral genome. This produces the U3,
R and U5 regions of the “strong-stop” sense DNA strand. The second transfer
event now occur, during which this short DNA segment translocates and base-
pairs to the 3’ end of the antisense DNA strand. This is then extended, forming a
dsDNA complex which now contains blunt-ended LTRs at both termini. This
entire process is thought to occur within the virion core. The dsDNA is now part
of a high molecular weight pre-integration complex, which is transported into
the nucleus.
Integration: Although retroviral particles contain two molecules of positive-
sense genomic RNA, only a single dsDNA pre-integration complex and therefore a
single provirus is produced from each virion (Hu & Temin, 1990). Integrase is
packaged within the mature virion and acts upon the un-integrated complex,
which is transported into the nucleus alongside viral structural and enzymatic
proteins (Goff, 1990a). Although some retroviruses may actively enter the
nucleus, gammaretroviruses passively enter during mitosis. Cleavage of the host
DNA and the introduction of viral DNA occur in a concerted event; the enzyme
makes a staggered cut within the host DNA, generating short overhangs with 5’
phosphorylated ends which can non-covalently associate with the nicked viral
DNA. Ligation (covalent fusion of the DNA molecules) is then mediated by a
separate domain of the integrase enzyme. After integration, host enzymes
correct the mismatched base pairs at the termini of the provirus, producing the
4 – 6bp of repeated sequence characteristic of retroviral integration sites (direct
repeats). Although there is limited specificity in the targeting of retroviral DNA
to specific host DNA sites, chromatin density may contribute, therefore
increasing the chances of the provirus being inserted into a transcriptionally-
active region. The provirus is then transcribed and translated as standard host
genes.
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Production of Viral Proteins and Nucleic Acid: Transcription of the provirus is
initiated at the U3-R boundary of the 5’ LTR. Polyadenylation of the transcript
then occurs at the R-U5 boundary of the 3’ LTR. Post-transcriptional processes,
including methylation and capping of the viral RNA, are mediated by cellular
enzymes (Stoltzfus, 1988) resulting in functional mRNA transcripts. Viral RNA
may be either directly exported or spliced within the nucleus, producing the
subgenomic RNA from which the majority of Env is translated. After export of
the RNA into the cytoplasm, the expression of Env proteins occurs from
membrane-bound polysomes, whereas the Gag and Pro-Pol protein precursors
are translated by free cytoplasmic ribosomes from the full-length genomic RNA.
Assembly, Egress and Maturation: Within the gammaretroviridae, the assembly
of structural proteins and genomic RNA into core viral particles occurs primarily
at the cellular membrane. For Type C retroviruses such as FeLV, virion
intermediates are therefore not detectable within the cytoplasm (Coffin, 1979).
This is not a conserved process within the simple retroviruses; betaretroviruses
assemble within the pericentriolar regions of the cytoplasm and are then
trafficked to the membrane (Arnaud, Murcia, & Palmarini, 2007; Sfakianos &
Hunter, 2003). Subgenomic mRNAs are excluded from the packaging process as
RNA dimerisation and interactions with NC proteins depend upon a functional
leader and packaging signal. The virion structural core, containing the RNA
dimer, buds from the host membrane and thereby acquires both the lipid bilayer
and Env glycoproteins. Cellular proteins are generally excluded from the
emerging virion. Once released the virion undergoes maturation to become an
infectious particle, hallmarked by cleavage of the Gag precursor proteins and
the accompanying condensation of the viral core.
1.4 Immune responses to FeLV infection
FeLV infection activates multiple branches of the adaptive immune response,
including antibody production and cytotoxic lymphocytes (CTLs) (Flynn, Hanlon,
& Jarrett, 2000). Although most recovered cats produce an efficient antibody
response, CTLs appear prior to VNAs (within a week of virus infection) and play
an essential role in viral clearance (Flynn, Dunham, Watson, & Jarrett, 2002).
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Cytokine responses are also essential for development of protective immunity
(Hanlon et al., 2001). Initial FeLV viraemia induces both Type I and II interferon
responses, as both IFN-ω and IFN-γ are up-regulated following infection (Garch 
et al., 2006).
However, chronic FeLV infection results in a decrease in both T lymphocyte
responses and cytokines such as IFN-γ (Good, Ogasawara, Liu, Lorenz, & Day, 
1990), contributing to the immunosuppression seen in many infected hosts. The
mechanism of this is unknown, however recent investigations into feline
neutrophils indicate that infection of these cells may contribute to FeLV
pathogenesis. Neutrophils play a central role in the innate immune response by
phagocytosing invading pathogens (Nathan, 2006). FeLV-induced immune-
suppression is thought to be partially due to chronic overstimulation of the
infected neutrophils, which are then unable to respond to novel pathogens
(Wardini et al., 2009). This overstimulation is seen in both clinically ill and
asymptomatic infected cats, although to a lesser extent in the latter group.
These neutrophils also display reduced chemotactic responses (Kiehl, Fettman,
Quackenbush, & Hoover, 1987) and impaired phagocytic activity (Hoffmann-
Jagielska et al., 2005). Collectively these reduced responses contribute to the
opportunistic infections often seen in FeLV-infected cats (Lewis, Duska, Stiff,
Lafrado, & Olsen, 1986). Although it is not known how FeLV infection mediates
these effects on neutrophils, it has been suggested that the Env TM domain may
be responsible rather than viral replication itself (Lafrado, Lewis, Mathes, &
Olsen, 1987). This region has been associated with the immunosuppressive
effects of other retroviruses (Cianciolo, et al., 1988; Ogasawara, et al., 1988).
Although the degree to which T cell-mediated and humoral immunity each
contribute to FeLV clearance and protection is still unknown, there has been
significantly more research conducted upon the antibody responses of infected
cats. This is mainly due to the assumption that the induction of VNAs was
required for a protective vaccine. There is now increasing evidence that VNAs
alone may not be sufficient for either protection against challenge or prevention
of disease. Additionally, as research into other retroviruses continues to uncover
novel host-virus interactions, it is becoming increasingly apparent that VNAs may
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play a significant role in FeLV evolution within a host (see Chapter 4). Therefore
much research is still required into the humoral responses to FeLV infection.
The first evidence that VNAs were involved in FeLV clearance was the
observation that transfusion of blood between infected and naïve cats correlated
with protective immunity (O. Jarrett, Russell, & Stewart, 1977). It was also
documented that recovered cats continued to produce VNAs after viraemia had
ceased, and these were notably absent from chronically-viraemic cats (Russell &
Jarrett, 1978a). The degree of Env antibody response to FeLV is now known to
be highly correlative with the disease outcome; by 3 weeks post-infection cats
with low antibody titres can be accurately predicted to develop progressive
infections whereas cats with higher titres will display regressive viraemia and
antigenaemia from that point (Hofmann-Lehmann, et al., 2001).
In addition to Env-specific VNAs, cats mount an immune response against
numerous gag-encoded proteins; however these do not provide protection or aid
viral clearance (W. D. Hardy, 1993). The immunologically dominant region is the
SU domain (Hoover & Mullins, 1991; Lutz, Higgins, Pedersen, & Theilen, 1979),
however the receptor-binding regions and the neutralising epitopes are separate
motifs within this protein (Ramsey, Spibey, & Jarrett, 1998). It is also probable
that the immunogenicity of SU relies heavily upon its glycosylation, as is the case
for other gammaretroviruses (Alexander & Elder, 1984). Recent investigations
into potential recombinant vaccines have also identified neutralising antibodies
against the TM domain (Langhammer, Fiebig, Kurth, & Denner, 2005;
Langhammer, Hubner, Kurth, & Denner, 2006; Marciani et al., 1991).
Neutralising monoclonal antibodies (MAbs) specific to a conserved epitope within
the central region of the SU domain are commercially available (Elder et al.,
1987; Nunberg, Rodgers, Gilbert, & Snead, 1984). This epitope (C11D8) appears
essential but not sufficient for a protective neutralising antibody response.
Although the genetic drift of viral genomes away from this peptide correlates to
an escape from clearance by the immune system (Sheets, Pandey, Klement,
Grant, & Roy-Burman, 1992), external administration of these MAbs do not aid
viral clearance (Weijer, UytdeHaag, Jarrett, Lutz, & Osterhaus, 1986). This
indicates additional VNA binding sites within Env exist and contribute to the
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antibody titre seen in infected hosts. Additionally, the C11D8 epitope is not
found in endogenous FeLV elements (see Section 1.5) (McDougall et al., 1994;
Sheets, Pandey, Jen, & Roy-Burman, 1993). However after the formation of
FeLV-B genomes (see Section 1.8), a single substitution event occurs (C750T)
which reintroduces the epitope into the exogenous viral genome (Pandey et al.,
1995). It is thought that this mutation is driven by further recombination
between FeLV-A and -B genomes occurring during viral replication, replacing the
non-neutralising endogenous epitope with the exogenous sequence (Pandey, et
al., 1995).
1.5 Outcomes of FeLV infection
FeLV infection is variably associated with acquired immunodeficiency syndrome
(AIDS)-like immunosuppression, anaemia and various neoplastic haematopoietic
disorders. The specific clinical manifestation reflects the subgroup present
within the host (see Sections 1.7 to 1.10). Approximately 72% of domestic cats
become infected after exposure (W. D. Hardy, 1993), however 60% of these are
predicted to recover (“regressor” cats) whilst 40% progress to chronic infections
and/or FeLV-related diseases (Hoover & Mullins, 1991). The likelihood of
clearance correlates highly with the cats’ age, with neonatal kittens displaying a
high susceptibility to infection which decreases over time (Grant, Essex,
Gardner, & Hardy, 1980; Hoover, Olsen, Hardy, Schaller, & Mathes, 1976). FeLV-
infected cats generally live for 2.4 years following diagnosis, as compared to 6.3
years for healthy controls (J. Levy, 2009).
Following initial viraemia, cats can be categorised according to the eventual
outcome; these are termed regressive, progressive, abortive and focal
infections. There is evidence that the early viral load (in plasma, saliva, faeces
and urine) correlates highly with the outcome of infection and hence the
classification of the host. Regardless of the eventual outcome, all cats display a
transient period of viraemia, hallmarked by detectable proviral and plasma viral
RNA loads (Hofmann-Lehmann, et al., 2008; Lutz et al., 1980).
Regressive Infection: A majority of cats clear the infection through a
combination of cell-mediated immunity and VNAs, and do not succumb to FeLV-
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related diseases. As these cats only display transient viraemia and antigenaemia
(Cattori et al., 2009), infection may only be detected through the presence of
antibodies and/or proviral DNA (W. D. Hardy, Jr., et al., 1976; Hofmann-
Lehmann, et al., 2001; Torres, et al., 2005). Infectious virus can occasionally be
induced from bone marrow, indicating a latent infection remains in regressor
cats (Madewell & Jarrett, 1983; Rojko, Hoover, Mathes, Krakowka, & Olsen,
1979; Rojko, et al., 1982). The duration of latency is highly variable (Pacitti &
Jarrett, 1985). It is thought that the occasional reactivation of proviral DNA may
contribute to the long term presence of VNAs in these so-called “recovered” cats
(J. Levy, et al., 2008; Torres, O'Halloran, Larson, Schultz, & Hoover, 2008).
Reactivation of a latent infection following years of viral inactivity has also been
observed in a single experimental infection, however as this cat was additionally
infected with FIV the reactivation may have been due to immunosuppression (A.
K. Helfer-Hungerbuehler et al., 2010). The relevance of this particular incident
is questionable considering there are no available data on the rate of natural
infection reactivation after years of latency.
Whether latent FeLV proviruses contribute to disease is a contentious issue.
FeLV latent infection has been associated with anaemia, panleukopenia and
suppurative inflammation, as well as an increase in secondary non-viral
infections (Suntz, Failing, Hecht, Schwartz, & Reinacher, 2010). However other
research has not found a correlation between latent FeLV infection and general
cytopenias in domestic cats (Stutzer et al., 2010). Additionally, FeLV latency has
been documented as correlating with lymphosarcoma in domestic cats (A. T.
Weiss, Klopfleisch, & Gruber, 2010). Given the disruptive and potentially
oncogenic nature of the retroviral replication cycle, this is a plausible
association; however other research has not been able to reproduce these
findings (Stutzer, et al., 2010; Suntz, et al., 2010). It may be that the length of
time required for the individual cat to clear the infection, and thus the degree
of replication and reintegration the virus undergoes, affects the likelihood of
disease occurring after viraemia ceases. Additionally, the role of latent viral
infections in disease development may only become apparent now that
vaccination is widespread, as this has caused the vast majority of infections to
be non-progressive.
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Progressive Infections: Chronic infections occur when the virus cannot be
cleared or contained by the immune system and therefore becomes established
within the bone marrow (Cattori et al., 2008; O. Jarrett, 1999; J. Levy, et al.,
2008). Persistent viraemia and antigenaemia is observed, particularly within
neutrophils and platelets which are unaffected by initial viraemia. FeLV-related
disease may develop depending on both the infecting strain and the
immunological response of the individual cat. The disease which manifests will
depend upon which viral subgroups subsequently develop within the host.
Compared to regressor cats, which do not maintain viral shedding, progressively-
infected cats shed infectious virus as early as 3 weeks post-infection and
maintain a high viral load (Cattori, et al., 2009).
Focal infections: Although rare, focal infections have been observed in both
naturally-infected and experimentally infected cats (Roy-Burman, 1996). Focal
infections are characterised by the host presenting with antigenaemia within
specific isolated tissues, including spleen, lymph nodes, mammary glands or the
small intestine although seroconversion and systemic viraemia do not occur
(Hayes et al., 1989; Hoover, Schaller, Mathes, & Olsen, 1977; Pacitti, et al.,
1986; Rojko, et al., 1982). It is not known to what extent these cats are at risk
of developing disease. It is assumed that the detectable viral antigens are non-
virion-associated and infection had been restricted to the affected organ/s
(Miyazawa & Jarrett, 1997).
Abortive Infections: Abortive infections have been observed only in
experimental infections to date. They are characterised by a confirmed initial
infection followed by an absence of both secondary viraemia and detectable
proviral DNA, indicating the cat successfully cleared all latently-infected cells
(Pacitti & Jarrett, 1985; N. C. Pedersen, Johnson, & Theilen, 1984; Torres, et
al., 2005). This is highly unlikely given the integrative nature of retroviral
infections and the longevity of their target cells. However with the advancement
of highly sensitive quantitative PCR assays the existence of abortive infections
may require reconsideration, as it is possible they represent hosts with
extremely low proviral loads undetectable by previous techniques.
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1.6 Endogenous FeLV elements
Endogenous retroviruses (ERVs) are formed when the integration of viral dsDNA
into the host genome occurs in either a germline cell or during early
embryogenesis. The provirus is therefore present at this locus in every cell of
the embryo, and the latent infection is transmitted vertically as a dominant
Mendelian element. Degradation and an accompanying loss of function occurs as
mutations accumulate within the provirus (Coffin, 1992), eventually resulting in
non-functional endogenous retroviral elements. ERVs are generally conserved
between individual members of a species and most are functionally inactive
(Boeke & Stoye, 1997).
There are 8 to 15 FeLV-related endogenous elements (enFeLV) within the
domestic cat genome (Benveniste & Todaro, 1975; Koshy, Gallo, & Wong-Staal,
1980; Okabe et al., 1976; Soe, Devi, Mullins, & Roy-Burman, 1983). They are
confined to the genomes of the Felis genus, one of the 11 genera within the
Felidae family. Therefore it appears that an ancestral exogenous FeLV initially
became stably integrated into the genome of the last common ancestor of the
Felis group, which now includes all small wildcats as well as domestic breeds (W.
E. Johnson et al., 2006; Mattern & McLennan, 2000; O'Brien, 1986).
EnFeLV are polymorphic elements and therefore each provirus is not necessarily
conserved between individuals (Koshy, et al., 1980; Roca, Nash, Menninger,
Murphy, & O'Brien, 2005). Interestingly, privately-owned cats harbour a much
higher enFeLV copy number than specific-pathogen free cats used for
experimental purposes. Domestic cats also exhibit higher enFeLV loads than
European wildcats (Tandon et al., 2007). This polymorphic nature indicates
reinfection and germline integration has continued over the millennia and
endogenisation of the cat genome is an on-going process. This is supported by
the fact that most enFeLV elements have intact LTRs (Soe, et al., 1983; Soe,
Shimizu, Landolph, & Roy-Burman, 1985), which would not be expected if they
were conserved ancient ERVs.
Theoretically, enFeLV-derived virions would utilise the Pit1 receptor for cellular
entry, as all enFeLV env genes studied to date contain Pit1-specific RBDs.
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However these elements are generally non-functional and do not form infectious
virions (Soe, et al., 1985); although expression of short transcripts has been
documented (Busch et al., 1983; McDougall, et al., 1994; Niman, Akhavi,
Gardner, Stephenson, & Roy-Burman, 1980) the degree of transcriptional activity
they possess remains to be firmly established. It has been suggested that some
defective elements contribute to the innate resistance to FeLV (McDougall, et
al., 1994). This is mediated by the expression of a 35kDa Env fragment,
corresponding to the N terminal region of SU, in both lymphoma and healthy
lymphoid primary cell lines which prevents infection by FeLV-B, presumably by
competitive receptor binding (McDougall, et al., 1994). This may explain the
observation that purified FeLV-B cannot be transmitted between individual hosts
(see Section 1.8) (O. Jarrett & Russell, 1978). However as cats are polymorphic
for each individual enFeLV locus, it is unlikely that every cat would produce
these protective Env fragments. It is possible that cats lacking the corresponding
enFeLV are the individuals that succumb to FeLV-B-related disease. The
protective peptide lacks the C11D8 VNA-inducing epitope (Neil, Fulton, Rigby, &
Stewart, 1991) and would therefore be unlikely to induce a humoral immune
response. A role for endogenous gammaretroviral elements in protection against
exogenous infection has been previously observed in MLV infections in mice and
is therefore a highly possible scenario (Bassin, Ruscetti, Ali, Haapala, & Rein,
1982; Ikeda, Ikeda, & Tsuchida, 1985; Jung, Lyu, Buckler-White, & Kozak, 2002;
T. Wu, Yan, & Kozak, 2005).
In contrast to this potentially protective role against infection, there is also
evidence that enFeLV proteins facilitate infection by exogenous FeLV-T, an
otherwise entry-defective FeLV subgroup (see Section 1.10). It may be that
individual enFeLV loci confer either protective or pathogenic qualities. However
the exact mechanism by which the enFeLV peptide FeLIX contributes to cellular
entry has not been elucidated.
It is apparent that further research is required to define the respective roles of
individual enFeLV loci in FeLV disease and/or resistance. However recent
research into enFeLV elements has focused upon the genomics and phylogenetics
of these polymorphic loci. Full length enFeLV elements with putatively
functional ORFs were recently identified, indicating they may be more active
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than previously assumed (GenBank Accession numbers AY364318 and AY364319)
(Roca, Pecon-Slattery, & O'Brien, 2004). That fact that some of these viral
genomes possess identical 5 and 3’ LTRs indicates they are relatively recent
additions to the Felis catus genome, which became established between half a
million to 2 million years ago (W. E. Johnson & Coffin, 1999). Supporting this
hypothesis are the facts that these enFeLV genomes are only present in 9 - 15%
of individual cats studied to date and have only been isolated from particular
breeds (Roca, et al., 2005). They are also not found in closely-related Felis
species, unlike truncated enFeLV loci (Roca, et al., 2004). Despite being “young”
ERVs, these proviruses still display higher nucleotide homology to enFeLV than
exogenous FeLV proviral genomes.
It is not known if these full-length enFeLV elements are being maintained
through selective pressure or if they will degrade and become defective over
time. The one potential benefit to the host (the protective role against FeLV-B
infection) appears adequately provided by defective enFeLV elements
(McDougall, et al., 1994). It would be of interest to investigate whether these
full-length enFeLV genomes are isolated incidences of recent proviral germline
integration or whether functional enFeLV genes are more widespread than
previously assumed. The transcriptional activity of such loci, and their potential
for incorporation into virions and subsequent horizontal transmission should also
be addressed as this would have implications for the potential generation of
pathogenic FeLV-B strains (see Section 1.8).
1.7 The FeLV subgroups and their host ranges
FeLV isolates can be classified into three main subgroups; FeLV-A, -B, -C (Russell
& Jarrett, 1978b) which are distinguished both by their pathogenic potential and
the receptors utilised for cellular entry. FeLV-T (Anderson, Lauring, Burns, &
Overbaugh, 2000) represents a rare defective virus that confounds classical
assays for viral subgroups; little is known about its frequency of occurrence in
the field. Therefore the main genetic differences between the subgroups lie in
the RBD of their respective SU proteins. Gammaretroviral cellular receptors are
generally proteins displaying multiple transmembrane domains that function as
transporters for small molecules (Overbaugh, Miller, & Eiden, 2001). The
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receptor utilised by a simple retrovirus determines its classification into one of
11 known interference groups (Sommerfelt, 1999). Interference assays rely upon
the fact that infection leads to downregulation or masking of the viral receptor
upon the cell surface, preventing re-infection by a virus that would normally
utilise the receptor. A cell can still be superinfected by a virus utilising a distinct
receptor. Until recently, interference assays and in vitro host range analysis
were the only available methods of classifying FeLV field isolates as the FeLV-A
and –C receptors had not been identified. As the receptors for all FeLV subgroups
have now been characterised and cloned, receptor usage assays utilising murine
cell lines engineered to express the cognate receptors are commonly used.
These allow more accurate analysis of the receptor choice of viral variants.
Although FeLV-A was generally regarded as ecotropic (i.e., able to only infect
feline cells) (W. D. Hardy, 1993; O. Jarrett, Laird, & Hay, 1973; Sarma, Jain, &
Hill, 1975) some isolates can infect canine and human cells in vitro (Moser,
Burns, Boomer, & Overbaugh, 1998). However there are no recorded instances of
humans or dogs being infected with FeLV (W. D. Hardy, Jr., et al., 1976;
Schneider & Riggs, 1973). FeLV-B and FeLV-C are always isolated in conjunction
with FeLV-A (O. Jarrett, Hardy, Golder, & Hay, 1978; Sarma & Log, 1973) and
FeLV-A is the only naturally transmissible variant. FeLV-B and –C exhibit an
expanded amphotropic host range, as they are both able to infect canine, human
and mink cells in vitro (Anderson, et al., 2000; Boomer, Eiden, Burns, &
Overbaugh, 1997; W. D. Hardy, Jr., et al., 1976; O. Jarrett, H.M. Laird, & D.
Hay, 1969b; O. Jarrett, et al., 1973). FeLV-C is also able to infect guinea pig
cells. The cell tropism of FeLV-T is limited to feline T cells, as this is the only
known cell lineage to express FeLIX, the FeLV-T co-receptor (Lauring, Anderson,
& Overbaugh, 2001) (See Section 1.10).
As FeLV-B and –C are generally more pathogenic than the transmissible FeLV-A,
it is of significant interest to identify the blocks to transmission which are acting
upon these subgroups. The observation that FeLV-B and –C cannot be
transmitted without simultaneous FeLV-A infection was previously explained by
the possibility of FeLV-A Env glycoproteins pseudotyping FeLV-B and/or FeLV-C
cores (O. Jarrett, Golder, Toth, Onions, & Stewart, 1984). Pseudotyping has also
been used to explain observations that simultaneous infection with FeLV-C and
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enFeLV-FeLV-C chimaeric viruses significantly increases the rate of disease
progression. In this case, the presence of enFeLV RBDs increases the tropism of
the infectious virus, contributing to the broader host range observed in these
experiments. However, only FeLV-C viruses established a chronic infection in
this study, suggesting that the chimaeric Env preferentially packaged FeLV-C
cores (Mathes et al., 1994).
However, recent studies have shown that co-expression of retroviral Env
glycoproteins may induce the formation of heterotrimers which decrease the
infectivity of the virus particles (Dewannieux & Collins, 2008). This was
suggested to be a novel restriction mechanism of infectious retroviruses, and
raises the question as to whether SU proteins form heterocomplexes in mixed
subgroup FeLV infections. This may contribute to the lack of FeLV-B and –C
transmission between hosts. Alternatively, it is possible that endogenous Env
interact with those of infectious virus and induce heterotrimer formation;
however this would require correct expression and glycosylation of the
endogenous protein, something which is not definitively found in enFeLV
elements to date.
1.8 FeLV-A
FeLV-A[Glasgow-1] is the prototypic strain of FeLV-A. However, much research
has also been conducted on the weakly pathogenic FeLV-61E (Donahue et al.,
1988). This was initially isolated as a helper virus for a highly pathogenic FeLV-
FAIDS-inducing variant (see Section 1.10). FeLV-A is the only subgroup commonly
transmitted between hosts and gives rise to FeLV-B and –C via intra-host
evolution.
1.8.1. FeLV-A receptor: feTHTR1
Early research indicated FeLV-A utilised a 70kDa membrane protein (A. K. Ghosh,
Bachmann, Hoover, & Mullins, 1992). It was later identified to be a thiamine
transporter protein, referred to as THTR1, encoded by the SLC19A2 gene. The
feline gene (feTHTR1) displays 93% amino acid identity to the human orthologue
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(huTHTR1) (Mendoza, Anderson, & Overbaugh, 2006) which also has the capacity
to function as a FeLV-A receptor. FeLV-A is the only retrovirus known to utilise
this receptor and therefore creates a unique interference group.
Both the feline and human THTR1 genes are expressed in a broad range of
tissues including small intestine, liver, kidney, skeletal muscle and peripheral
blood lymphocytes (Diaz, Banikazemi, Oishi, Desnick, & Gelb, 1999; Dutta et al.,
1999), supporting the broad ecotropic in vitro cell tropism of FeLV-A (Rojko,
Hoover, Mathes, Olsen, et al., 1979). FeTHTR1 transcripts are also found in
exceptionally high levels in oral mucosal tissues, corresponding to this being the
initial site of FeLV-A entry and replication (K. A. Helfer-Hungerbuehler et al.,
2011). Notably, the level of feTHTR1 transcripts in this tissue does not vary
significantly in relation to a cats’ age; therefore receptor expression levels
cannot be responsible for the age-related resistance to FeLV-A infection that
domestic cats display. It is also unlikely to be the lack of a functional receptor
that protects most large felids from FeLV-A infection as feTHTR1 appears highly
conserved across the Felidae family (K. A. Helfer-Hungerbuehler, et al., 2011).
The physiological role of THTR1 is to aid absorption of thiamine, or vitamin B1,
in the intestinal tract and kidneys. It is not known whether FeLV-A binding and
the subsequent infection impairs feTHTR1 function; however genetic disorders
have been characterised indicating defective huTHTR1 proteins correlate with a
decrease in intracellular thiamine and the onset of thiamine-responsive
megaloblastic anaemia (Diaz, et al., 1999; Labay et al., 1999; Raz et al., 2000).
The variety of non-thiamine-related disorders seen in infected cats does not
support the hypothesis that FeLV-A binding to feTHTR1 causes a predictable
impairment in function.
1.8.2. Pathogenesis of FeLV-A infection
FeLV-A isolates are often mistakenly regarded as minimally pathogenic
(Donahue, et al., 1988; Roy-Burman, 1996) as severe FeLV-associated diseases
more commonly develop in the presence of subgroups B or C. However highly
pathogenic FeLV-A variants have been characterised, for example the FeLV-945
isolate (Chandhasin, Coan, & Levy, 2005; Chandhasin, Lobelle-Rich, & Levy,
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2004) which causes non-T-cell multicentric lymphomas. This is due to a unique
LTR and an unusually variable envelope sequence which together confer a
replicative advantage and heightened pathogenicity to this isolate (Bolin,
Chandhasin, Lobelle-Rich, Albritton, & Levy, 2011; Chandhasin, et al., 2005;
Prabhu, Lobelle-Rich, & Levy, 1999). Infection with other FeLV-A isolates is
commonly associated with thymic T-cell lymphoma, although a pathogenic
mechanism has not been established (Neil, et al., 1991). Numerous other
diseases have been associated with FeLV-A infection, including inflammatory and
degenerative liver disease (Reinacher, 1989), chronic enteritis (Reinacher, 1987)
and benign peripheral lymphadenopathy (Moore, Emerson, Cotter, & DeLellis,
1986). This confirms that most FeLV-A isolates have pathogenic potential,
although it may not manifest as clearly as during FeLV-B or –C infection.
As FeLV-A does not encode a viral oncogene and infection is not routinely
associated with a specific disease, the pathogenic mechanism/s have not been
definitively established. As binding of FeLV-A Env to feTHTR1 does not appear to
impair its function, it is possible FeLV-A pathogenesis is mostly mediated through
insertional activation of cellular proto-oncogenes. Recent research indicates
common retroviral integration sites exist within feline chromosomes A2 and B2
which may be targeted during FeLV-A infection of lymphoid cells (Fujino, Satoh,
Ohno, & Tsujimoto, 2010). This has been suggested previously; the oncogene c-
myc is activated in up to 30% of FeLV-induced tumours and leukaemias (L. S.
Levy, Gardner, & Casey, 1984; Miura et al., 1987; Mullins, Brody, Binari, &
Cotter, 1984; Neil et al., 1984), indicating it may be preferentially activated
during integration. There is also evidence that the flvi-2 locus is often affected
by insertional mutagenesis during FeLV infection (L. S. Levy & Lobelle-Rich,
1992; L. S. Levy et al., 1993); this is additionally observed in multiple murine
lymphomas and hence may be a conserved viral integration site within the
gammaretroviridae (Uren, et al., 2005). Together c-myc and flvi-2 activation
contribute to approximately half of feline T-cell tumours (L. S. Levy, Lobelle-
Rich, Overbaugh, et al., 1993). Other loci commonly involved in FeLV lymphoma
development are pim-1, bmi-1, flvi-1, fit-1 and flit-1 (Fujino et al., 2009;
Fujino, Ohno, & Tsujimoto, 2008; Levesque, Bonham, & Levy, 1990; L. S. Levy,
Lobelle-Rich, & Overbaugh, 1993; Tsatsanis et al., 1994). It is possible these
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proto-oncogenes contribute to human cancer progression, highlighting the role
of FeLV as a model for other diseases and potential tool for oncogene discovery.
1.9 FeLV-B
FeLV-B isolates are found in approximately 40% of field cases, always alongside
FeLV-A infection (Phipps, Hayes, Al-dubaib, Roy-Burman, & Mathes, 2000; Russell
& Jarrett, 1976). The prototype strain is FeLV-B[Gardner-Arnstein] (Elder &
Mullins, 1983; Nunberg, Williams, & Innis, 1984). FeLV-B genomes are formed via
recombination of FeLV-A genetic material with endogenous proviral transcripts
(Neil, et al., 1991; Overbaugh, Riedel, Hoover, & Mullins, 1988; Stewart et al.,
1986). The phenomenon of retroviral variants arising through recombination is
not restricted to FeLV; other examples include the pathogenic murine mink cell
focus-forming viruses (L. H. Evans & Cloyd, 1984; Khan, 1984) and avian
retroviruses (R. A. Weiss, Mason, & Vogt, 1973).
1.9.1. Evolution of FeLV-B envelope genes
The recombination event that leads to FeLV-B formation is hypothesised to occur
during co-packaging of transcripts from both FeLV-A and enFeLV proviruses
(Overbaugh, Riedel, et al., 1988; Tzavaras et al., 1990). Although the co-
packaging of two distinct FeLV genomes within one viral core has not been
directly observed, co-packaging of MLV retroviral RNAs resulting in a novel
recombinant genome has been documented in vitro (Yin & Hu, 1997).
Additionally, co-transfection of cell lines with multiple retroviral molecular
clones gives rise to recombinant viruses, indicating heterodimeric RNA genomes
must be produced (Pandey et al., 1991).
Although most of the enFeLV gag genes studied to date are highly mutated and
thus assumed to be defective, both the packaging signal (Ψ) and leader 
sequences are intact (Berry, et al., 1988); it is therefore feasible that expression
and packaging of RNA transcripts may occur from these loci. However the
specific enFeLV loci that contribute to FeLV-B formation have not been
identified; it is possible that the recently-characterised full length enFeLV env
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genes (Roca, et al., 2004) contribute to the majority of FeLV-B genomes. Due to
their intact LTRs and ORFs they are more likely to be transcriptionally active.
The endogenously-derived portions of FeLV-B env genes display >98% identity to
enFeLV elements (Mullins, Hoover, Quackenbush, & Donahue, 1991), however
the length of this enFeLV-related portion differs significantly between isolates
and influences the replicative capacity of the final virus. This indicates that not
all enFeLV loci have an equal capacity for replication-competent FeLV-B
formation. The location of the recombination break points differs between
isolates, although a central 250bp region of SU appears preferential (Sheets, et
al., 1992). However, occasional 5’ recombination points in FeLV-B genomes have
been found in the pol gene indicating that this region must be transcriptionally
active in at least some enFeLV loci (Overbaugh, Riedel, et al., 1988; Pandey, et
al., 1991). This again indicates the full-length enFeLV loci are likely to be the
contributing elements.
Although there is evidence from experimental infections that FeLV-A isolates
differ in their capacity to recombine and produce FeLV-B (Phipps, Chen, Hayes,
Roy-Burman, & Mathes, 2000), it is obvious that the transcriptional activity of
specific enFeLV elements in the host is the main deciding factor determining
whether FeLV-B arises during an infection. This is supported by the fact that the
rate at which FeLV-B arises in vitro differs during infection of particular cells
lines, an indication of the differing transcription levels of enFeLV loci in variable
tissue types (Overbaugh, Riedel, et al., 1988).
Given the increase in pathogenicity and mortality associated with FeLV-B
development in a host (see below), an accurate analysis of the transcriptional
activity of various enFeLV loci and their subsequent contribution to FeLV-B
formation would be highly informative. Recent advancements in both feline
genomics and bioinformatics, as well as the ever-decreasing price of genetic
sequencing, would now allow these questions to be readdressed.
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1.9.2. FeLV-B receptor: fePit1
During formation of FeLV–B, the acquisition of a novel enFeLV-encoded RBD
leads to a switch in receptor usage and subsequently an extended host range.
FeLV-B can therefore infect human and canine cell lines in vitro, as well as the
feline cell lines susceptible to FeLV-A (Hoover & Mullins, 1991). The cellular
receptor for FeLV-B is the inorganic phosphate-sodium symporter, Pit1 (Rudra-
Ganguly, Ghosh, & Roy-Burman, 1998). Both the human and feline proteins are
functional viral receptors (Takeuchi et al., 1992) however the murine orthologue
is not (Wilson, Farrell, & Eiden, 1994). This explains the restriction seen in
rodent cell lines despite the broad expression of murine Pit1.
Some FeLV-B isolates can also utilise the homologous fePit2 cellular surface
protein (Anderson, Lauring, Robertson, Dirks, & Overbaugh, 2001; Boomer, et
al., 1997), which displays 60% amino acid identity to Pit1 and is the viral
receptor for the amphotropic MLV (Miller, Edwards, & Miller, 1994; van Zeijl et
al., 1994). The proportion of env which has originated from enFeLV loci
determines whether a FeLV-B isolate can utilise Pit2 (Boomer, et al., 1997), as
there are particular sequences within both the RBD and the SU C domain of Env
that are required for successful utilisation of this protein (Boomer, et al., 1997;
Sugai et al., 2001). The C domain of FeLV-B Env also contributes to the
recognition of particular Pit1 orthologues (Faix, Feldman, Overbaugh, & Eiden,
2002), highlighting that the determinants of gammaretroviral receptor usage are
not restricted to the prototypic RBD. It is thought that the C domain affects the
post-binding steps of viral entry.
1.9.3. Pathogenesis of FeLV-B infection
Compared to other outbred species, both leukaemia and lymphoma occur
amongst domestic cats at significantly high rates (Dorn, Taylor, & Hibbard,
1967). Specifically, FeLV-B infection is highly associated with lymphomas
(Sheets, et al., 1993; Tsatsanis, et al., 1994; Tzavaras, et al., 1990), which
occur in 10% of persistently FeLV-infected cats (Cotter, Hardy, & Essex, 1975; W.
D. Hardy, Jr., et al., 1976). FeLV-B is also more commonly observed in
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leukaemic cats than FeLV-A (O. Jarrett, et al., 1978; Tzavaras, et al., 1990).
Despite these associations, a conserved oncogenic mechanism during FeLV-B
infections has not been identified.
The most common FeLV-induced tumours are clonal T lymphoid tumours, which
display fixed sites of viral integration across numerous cells (Casey, et al.,
1981). They are generally classified according to their location; thymic
(mediastinal), alimentary, multicentric (peripheral), and extranodal lymphomas
have been identified and classified as “FeLV-B induced” (Lutz, et al., 2009).
Although single tumours are most common, disseminated tumours involving
multiple organs have been observed on occasion (Reinacher & Theilen, 1987).
The long latency period associated with these diseases (between 2 and 3 years)
implies FeLV-B infection is necessary but not always sufficient for lymphoma
development, and its causative role(s) in these cancer progressions has not been
determined. Notably, the presence of FeLV-B is specifically highly associated
with thymic lymphoma, whereas non T-cell diseases (such as multicentric
lymphoma) are associated with pure FeLV-A infections (Ahmad & Levy, 2010).
This association indicates FeLV-B has an as-yet undefined pathogenic mechanism
which causes such conditions.
It is generally thought that in addition to altering the clinical outcome, the
development of FeLV-B accelerates disease progression, as a solely FeLV-A
infection may remain asymptomatic indefinitely. However recent evidence
indicates that co-inoculation of cats with FeLV-A and –B actually decreases both
the rate of disease progression and development of chronic viraemia in a titre-
dependent manner (Phipps, Hayes, et al., 2000). It may be that the genotype of
the initial infecting FeLV-A contributes to the pathogenicity of the related FeLV-
B.
It has been suggested that the main contributing factor to the increased
pathogenicity of FeLV-B is the extended host range, conferred by the novel use
of the fePit1 receptor. In addition to infection of naïve cells, this would also
allow reinfection of chronically infected cells as the fePit1 protein would not be
downregulated following the initial FeLV-A viraemia. However FeLV-B associated
diseases do not always show a common cellular progenitor indicating this virus
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does not preferentially target and disrupt a specific cell type. For example,
neurological disorders have been associated with FeLV infection (Carmichael,
Bienzle, & McDonnell, 2002) and recent studies found that both FeLV-B and
enFeLV Env glycoproteins allow viral entry into cerebral endothelial cells
(Chakrabarti, Hofman, Pandey, Mathes, & Roy-Burman, 1994). These are
naturally resistant to FeLV-A and –C and so it appears FeLV-B would be the
clinical cause of such symptoms. However this is not routinely observed; it is
therefore highly difficult to predict disease outcome based purely upon the
cellular tropism of the FeLV-B isolate. It is apparent, however, that FeLV-B
formation is a hallmark for increased disease potential in the host. Research
should be conducted into defining the molecular events which redirect disease
outcome to lymphoma and/or leukaemia in such a large percentage of FeLV-B
infections.
1.10 FeLV-C
FeLV-C is unique amongst the FeLV subgroups as it consistently induces pure red
cell aplasia (PRCA) in infected cats, although it is not associated with any
proliferative (neoplastic) disorders. It is extremely rare and is thought to affect
only 1% of FeLV viraemic cats (Hoover, Kociba, Hardy, & Yohn, 1974; O. Jarrett,
et al., 1984; O. Jarrett, et al., 1978; Mackey, Jarrett, Jarrett, & Laird, 1975).
FeLV-C(Sarma), cloned and genetically sequenced in 1986 (Riedel, et al., 1986),
is the prototype FeLV-C isolate. Experimental infections with this molecular
clone induce the hallmark symptoms of FeLV-C infection, being fatal aplastic
anaemia caused by a suppression of erythroid cellular development within 8
weeks of infection (Onions, Jarrett, Testa, Frassoni, & Toth, 1982; Riedel, et al.,
1986). FeLV-C utilises the cellular protein FLVCR1 as a viral receptor (Tailor,
Willett, & Kabat, 1999).
Similarly to FeLV-B, FeLV-C is only found alongside FeLV-A in naturally infected
cats. Experimentally infected weanling kittens can clear FeLV-C infections unless
it is administered alongside FeLV-A, and in these cases FeLV-C viraemia and the
accompanying anaemia only appeared 20 weeks after FeLV-A (O. Jarrett, et al.,
1984). However experimentally infected neonatal kittens can develop chronic
viraemia and PRCA from FeLV-C alone, provided the virus is administered via
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infected cell inoculation directly into the bone marrow (Dornsife, Gasper,
Mullins, & Hoover, 1989). This correlates with two previous hypotheses; that
FeLV in general displays age-restricted infectivity and FeLV-A is required to
function as a helper virus to establish initial FeLV-B and FeLV-C infections (O.
Jarrett, et al., 1984). It has been suggested that FeLV-A Env may pseudotype
FeLV-C genomes, thus increasing the likelihood of the FeLV-C genome reaching
cells wherein it may replicate and establish an infection (O. Jarrett, et al.,
1984).
1.10.1. Evolution of FeLV-C envelope genes
FeLV-C was originally thought to arise through recombination with enFeLV, in a
manner similar to that of FeLV-B (O. Jarrett & Russell, 1978; Overbaugh, Riedel,
et al., 1988) as the SU of FeLV-C(Sarma) possesses two short regions with
homology to enFeLV (Riedel, Hoover, Dornsife, & Mullins, 1988; Riedel, et al.,
1986). FeLV-C also exhibits the extended host range of FeLV-B (thus it is not
ecotropic) but has the additional capacity to infect guinea pig cells. However,
most FeLV-C isolates do not contain enFeLV domains. It is now assumed that
FeLV-C arises within a host after infection with FeLV-A through genetic drift of
the viral genome, although this has never been shown experimentally. This leads
to a switch in both the receptor usage and the pathogenic potential of the
isolate. Thus FeLV-C isolates arise independently of each other, which is
reflected by the lack of highly conserved regions within the Env of individual
isolates (Rigby, et al., 1992), and the final genetic sequence partially reflects
the original FeLV-A isolate. The specific mutations required within the Env
protein to induce the FeLV-C phenotype and the pressures that may influence
these mutations have not been identified.
Early research identified sequences within the RBD of specific isolates that
correlated with the development of PRCA (Riedel, et al., 1988; Rigby, et al.,
1992), and it was established that a mutation of 11 specific amino acids within
this region of FeLV-A was sufficient to confer a FeLV-C cell tropism (Rigby, et
al., 1992). However comparison of the RBDs from independently-isolated FeLV-C
strains did not reveal any similarities, hence there does not appear to be a
specific mutation essential for FeLV-C development. Mutations have been
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identified that are conserved amongst numerous FeLV-C isolates; however when
these are introduced into FeLV-A genomic backbones they do not alter the cell
tropism (Brojatsch et al., 1992) and are not sufficient to induce PRCA. These
mutations are also not conserved between all FeLV-C isolates characterised since
this report.
As these isolates all induced PRCA in their hosts yet possessed differential
mutations in the RBD, it appears that areas other than the traditional RBD of Env
must contribute to both receptor recognition and disease progression. Mutations
may be required across the entire Env protein to induce a switch from THTR1 to
FLVCR and the subsequent PRCA. This hypothesis was supported by studies
utilising chimaeric Env proteins, which found that replacing the 5’ region of the
FeLV-A RBD with that of FeLV-C did not induce hallmark PRCA symptoms (Rey,
Prasad, & Tailor, 2008). Rather, the chimaeric viruses displayed an altered cell
tropism and induced macrocytic anaemia. It was suggested that the chimaeras
may have been able to utilise both THTR1 and FLVCR, albeit with lower
efficiency (Rey, Prasad, et al., 2008).
Further investigations found the C-terminal region of the FeLV-C SU forms a
second RBD, which binds FLVCR1 independently of the prototype N-terminal RBD
(Rey, Prasad, et al., 2008). This “Cdom” is essential for successful viral binding
and entry. Its binding to FLVCR1 is dependent upon the presence of the C2
disulphide-bonded loop within the C terminal of SU. However the sequence of
the C2 loop is highly divergent between FeLV subgroup env genes, indicating it
may indirectly play a role in receptor recognition. Although it appears that Cdom
and the N-terminal RBD interact, soluble Cdom from FeLV-C is able to bind
FLVCR1 in the absence of the N terminal RBD. The Cdom of FeLV-A may also
recognise FLVCR1 independently of the traditional FeLV-C RBD (Rey, Prasad, et
al., 2008). This observation supports the hypothesis that FeLV-C arises through
the genetic drift of FeLV-A, and may explain why individual isolates may possess
divergent sequences and yet consistently induce PRCA. It has been suggested
that whilst the N terminal RBD confers receptor specificity, the Cdom provides a
secondary receptor binding motif which binds to the viral receptor
independently of the RBD, allowing viral entry to occur (Rey, Prasad, et al.,
2008). A potential role for both the C2 loop and Cdom of SU in receptor
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recognition is not restricted to FeLV, as similar hypotheses have been suggested
for other gammaretroviruses (Barnett & Cunningham, 2001; M. Gemeniano,
Mpanju, Salomon, Eiden, & Wilson, 2006; Lavillette, et al., 2001).
The hypothesis that the viral genome undergoes a series of mutations mediating
the transition from FeLV-A to FeLV-C is supported by the recent discovery that
an isolate previously characterised as being a mixture of FeLV-A, -B and –C was
composed of a heterogeneous viral population including a tri-tropic Env protein
able to use THTR1, FLVCR1 and FLVCR2 (Shalev et al., 2009). This Env contains a
PRR and Cdom (including the C2 loop) similar to FeLV-A while the RBD region
displayed mutations conserved with other FeLV-C genomes. This may contribute
to the extended tropism seen in this isolate. It was suggested that this virus is in
an intermediate stage of evolution towards FeLV-C. It is possible that eventually
intermediate FeLV strains lose the ability to utilise feTHTR1 as mutations
accumulate. Henceforth the viral variant would be limited in its transmission
potential, explaining why FeLV-C is unable to transmit between cats.
1.10.2. FeLV-C receptor: feFLVCR1
As with the majority of retroviral receptors, FLVCR1 (feline leukaemia virus C
receptor) is a membrane-spanning cellular transporter, with 12 transmembrane
domains and 6 extracellular loops. The feFLVCR1 cDNA, sequenced prior to the
discovery of the protein’s function, was predicted to encode a protein
approximately 560 amino acids in length, with a molecular weight of 60kDa
(Tailor, et al., 1999). FLVCR1 was subsequently established as a haem exporter,
a member of the major facilitator superfamily (Quigley et al., 2004; Tailor, et
al., 1999).
The intracellular synthesis of haem proteins commences during maturation of
BFU-E (Burst Forming Units – Erythroid) to CFU-E (Colony Forming Units –
Erythroid). Under natural conditions a negative feedback system is in operation,
as the haem proteins regulate the function of a transcriptional repressor, Bach1,
which then regulates the transcription of globin genes (Rafie-Kolpin et al.,
2000). Thus the presence of haem indirectly initiates the production of globins,
which associate with the haem and are subsequently exported. It is hypothesised
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that the wildtype function of FLVCR1 is as an “overflow valve” (Quigley, et al.,
2004), operating to reduce levels of cytoplasmic haem in both erythroid
precursors and erythrocytes. Inhibition of this function (such as binding of FeLV-
C Env proteins) impairs erythroid maturation by increasing the cellular haem
content, eventually leading to cellular apoptosis (Quigley, et al., 2004) and the
non-regenerative anaemia seen in affected cats. Although expression of FLVCR1
is found in multiple haematopoietic lineages (Tailor, et al., 1999), impairment of
this protein is only detrimental to erythrocytes and their progenitors (BFU-E and
CFU-E cells) and does not affect granulocytes (Quigley et al., 2000).
The functional human orthologue, hFLVCR1, displays 88% nucleotide identity and
83% amino acid identity to the feline protein (Tailor, et al., 1999). A paralogue,
hFLVCR2, has also been identified and displays 52% nucleotide identity to
hFLVCR1. Although this protein functions as a haem transporter it cannot
mediate infection by FeLV-C(Sarma) (Duffy et al., 2010). Although murine cells
are resistant to all subgroups of FeLV, the murine FLVCR1 orthologue appears
functional when over-expressed in host cells (Tailor, et al., 1999). There are
multiple domains within FLVCR1 that contribute to its function as a viral
receptor. Specifically, an aspartic acid residue (D487) within extracellular loop 6
confers receptor functionality upon FLVCR2 (J. K. Brown, Fung, & Tailor, 2006).
Conversely this residue is not essential for FLVCR1, as replacement of D487 with
the corresponding asparagine (N463) found in FLVCR2 does not deplete receptor
functionality. The specific sequence of the first extracellular loop also appears
necessary for the receptor function of FLVCR1, although individual essential
residues within this loop have yet to be elucidated (J. K. Brown, et al., 2006).
Rearrangements within the hFLVCR1 gene have been associated with the
presence of Diamond-Blackfan anaemia (Heyn, Kurczynski, & Schmickel, 1974), a
fatal human congenital disorder characterised by an anaemia highly similar to
feline PRCA. Other individuals with a similar disorder express alternatively
spliced isoforms of FLVCR1 RNA transcripts (Rey et al., 2008). Thus impairment
of the natural function of FLVCR1 may occur without viral interactions and may
result in similar disease manifestations.
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1.10.3. Pathogenesis of FeLV-C infection
During erythropoiesis, early erythroid progenitor cells (BFU-E) develop into late
erythroid progenitor cells (CFU-E). CFU-E then develop into erythroid precursor
cells, which later fully differentiate into erythrocytes. FeLV-C infection impairs
the development of CFU-E cells from BFU-E both in vivo (Abkowitz, Holly, &
Grant, 1987) and in vitro (Rojko et al., 1986), depleting the number of
circulating CFU-E cells. The depletion of BFU-E is not as severe (Boyce, Hoover,
Kociba, & Olsen, 1981; Onions, et al., 1982) although their growth kinetics are
affected (Abkowitz, 1991; Abkowitz, Holly, & Adamson, 1987). The decrease in
CFU-E and BFU-E coincides with the appearance of reticulocytopaenia and
precedes the appearance of PRCA by approximately 2 to 3 weeks (Dornsife, et
al., 1989). Clinical PRCA, hallmarked by a non-regenerative absence of
circulating reticulocytes (Cotter, 1979; Mackey, et al., 1975) is evident by 6
weeks following experimental infection (Onions, et al., 1982); until the anaemia
is quite far advanced non-specific clinical signs including fever, weight loss and
fatigue may be observed. The SU domain of the Env of FeLV-C therefore acts as
a dominant-negative protein, effectively inducing the PRCA phenotype by
reducing and/or interfering with the cellular surface display of feFLVCR1
(Quigley, et al., 2000; Quigley, et al., 2004).
Colony Forming Units – Granulocyte-Macrophage (CFU-GM) cells, which originate
and mature in the bone marrow, are infected but not functionally impaired
during FeLV-C infection (Rojko, et al., 1986; Testa, Onions, Jarrett, Frassoni, &
Eliason, 1983), however myelofibrosis (the replacement of bone marrow with
scar tissue or collagen) has been observed in numerous FeLV-C infections (J. C.
Olsen & Watson, 1980; Onions, et al., 1982). A pathogenic mechanism has not
been determined and it is not known if this contributes to disease symptoms. It
has been suggested that most cats simply die before these symptoms develop.
FeLV-C replication is also associated with the aggregation and subsequent
apoptosis of T lymphoma cells, a phenomenon only seen in infection with either
FeLV-C or FeLV-C-based recombinants (Pandey, et al., 1991). This is thought to
be due to the higher transcriptional activity of the FeLV-C LTR in these cell lines
compared to fibroblastic cultures (Rojko et al., 1992). The implications of this
phenomenon for the host have not been examined.
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There have been attempts to treat the erythroid aplasia seen in FeLV-C
infections with human interferon-α, however these treatments have produced 
conflicting results (Cummins, Tompkins, Olsen, Tompkins, & Lewis, 1988;
Kociba, Garg, Khan, Reiter, & Chatfield, 1995). Treatment of naturally infected
cats which displayed FeLV-C-associated disease with bovine interferon-β also 
reported a decrease in symptoms and short-term recovery (Tompkins &
Cummins, 1982). This is intriguing as FeLV-C infection disrupts the natural
development of erythroid progenitor cells, making regeneration of erythrocytes
highly unlikely whilst the virus is still actively replicating. Generally FeLV-C is
regarded as fatal and with limited options for treatment.
1.11 FeLV-T
FeLV-T was isolated from a FeLV-A infected cat (Rohn, Linenberger, Hoover, &
Overbaugh, 1994) and is a T-cell tropic subgroup of FeLV that induces lymphoid
depletion and immunodeficiency in hosts. It appears to utilise the Pit1 receptor,
despite having an apparently-THTR1-binding domain within Env. This is partially
due to the lack of a functional fusion motif in the 5’ region of SU, as the
prototype FeLV-T virus possesses an asparagine (N) in place of the required
histidine (H) in the fusion motif of SU (SPNQ, not SPHQ). To rescue this defect in
cellular entry, FeLV-T requires expression of a cofactor in order to successfully
infect T-lymphocytes (FeLIX). FeLV-T is the only gammaretrovirus identified to
date that requires a cofactor for cellular entry (Lauring, et al., 2001; Overbaugh
& Bangham, 2001) and thus does not display a traditional receptor-virus
relationship. FeLIX (FeLV Infectivity X-accessory protein) is a truncated enFeLV
envelope protein expressed in certain feline tissues, including T cells (Anderson,
et al., 2000; Lauring, et al., 2001). As Pit1 is widely expressed in feline cells,
FeLIX expression is the main factor limiting the tropism of FeLV-T. A mechanism
of infection regarding how the combination of FeLV-T and FeLIX utilise the Pit1
receptor has not yet been elucidated.
FeLV-associated feline AIDs (FeLV-FAIDS) had been described prior to the
discovery of FeLV-T, and the recent characterisation of FeLV-T and FeLIX mean
that these observations may now be reinterpreted. For example, early research
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identified an isolate that induced immunodeficiency, displayed a host range
limited to T cells, and required the presence of a closely-related helper virus
(Overbaugh, Donahue, Quackenbush, Hoover, & Mullins, 1988; Overbaugh et al.,
1992). It is possible that this virus strain was an early isolation of FeLV-T.
1.11.1. FeLV-T envelope, FeLIX and Pit1 binding
FeLV-T arose through mutations in the SU domain of FeLV-A and the two
subgroups display approximately 96% nucleotide identity (Donahue et al., 1991;
Overbaugh, Donahue, et al., 1988). It is assumed that FeLV-T arose through
genetic drift in a manner similar to that of FeLV-C (Gwynn, Hankenson, Lauring,
Rohn, & Overbaugh, 2000; Rohn, Moser, Gwynn, Baldwin, & Overbaugh, 1998).
The switch in receptor usage may result in FeLV-T being able to re-infect the
initially infected cells, despite the down-regulation of the FeLV-A receptor
(feTHTR1) which would usually prevent super-infection. This correlates with
early evidence that FeLV-FAIDS isolates did not establish interference against
homologous challenge (Moser, et al., 1998; Rohn, et al., 1998).
FeLV-T receptor specificity (that is, the ability to utilise Pit1 alongside a
requirement for FeLIX expression) has been attributed to amino acids 6, 7 and 8
of the SU protein and the presence of a four amino acid insertion, with an
additional adjacent mutation, in the C terminal of envelope glycoprotein (Cheng
et al., 2006). This supports mounting evidence that both the C and N terminal
regions of Env contribute to the receptor usage of FeLV variants, not merely the
traditional RBD. This is further supported by the fact that some viruses
displaying chimaeric envelope glycoproteins can utilise FeLV-C and FeLIX entry
pathways (Cheng, et al., 2006).
FeLIX is 273 amino acids in length and displays 92.3% identity to the FeLV-B SU
domain; in fact FeLV-B SU domains can functionally substitute for FeLIX
(Lauring, Cheng, Eiden, & Overbaugh, 2002). It also possesses a putative signal
peptide marking it for extracellular transport and is therefore a secreted
peptide, as it lacks the hydrophobic transmembrane anchor. The secretion of
FeLIX is confirmed by the fact that it functions in trans, as cell-free FeLIX
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renders previously resistant Pit1-expressing cell lines susceptible to FeLV-T
infection. However secretion is not essential for FeLIX function (Anderson, et
al., 2000). Studies of the crystal structure of FeLIX indicate that it aids infection
by catalysing the membrane-fusion event following receptor binding (Barnett,
Wensel, Li, Fass, & Cunningham, 2003). This supports suggestions that FeLIX is
an endogenous Env peptide that may rescue non-functional exogenous FeLV
isolates. The concept of a soluble RBD transactivating the entry of heterologous
retroviruses has been raised previously. In the case of the porcine endogenous
retroviruses, the ability to infect otherwise restrictive cells is due to the
presence of a soluble heterologous RBD and its cognate receptor (Lavillette &
Kabat, 2004). It is possible that FeLIX allows entry of all non-functional FeLV
isolates in this manner, regardless of their individual subgroup.
Notably, even though FeLV-B is able to utilise Pit2 for cellular entry, only Pit1 is
able to mediate the binding of either FeLV-B SUs or FeLIX to allow FeLV-T
progressive infection. Studies involving chimaeric Pit1/2 proteins have identified
three regions within Pit1 that determine successful FeLIX binding, however these
are not required for FeLV-B infection (Lauring, et al., 2002). Pseudotype assays
with both FeLV-B and FeLV-T envelopes, conducted in the presence of soluble
FeLIX indicated that FeLIX does not interfere with FeLV-B infection, confirming
that they utilise different regions of Pit1 during viral binding (Shojima, Nakata,
& Miyazawa, 2006). Therefore in addition to FeLIX, FeLV-T itself may be
required to bind to Pit1 to ensure successful infection (Lauring, et al., 2002). To
date, although FeLIX binding to Pit1 is known to be essential for FeLV-T
infection, it is not known if FeLV-T itself is able to bind to any cellular receptor.
1.11.2. Pathogenesis of FeLV-T infection
FeLV-induced immunosuppression occurs in every infected cat to a degree, as all
FeLV subgroups are able to infect haematopoietic cells. It may have numerous
manifestations, including thymic atrophy, lymphopaenia, neutropaenia, and the
loss of CD4+ and CD8+ lymphocytes (Ogilvie, Tompkins, & Tompkins, 1988;
Orosz, Zinn, Olsen, & Mathes, 1985a, 1985b; Perryman, Hoover, & Yohn, 1972).
FeLV-FAIDS is clinically characterised by persistent viraemia, weight loss and
lymphoid hyperplasia followed by severe lymphoid depletion and a subsequent
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high susceptibility to opportunistic secondary infections (Hoover, Mullins,
Quackenbush, & Gasper, 1987). These clinical symptoms are assumed to be a
result of cytopathic effect (CPE) within the infected lymphocytes, as FeLV-T
infection of T cells induces syncytia in vitro (Rohn, et al., 1998). In addition to
the lack of circulating T lymphocytes, immunosuppression may be partially due
to the impaired ability of FeLV-T infected hosts to produce a primary antibody
response against invading pathogens. This is associated with the presence of a 34
amino acid region within the C terminal of the SU domain of FeLV-T isolates.
Although a mechanism has not been identified, it is thought that these isolates
may display a heightened ability to infect and impair the function of certain
immune cell subsets (Quackenbush et al., 1990).
Experimental inoculation of cats indicates a fatal immunodeficiency develops
after an incubation period as short as 60 days, dependent on the age of the cat
upon inoculation (Mullins, Chen, & Hoover, 1986). However survival rates depend
highly upon the rate of immunosuppression; cats displaying a rapid depletion of
circulating T-lymphocyte progenitor cells usually survive for approximately 3
months after the onset of clinical symptoms (Quackenbush, Mullins, & Hoover,
1989). However survival for up to a year has been observed in individuals
displaying gradual immunosuppression, although this is associated with a higher
rate of extranodal lymphoma (Hoover, et al., 1987; Mullins et al., 1989).
Unusually high levels of un-integrated viral DNA are often observed prior to the
onset of clinical symptoms, mainly within the bone marrow, intestine and
lymphoid tissues (Mullins, et al., 1986; Mullins, et al., 1991). Although it is
difficult to detect in vivo due to the low level of synchronously infected cells, in
vitro studies indicates this occurs a few days after infection (Hofmann-Lehmann,
et al., 2001). It is not known if this contributes to or is a symptom of the clinical
diseases seen in these infections.
It has been suggested that “discordant” cats, which present with antigenaemia
but are negative in virus-isolation assay, may be infected with fusion-defective
FeLV-T-like isolates which utilise the endogenous FeLIX expressed in T-
lymphocytes. An assay has therefore been developed recently to detect
defective FeLV-T virions in clinical samples. This relies upon an indicator cell
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line which constitutively expresses FeLIX, thus allowing the otherwise-defective
virus to replicate and induce a hallmark syncytia in the monolayer (Nakaya,
Shojima, Hoshino, & Miyazawa, 2010). It remains to be seen whether this assay
proves informative in the characterisation of potentially-defective viruses. It is
true that isolates possessing defective fusion motifs have been identified
previously (Chandhasin, et al., 2005), however as these were present within a
whole viral population they may not require FeLIX expression to enter a cell.
Although there are numerous aspects of FeLV-T infection and replication which
remain un-investigated, the extreme rarity of this subgroup makes this research
less of a priority compared to further characterisation of the pathogenic –B and –
C subgroups.
1.12 Other feline retroviruses
Apart from FeLV, there are numerous other infectious retroviruses of felines
which differ in their pathogenicity and disease associations. Two of these are
complex retroviruses; feline immunodeficiency virus (FIV) is a highly pathogenic
lentivirus, whilst feline foamy virus (FeFV) is an entirely apathogenic
spumavirus. Within the simple retroviruses, feline sarcoma virus (FeSV) is a rare
derivative of FeLV associated with spontaneous sarcoma development.
Additionally, the domestic cat genome contains numerous non-FeLV related
endogenous retroviral elements, including the infectious retrovirus, RD114.
1.12.1. Feline immunodeficiency virus
FIV was isolated in 1986 in the USA (N. C. Pedersen, Ho, Brown, & Yamamoto,
1987). As a lentivirus, it is a complex retrovirus displaying high similarity in both
its genomic structure and pathogenic mechanisms to HIV. However HIV is
commonly transmitted through sexual contact, whereas the primary mode of
transmission of FIV is via salivary transmission. FIV has a worldwide distribution
and the prevalence of infection varies between 1 and 15% of healthy cats,
according to geographic region. Some estimates reach an infection rate of 44%
amongst sick cats (Miyazawa & Mikami, 1993).
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FIV infection is associated with a range of diseases, including gingivostomatitis,
anaemia, neurological conditions and various degrees of immunosuppression
(Ishida, Washizu, Toriyabe, & Motoyoshi, 1988; Yamamoto et al., 1989).
Although FIV is often regarded as a fatal infection, disease progression may only
occur after a long latency period. FIV is thought to escape immune clearance
during this period by acquiring mutations in immunodominant hypervariable
regions (Pancino et al., 1993). It is not known whether FeLV utilises a similar
mechanism to avoid viral clearance.
The initial acute phase of FIV infection is characterised by high viral loads in
circulating blood. This is followed by an extended asymptomatic phase during
which cats may not be shedding infectious virus particles. The third phase of
infection is characterised by a generalised lymphadenopathy, followed by severe
AIDS-related disorders and a final terminal AIDS condition. Opportunistic
infections, including upper respiratory tract infections and gastrointestinal
problems, commonly occur during this latter period, at which point the immune
system is chronically depleted (Ishida & Tomoda, 1990; Miyazawa, 2002).
Vaccines that induce protective immunity are commercially available, however
as vaccinated cats are serologically indistinguishable from infected cats their use
is not routinely recommended (J. Levy, et al., 2008). Cats produce antibodies
against SU, TM, and multiple gag-encoded proteins after approximately four
weeks of infection (Hosie & Jarrett, 1990). However the duration of this humoral
response is questionable (Kohmoto et al., 1998). Protection is also provided by
CTL activity which contributes to viral clearance (Flynn et al., 1995).
Similar to FeLV, the FIV genome contains the gag, pol, and env essential genes
(Maki et al., 1992; Olmsted, Hirsch, Purcell, & Johnson, 1989). However unlike
gammaretroviruses the Gag and Pol proteins are not produced from a singular
polyprotein; although a single RNA transcript is produced, Pol is only translated
following a ribosomal frameshift (Morikawa & Bishop, 1992). Additionally, both
the TM and SU domains of Env are heavily glycosylated (Maki, et al., 1992;
Olmsted, et al., 1989; Poss, Dow, & Hoover, 1992), in comparison to FeLV where
glycosylation is restricted to the SU domain. FIV also contains three accessory
genes, vif, rev and ORF-A. Rev is a regulatory protein involved in the transport
63
of immature viral mRNAs from the nucleus into the cytoplasm preceding
translation (Kiyomasu et al., 1991; Phillips et al., 1992; Tomonaga et al., 1993).
The role of ORF-A has yet to be fully elucidated, however it appears to be
involved in post-transcriptional processing of RNA and is essential for viral
infectivity (M. C. Gemeniano, Sawai, Leutenegger, & Sparger, 2003). The Vif
(viral infectivity factor) protein is conserved amongst lentiviruses and is critical
for virus expression from otherwise-resistant cells.
1.12.2. Feline foamy virus
Feline foamy virus (FeFV), also known as feline syncytium-forming virus, is a
complex retrovirus of the Spumavirus genus. It was isolated in 1969 (Fabricant,
Rich, & Gillespie, 1969; Riggs, Oshirls, Taylor, & Lennette, 1969) and
epidemiological studies indicate a worldwide distribution amongst both domestic
and wild felids (Daniels, et al., 1999; Winkler, Lochelt, & Flower, 1999).
Prevalence of infection is estimated to be between 14 to 28% of domestic cats
(Miyazawa, 2002) however it has been suggested that this may rise to 70%
amongst older cats (Flower, Wilcox, Cook, & Ellis, 1985; Winkler, Flugel,
Lochelt, & Flower, 1998; Winkler, et al., 1999). This is reflective of the fact that
infections are of a lifelong duration with chronic viraemia (German, Harbour,
Helps, & Gruffydd-Jones, 2008; Meiering & Linial, 2001). The virus displays a
broad cell tropism both in vitro and in vivo (German, et al., 2008) (Gaskin &
Gillespie, 1973), although the receptor has yet to be identified. Additionally, the
methods of transmission have not been elucidated (Winkler, et al., 1999),
although it is suspected to be through mutual grooming and/or fighting (i.e., an
oronasal primary route of transmission, similar to that of FeLV and FIV).
Spumaviruses are generally regarded as apathogenic (Meiering & Linial, 2001).
However CPE, including syncytia formation and vacuolisation leading to
apoptosis, has been observed in some infected cell lines (Meiering & Linial,
2001) and there has been recent controversy regarding whether or not they are
truly apathogenic (German, et al., 2008). FeFV infection has been associated
with chronic progressive arthritis, although this may merely be due to the high
prevalence of the virus (N. C. Pedersen, Pool, & O'Brien, 1980). Supporting this
hypothesis is the fact that experimentally infected cats did not display any
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clinical symptoms through six months of infection, although histopathology was
noted in the lungs and kidneys upon autopsy (German, et al., 2008). Multiple
previous studies of experimentally infected cats also indicated FeFV is purely
apathogenic (Schwantes, Ortlepp, & Lochelt, 2002) (Alke, Schwantes, Zemba,
Flugel, & Lochelt, 2000; Gaskin & Gillespie, 1973). Despite the asymptomatic
infection, cats mount immune responses to FeFV infection and antibodies can be
detected approximately two weeks post-infection (German, et al., 2008). This
serology can be used to distinguish between the two genetically-distinct
subtypes of FeFV (Flower, et al., 1985) which display 57% nucleotide identity
within the SU domain of their Env proteins (Winkler, et al., 1998). However this
does not correlate to differences in their host range, as would be expected for
FeLV.
As spumaviruses are complex retroviruses, their genomes contain additional
accessory genes as well as the standard gag, pol and env ORFs. FeFV possesses
two accessory genes, both encoding non-structural proteins; tas (previously
termed bel-1) and bet. The bet ORF is not essential for viral replication and is
thought to aid in viral cellular defence by binding to feline restriction factors
(Chareza et. al., 2012). However the Tas protein is essential for viral replication
and plays a role in transactivation of the LTR promoter elements (Keller et al.,
1991). Despite the conserved presence of accessory genes, there are numerous
features that distinguish spumaviruses from their complex lentiviral relatives:
(1) Although the majority of intracellular (immature) virions contain viral RNA,
mature foamy virus particles contain DNA (Roy et al., 2003). The RNA is reverse
transcribed within the particle before viral adsorption and cell entry (Yu,
Baldwin, Gwynn, Yendapalli, & Linial, 1996).
(2) Spumavirus genomes contain an internal promoter within the env gene which
drives transcription of both tas and bet (Lochelt, Flugel, & Aboud, 1994).
(3) FeFV pol genes are expressed from spliced sub-genomic transcripts (Bodem,
Lochelt, Delius, & Flugel, 1998), whereas in other retroviruses a large
polyprotein is translated and cleaved into the respective viral enzymes.
(4) The FeFV virions appear immature, even after budding (a hallmark of
spumaviruses). This is partially due to inefficient cleavage of the Gag
polyproteins and to the Env protein containing a different leader peptide to
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other retroviruses. This induces virion release from the ER, rather than the
plasma membrane (Goepfert, Wang, & Mulligan, 1995).
(5) FeFV is also unique as the Gag proteins do not localise to the nucleus at any
point in the viral replication cycle (Bodem, et al., 1998), unlike the simian
foamy viruses (Schliephake & Rethwilm, 1994). The Gag proteins of other
retroviruses (including FeLV) translocate to the nucleus in order to interact with
nucleic viral RNA prior to nuclear export (Garbitt-Hirst, Kenney, & Parent,
2009).
Due to its apathogenicity and broad cell tropism, FeFV has not been studied in
detail in recent years, and the majority of recent research has centred around
its use as a viral vector for gene therapy applications (Bastone & Lochelt, 2004;
Schwantes, Truyen, Weikel, Weiss, & Lochelt, 2003). Interest in the
spumaviruses has also been revived recently by the discovery of an endogenous
spumavirus within the genome of the two-toed sloth (Choloepus hoffmanni)
(Katzourakis, Gifford, Tristem, Gilbert, & Pybus, 2009) indicating these viruses
have been present as infectious agents of mammals for at least 100 million
years. This was the first endogenous foamy virus to be characterised and indeed
one of the first endogenous complex retroviruses (the first being the discovery of
an endogenous lentivirus of rabbits in 2007 (Katzourakis, Tristem, Pybus, &
Gifford, 2007)).
1.12.3. Feline sarcoma virus
Feline sarcoma virus (FeSV) is a rare retrovirus which induces approximately 2%
of fibrosarcomas in cats. Although this virus has not been the focus of recent
studies, early research indicated it was especially prevalent in young cats
presenting with fibrosarcomas (Snyder, 1971). FeSV isolates are all genetically
unique, as the virus arises from recombination events between exogenous FeLV-
A and host cellular DNA (Frankel, Gilbert, Porzig, Scolnick, & Aaronson, 1979;
Guilhot, Hampe, D'Auriol, & Galibert, 1987). The recombination events ensure
the FeSV genome does not contain intact env sequences; thus all FeSV viruses
are replication defective (Henderson, Lieber, & Todaro, 1974) and require the
continued presence of replicating FeLV to spread. Infected cells therefore
express chimaeric virus-host proteins that induce malignancy. Although the
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specific oncogenic mechanism differs between isolates, the activation and
transduction of a cellular proto-oncogene is essential. For example, the fes gene
is activated in the Snyder-Theilen FeSV strain (Sherr, Fedele, Oskarsson, Maizel,
& Woude, 1980), inducing transformation of the infected cells.
Although systemic FeLV viraemia may be observed in the affected cat, the FeSV
virus is contained within the tumour itself (de Noronha, Grant, Lutz, Keyes, &
Rowston, 1983). Therefore FeSV is not transmissible under natural conditions,
although cats have been experimentally infected with a mixture of both FeSV
and FeLV viruses (de Noronha, et al., 1983). Transfection of naïve cells with the
recombinant proviral genome, in the absence of FeLV, is also sufficient to induce
initial transformation of the host cell (Barbacid, 1981) although the virus is
unable to spread.
FeSV has been reported worldwide and there is no indication that specific FeLV-
A strains are more likely to result in FeSV formation. However there is evidence
of preferential transduction and activation of cellular tyrosine-specific protein
kinases (Barbacid, Beemon, & Devare, 1980; Hampe, Gobet, Sherr, & Galibert,
1984; Naharro et al., 1983; Van de Ven, Khan, Reynolds, Mason, & Stephenson,
1980; Ziemiecki et al., 1984). These genes tend to be highly conserved across
species and transduction of orthologues by other oncogenic retroviruses has been
documented (reviewed in Hampe, et al 1984) therefore they may represent
common retroviral integration sites. FeSV-induced tumours are also distinct from
the vaccination site-associated sarcomas initially described in 1991 (Hendrick &
Goldschmidt, 1991). These are associated with an increased inflammatory
response following vaccination with adjuvanted inactivated FeLV and rabies
vaccines (Hendrick, Goldschmidt, Shofer, Wang, & Somlyo, 1992; Macy, 1995).
FeSV was previously associated with the presence of FOCMA (feline oncornavirus-
associated cell-membrane antigen) (Essex, Grant, Cotter, Sliski, & Hardy, 1979),
which was originally termed a “non-virion tumour specific surface antigen”
(Sliski, Essex, Meyer, & Todaro, 1977). FOCMA is detected at the cellular surface
of infected lymphoid cells within the tumour, but not within non-transformed
cells regardless of their FeLV status. It was thought to be a cellular protein,
induced by either transformation events or the expression of FeSV recombinant
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proteins (Sliski, et al., 1977) as it was found to be immunologically distinct from
viral antigens (Stephenson, Essex, Hino, Hardy, & Aaronson, 1977). It was also
suggested that FOCMA may be incorporated into FeSV pseudotypes (Sliski &
Essex, 1979), therefore cats with sufficient anti-FOCMA antibodies will clear
FeSV infection and exhibit tumour regression, while FeLV continues to circulate
(Essex, 1977; Essex, Klein, Snyder, & Harrold, 1971).
However FOCMA is now known to be a combination of several viral components
and not a tumour-specific antigen as previously thought (Lutz, et al., 2009). The
absence of previous evidence for this may be partially explained by the fact that
although anti-FOCMA MAbs displayed high reactivity to FeLV-C antigens (Vedbrat
et al., 1983), the antibodies only bound to immature viral particles. FOCMA-
specific antibodies were also found in the sera of FeLV “regressor” cats, which
had successfully cleared the active infection but may express occasional
immature viral proteins (Rojko, et al., 1982).
1.12.4. Endogenous retroviruses: RD114 and FcEV
The genome of the domestic cat, Felis catus, contains ERVs from 3 families,
being the primate retrovirus MAC-1, RD114- and FeLV-related elements (enFeLV)
(O'Brien, 1986). Recently a further ERV, Felis catus endogenous virus (FcEV) was
identified as a Type C ERV present as multiple defective copies throughout the
domestic cat genome (van der Kuyl, Dekker, & Goudsmit, 1999).
Similarly to enFeLV, the RD114 viruses are only found within the Felis genus and
have been identified in the genomes of numerous wild small felids (Benveniste &
Todaro, 1975; Reeves & O'Brien, 1984). The Felis genus split from the Felidae
main lineage approximately 6.2 million years ago (W. E. Johnson, et al., 2006),
indicating exogenous RD114 integrated into the Felis ancestral germline at this
time. RD114 is a recombinant retrovirus possessing the gag-pol and LTR regions
of FcEV (van der Kuyl, et al., 1999) alongside the env gene of baboon
endogenous retrovirus, an inducible endogenous betaretrovirus found in
numerous primate species. Comparison of the baboon endogenous retrovirus and
FcEV genomes identified two highly homologous regions which would facilitate
recombination (van der Kuyl, et al., 1999). FcEV and RD114 also both contain an
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intergenic spacer between the pol and env genes (van der Kuyl, et al., 1999),
which is unusual for gammaretroviruses (Thayer et al., 1987). During
recombination these regions ensured reading frames were not disrupted,
allowing for the production of a functional retrovirus.
RD114 belongs to the Type D interference group (Sommerfelt & Weiss, 1990) and
the RD114 receptor is a neutral amino acid transporter (Rasko, Battini,
Gottschalk, Mazo, & Miller, 1999; Schnitzer, Weiss, Juricek, & Ruddle, 1980).
This gene is highly conserved between species and widely expressed across
various tissues (Green, Lee, & Rasko, 2004). The in vitro host range of RD114 is
therefore broad and yet does not include murine cells, similarly to FeLV (Kakimi
et al., 1990; Rasko, et al., 1999). Until recently RD114 was regarded as an
endogenous xenotropic virus as the majority of virus isolates could not
exogenously infect feline cells (Livingston & Todaro, 1973). Although released at
low levels in numerous feline cell lines (Baumann, Gunzburg, & Salmons, 1998;
East, Knesek, Allen, & Dmochowski, 1973; Fischinger, Peebles, Nomura, &
Haapala, 1973; O. Jarrett & Ganiere, 1996; Okabe, Gilden, & Hatanaka, 1973)
and inducible in others (Livingston & Todaro, 1973; Todaro, Benveniste, Lieber,
& Livingston, 1973) it was not thought to be expressed in vivo. However there is
recent evidence that RD114 may be able to infect various feline cells (Sakaguchi,
Okada, Shojima, Baba, & Miyazawa, 2008), although mechanisms to restrict this
may exist. Resistance to infection by two RD114-related viruses with distinct
envelope proteins has been observed (Haapala, Robey, Oroszlan, & Tsai, 1985),
indicating some feline cells restrict viral infection via an envelope glycoprotein-
independent method. This is in addition to a reported novel restriction
mechanism, which indicated that both the producer cell line and the
glycosylation state of the host cell receptor determine the infectious titre of the
virus (Dunn, Yuan, & Blair, 1993), similar to results found in ecotropic MLV
studies (Knoper, et al., 2009). There is also evidence that host-mediated
silencing may reduce potential proviral expression (Spodick, Ghosh, Parimoo, &
Roy-Burman, 1988). The extent of this silencing may be reduced in tissue
culture, leading to the elevated retroviral expression in vitro compared to that
found in actual tissue.
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The copy number of FcEV and RD114-related sequences within the domestic cat
genome is approximately 20 (Reeves, Nash, & O'Brien, 1985). However, only a
single copy of RD114 is responsible for viral production (Reeves, et al., 1985).
The fact that the env genes of many FcEV proviruses are heavily deleted whilst
RD114 has maintained functionality indicates there is a selective pressure upon
RD114, supported by the fact that all RD114-related proviruses identified to date
contain intact LTRs (Reeves, et al., 1985). There may be pressure to maintain
functional 5’ LTRs to drive transcription of the gag-pol genes, which would
contribute to the intracellular transcripts found in many studies (Niman, et al.,
1980).
Increased RD114 expression has been observed in numerous malignant tissues,
predominantly lymphomas. However many of the cancer-affected cats exhibiting
elevated RD114 expression were also exogenously infected with FeLV. It is
possible that expression of RD114 is up-regulated following FeLV infection,
although whether this is a contributing factor to cancer development or a
subsequent effect has not been determined. However FeLV-negative lymphomas
also exhibit elevated RD114 expression in some cases (Niman, Stephenson,
Gardner, & Roy-Burman, 1977), indicating the putative FeLV-R114 interaction is
not essential for RD114 production in malignant tissues. There are also reports of
CPE (mainly syncytia formation) occurring in numerous infected cell lines
(Germain, Roullin, Qiao, de Campos Lima, & Caruso, 2005; Klement & McAllister,
1972; Rand & Long, 1973). Despite these observations, no diseases are
definitively associated with RD114 expression or infection and there is no
evidence that domestic cats produce RD114-specific antibodies (Mandel,
Stephenson, Hardy, & Essex, 1979). Research upon this endogenous virus is
therefore not a priority when compared to the numerous aspects of FeLV which
require attention.
1.13 Scope and aims of this thesis
After an extensive review of the literature, it is apparent that despite the
volume of research conducted since the discovery of FeLV (W. F. Jarrett, et al.,
1964) there remains many areas in which further study is required. These include
clinical aspects, such as the development of safer and more efficient vaccines
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and treatments, identification of the protective correlates of the feline immune
response and the respective roles of both VNAs and CTL responses in FeLV
protection. Considering the threat FeLV represents to endangered wild felids,
such as the Iberian lynx and Florida panthers (M. A. Brown, et al., 2008; Luaces
et al., 2008), this should be a priority for FeLV research despite the decreasing
prevalence of the virus in domestic cats.
In addition to clinical research, there are many questions regarding FeLV
genetics and retroviral biology that require renewed attention, such as
investigating the factors which restrict inter-host transmission of FeLV-B and -C.
Considering the recent advancements in molecular biology and ever-expanding
knowledge of host-retroviral interactions (mainly due to HIV research), many of
these areas may now be revisited.
Firstly, as FeLV-B and –C are highly pathogenic, it is of significant interest to
ascertain which factors influence the development of these subgroups within the
host. Is it purely based upon the infectious strain or do host-derived factors play
a role in the development of FeLV variants? If FeLV-B evolution simply requires
the presence of enFeLV transcripts, what factors prevent transmission of either
wholly enFeLV virions and/or purely FeLV-B viruses to naïve hosts? The recent
discovery of polymorphic putatively-functional enFeLV genomes (Roca, et al.,
2004) has provided novel tools which will prove useful for this research.
Regarding FeLV-C evolution, what factors influence the development of these
viral variants, and why does this occur in only a minority of natural infections? Is
development of FeLV-C purely due to the genotype of the initially infectious
FeLV-A; or does the host immune system affect FeLV-C development, in a
process similar to that seen in other retroviruses to escape the humoral
response? The recent discovery of dual-tropic Env variants in a FeLV-C primary
isolate (Shalev, et al., 2009) suggests that FeLV-A evolves into FeLV-C through
the stepwise acquisition of mutations. If this is the case, can this process be
mimicked in vitro and the Env determinants of FLVCR1 usage mapped?
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It is apparent that these questions, which may have been difficult to address
previously, now have the potential to be solved using modern molecular
techniques. The overall aims of this thesis were therefore:
- To identify Env determinants which may predispose FeLV-A strains to
preferentially develop into FeLV-C variants;
- To investigate potential roles of the host humoral response in FeLV-C
evolution;
- To determine the potential for inter-host FeLV-B transmission without the
additional presence of a FeLV-A “helper” virus;
- To characterise the functionality of enFeLV elements and the possibility
of enFeLV horizontal transmission between hosts.
The results of these investigations will contribute to the knowledge of feline
genetics and immunology, FeLV clinical prognosis and retroviral biology and
evolution.
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2. Materials and Methods
2.1 Cell culture techniques
2.1.1. Maintenance of cell lines
Mus dunni tail fibroblast (MDTF) cells (ATCC Catalogue CRL-2017) and guinea
pig foetal (104C1) cells (C. H. Evans, Cooney, & DiPaolo, 1975) were
maintained in low-glucose DMEM (Life Technologies, Paisley, U.K.),
supplemented with 10% foetal bovine serum, 100U/mL penicillin and
100µg/mL streptomycin. MDTF cells expressing the human Pit1 protein were
kindly donated by Prof C. Tailor, University of Toronto.
Human embryo kidney (HEK293T) cells (Graham, Smiley, Russell, & Nairn,
1977) and QN10 (S+L- feline embryonic fibroblastic AH927) cells were
maintained in high-glucose DMEM (Life Technologies), supplemented with 10%
foetal bovine serum, 100U/mL penicillin and 100µg/mL streptomycin.
Feline embryo A (FEA) cells (O. Jarrett, et al., 1973) were maintained in high-
glucose DMEM (Life Technologies), supplemented with 10% foetal bovine
serum, 100U/mL penicillin, 100µg/mL streptomycin, 2mM L-Glutamine and 0.1
mg/mL sodium pyruvate. FEA cells chronically infected with multiple strains
and isolates of FeLV were obtained from the University of Glasgow Companion
Animal Diagnostics facility.
All cells were regularly subcultured when approaching confluency. During
subculturing, cells were washed with phosphate-buffered saline (PBS) and
treated with 0.5-2mL of 0.05% Trypsin-EDTA (Life Technologies).
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2.1.2. Transient transfection of adherent cells
Adherent cells were transfected with Superfect Reagent (Qiagen, Crawley,
U.K.) according to the manufacturer’s protocol. Cells were seeded the day
before transfection into 10cm plates, to approximately 60% confluency. The
day of transfection, 60µL of Superfect reagent was mixed with 12µg plasmid
DNA and made up to 300µL with incomplete, serum and antibiotic-free DMEM.
Following 15 minutes incubation at room temperature, the DNA-Superfect
complexes were then added directly to the cells and allowed to incubate for 3
hours at 37°C. DNA complexes were then removed and complete DMEM added
to plates. After three days, transfection products were harvested, passed
through a 0.45µm filter and stored at -80°C prior to use.
2.1.3. X-Gal staining of lacZ-expressing cells
Pseudotypes encapsidating transcripts of the pMFG plasmid lead to expression
of the lacZ reporter gene after infection of the target cell. X-gal staining was
performed to detect this expression. Briefly, confluent monolayers of cells
were washed in PBS before being fixed with 0.5% glutaraldehyde (in PBS) for a
minimum of 30 minutes. Fixative solution was removed and cells re-washed
before the addition of staining solution (PBS containing 0.02% X-Gal, 3mM
ferro-cyanide, 3mM ferri-cyanide, 1.3mM MgCl2). Plates were stored at 4°C
overnight before the lacZ-expressing cells (indicated by a blue appearance)
were counted manually.
2.1.4. Stable transduction of cell lines
To engineer MDTF cell lines that stably expressed specific retroviral receptors,
adherent cells were infected with VSV-G-enveloped pseudotypes. The
pseudotypes encapsidated transcripts of the pFB-NEO plasmid containing the
cDNA of the desired receptor. Constructs were kindly provided by Prof. C.
Tailor, University of Toronto. Prior to transduction, 1x105 cells were seeded in
a T25 flask (Thermo Scientific, Loughborough, U.K.) and allowed to adhere
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overnight. The media was then removed and 2mL of pseudotypes, including
4µg/mL hexadimethrine bromide (polybrene, Life Technologies), was added on
to the cells. After eight hours incubation, this medium was removed and
replaced with whole DMEM. Selection of transduced cells was induced two to
three days later by the addition of 800µg/mL G418 (Life Technologies). Cells
were subcultured twice weekly upon confluency for three weeks, at which
point G418 concentration was reduced to 400µg/mL to maintain expression of
the target genes.
2.1.5. Interference assay
Interference assays are a traditional technique in retrovirology used to classify
receptor usage of novel viruses. FEA cells chronically infected with FeLV-A, -B
and –C (“indicator” cells) were kindly provided by the Companion Animal
Diagnostics Unit, University of Glasgow. To classify novel FeLV strains, naïve
FEA cells were infected with a sample of the primary isolate and cultured for
10 days. At this point, supernatant from the cells was titrated upon the
various indicator cells lines. 3 days post-infection, cells were scored for
cytopathic effect. Superinfection was indicated by the presence of multiple
rounded, apoptosing cells, as opposed to the fibroblastic monolayer of FEA
cells usually displayed. A lack of superinfection indicated the novel sample
contains that particular subgroup of FeLV as the downregulated receptor is not
available for cellular entry.
2.1.6. Reverse interference assay
Traditional interference assays require the viruses to have identical producer
cell lines (in the case of FeLV, FEA cells are used). For this reason, reverse
interference assays were utilised to compare receptor usage of viruses from a
range of producer cells, including HEK293Ts. Reverse interference assays also
allow detection of which viral receptors are masked or downregulated within a
cell line infected with a novel isolate. Briefly, virus was harvested from
chronically infected HEK293T and FEA cell lines and passed through a 0.45 nm
filter, before being titrated on to QN10 (S+L-) cells at 20% confluency (the
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primary indicator cells). QN10 cells are feline fibroblastic cells stably
expressing a defective sarcoma virus genome, which may be co-packaged and
transmitted during infection with an exogenous functional retrovirus.
Transformation of this cell line is therefore indicative of the sarcoma viral
genome being mobilised by a functional FeLV; these mixed-population virions
possess the envelope glycoprotein of the novel sample. After transformation
was observed, supernatant was harvested, filtered and titrated upon FEA cells
chronically infected with FeLV of known or unknown classification (the
secondary indicator cells). The presence of transformation, indicative of
superinfection, was scored 3 days after infection.
2.1.7. QN10 focus-forming assays
QN10 (S+L-) cells were seeded into 6 well plates at 20% confluency and
allowed to adhere overnight prior to infection. Titrations of infectious virus
was used to infect the cells for two hours at 37°C. 72 hours post-infection, the
numbers of foci were manually counted and the viral titre (in FFU/µL) was
calculated.
2.2 Protein-based assays
2.2.1. Reverse transcriptase detection assay
A commercially-available ELISA-based kit was used to detect and/or quantify RT
activity within viral supernatants (C-type RT Activity Kit, Cavidi Technology,
Uppsala, Sweden). This utilises a 96-well ELISA plate coated with an RNA
template, which is reverse-transcribed by RT present within the sample. During
reverse transcription BrdUTP is incorporated into the nascent DNA strand. In
accordance with manufacturer’s instructions, samples were prepared with the
provided Dilution Buffers before the ELISA plate was incubated at 33°C for three
hours. After washing, the RT-Product Tracer component was added and the plate
incubated at 33°C for 90 minutes, during which time an alkaline phosphatase-
labelled anti-BrdU antibody binds to the RNA-DNA heteroduplexes. Following a
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secondary wash, alkaline phosphatase substrate is added to the sample. The
processing of this substrate produces a colorimetric reaction which can be
quantified using a spectrophotometer (Ascent Multiskan, U.K.).
2.2.2. SDS-PAGE and immunoblots
Immunoblots were performed to detect expression of specific proteins in both
cell lysates and concentrated virus preparations (prepared by
ultracentrifugation of cell-free virus supernatant, at 30 000 rpm for one hour
in a Beckman Ultracentrifuge with a SW40 rotor). Samples were diluted to the
desired volume using BPB Protein Loading Buffer and heated to 90°C for five
minutes prior to electrophoresis. Electrophoresis was conducted in either 4-
12% gradient precast polyacrylamide gels (Life Technologies) at 90V for two
hours in MES buffer, or in SDS-polyacrylamide gels of variable percentages in
Tris-Glycine buffer. Proteins were transferred to nitrocellulose membranes
using the iBlot transfer system (Life Technologies).
Membranes were blocked overnight using 2% skimmed milk powder and 0.1%
(v/v) Tween-20 in PBS. Primary antibodies were used at suitable dilutions in
blocking buffer, for one hour at room temperature. The anti-capsid (p27) MAb
(clone VPG19.1) was used unpurified as a hybridoma culture supernatant at a
dilution of 1:500. Purified anti-SU (gp70) MAb was used at 1:105. Anti-RD114
SU primary antibody (a kind gift from Hans Lutz) was used at 1:104. The anti-
HA MAb was used unpurified as a hybridoma culture supernatant at a dilution
of 1:500.
After incubation with the primary antibody, membranes were washed three
times in PBS with 0.1% Tween-20 prior to incubation with secondary antibody.
Biotinylated secondary antibodies from various species were utilised (Vector
Laboratories, Peterborough, U.K.) at a 1:1000 dilution in blocking buffer for
one hour at room temperature. The “ABC-AmP” kit (Vector Laboratories) was
then utilised to allow highly sensitive detection of proteins. Following
treatment with the secondary antibody, an alkaline phosphatase-labelled
avidin complex was bound to the membrane. Proteins were then visualised
using a chromogenic alkaline phosphatase substrate.
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Cell membranes to be assayed in immunoblots were prepared from cultured
cells according to previous descriptions (J. K. Brown, et al., 2006). Briefly,
1x106 MDTF cells were Dounce-homogenised in 1mL PBS, after which the
nuclei were removed by centrifugation at 1000g for 15 minutes. Membrane
fractions were then pelleted by ultracentrifugation at 30,000rpm for one hour
at 4°C before being resuspended in 20µL PBS or bromophenol blue protein
loading buffer.
2.2.3. Immunofluorescence
Immunofluorescence was utilised to detect expression of specific proteins in
cell cultures. For the detection of haemagluttinin (HA)-tagged retroviral
receptors, 3x104 receptor-expressing MDTF cells were seeded into each well of
8-well multi-test glass slides (Flow Laboratories, Surrey, U.K.) and allowed to
adhere overnight. Cells were fixed in 3.7% paraformaldehyde for 10 minutes.
Rabbit anti-HA IgG (Sigma-Aldrich, Gillingham, U.K.) was used at a 1:35
dilution (in PBS with 0.1% azide, 1% bovine serum albumin) at room
temperature for 45 minutes. Cells were washed before incubation with a 1:500
dilution of FITC-labelled goat anti-rabbit IgG (Sigma-Aldrich) for 30 minutes
prior to visualisation using a UV microscope (Leica Microsystems, U.K.).
For the detection of internal enFeLV Env proteins within FEA cells, a
permeabilisation step was included after fixation by paraformaldehyde. This
involved incubating cells with cold methanol at -20°C for 10 minutes, before
washing and incubating with the primary antibody (murine anti-gp70 MAb).
2.2.4. Flow cytometry
MDTF cells were dispersed using 1mM EDTA before 50µL of supernatant
containing the protein of interest was incubated with 105 cells, for 30 minutes
on ice. Cells were washed with PBS containing 1% bovine serum albumin and
0.1% sodium azide (PBS-BSA-Az). 0.5µg of PE-labelled antibody specific for
human IgG (eBiosciences, Hatfield, U.K.) was then added to each reaction and
incubated for a further 30 minutes on ice. Cells were washed and re-
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suspended in PBS-BSA-Az before being analysed on a Beckman Coulter
Cytomics FC500 flow cytometer.
2.3 Molecular cloning techniques
2.3.1. Cellular nucleic acid extraction
Genomic DNA was extracted from 1x106 cells using a commercially available
kit (QIAamp Blood Mini kit, Qiagen) according to manufacturer’s instructions.
This protocol utilises DNA binding to a silica gel membrane before repeated
washing in 70% ethanol-based buffers. Purified gDNA was eluted with water
and its concentration and purity analysed with a Nanodrop spectrophotometer
(Thermo Scientific).
Whole RNA was extracted from feline tissue samples using a commercial kit
(RNEasy, Qiagen). Tissue samples were taken from uninfected negative control
cats during in a previous study, snap-frozen in liquid nitrogen and stored at -
80°C. Briefly, 300mg of tissue was disrupted with a mortar and pestle in liquid
nitrogen without thawing. Lysates were passed through a homogenising
column (QIAshredder, Qiagen) before the RNA was purified using the RNEasy
columns and protocol. Final RNA concentration and purity was analysed with a
Nanodrop spectrophotometer.
2.3.2. Viral RNA extraction
Viral supernatant from confluent cultures was harvested and passed through a
0.45µm filter, prior to centrifugation in a Beckman ultracentrifuge (SW40
rotor) at 30 000rpm for one hour at 4°C. Viral pellets were resuspended
overnight at 4°C in PBS. Viral RNA was extracted using the QIAamp UltraSens
Viral kit (Qiagen) according to manufacturer’s instructions. As the silica-based
membranes utilised in this protocol bind all nucleic acid, following elution
with water RNA was DNase-treated to remove potential contaminating cellular
gDNA (Amplification-grade DNase, Life Technologies). In order to allow
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subsequent cDNA synthesis, DNase was inactivated by EDTA-treatment and
heating the sample to 65°C for 15 minutes.
2.3.3. cDNA synthesis
First-strand cDNA synthesis was conducted with a commercial MLV RT enzyme
(Life Technologies) according to manufacturer’s instructions. In order to
preferentially reverse-transcribe polyadenylated mRNA (including viral
genomes) oligo-dT primers were used. Dithiothreitol was included to reduce
secondary structures within the template RNA. Ribonuclease inhibitors
(RNaseOUT, Life Technologies) were included in all cDNA synthesis
preparations.
2.3.4. Plasmid constructs
The pMDG plasmid (Naldini et al., 1996), expressing vesicular-stomatitis virus
G protein (VSV-G), was used to produce pseudotypes that would enter cells
through endocytosis.
The pMFG plasmid (Ohashi et al., 1992), encoding β-galactosidase (lacZ) with 
a MLV-packaging signal, was used to detect pseudotype entry and retroviral
integration through expression of the lacZ reporter gene. LacZ expression was
measured by 5-bromo-4-chloro-3-indolyl-β-d-galactoside (X-Gal) staining. 
The pCMVi plasmid (Towers et al., 2000), encoding MLV gag-pol, was used to
produce MLV(FeLV) pseudotypes. The FGA construct contains a functional
molecular clone of the FeLV-A(Glasgow-1) viral genome, in the pUC18 vector.
Retroviral expression vectors, based upon the pFB-NEO plasmid (Agilent
Technologies, Wokingham, U.K.) containing the complete cDNA of various
retroviral receptors with 5’ haemagluttinin (HA) tags were kindly obtained
from Prof C. Tailor (J. K. Brown, et al., 2006; Rey, Prasad, et al., 2008). The
pVR1012 plasmid (Vical Inc., San Diego, U.S.A.) is an expression vector
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modified from the pUC plasmid (Hartikka et al., 1996) containing a
cytomegalovirus early promoter to drive target gene expression.
The pTORSTEN mammalian expression vector drives expression of soluble
proteins with an incorporated C-terminal human IgG1-Fc tag upon transfection
of susceptible cell lines (Spiller et al., 2006).
2.3.5. General cloning techniques
pVR1012 (described above), pcDNA3.1 (Life Technologies) and pBR322 (Bolivar
et al., 1977) vectors were utilised for cloning various genes and sections of
FeLV genomes. Although most PCR protocols incorporated restriction enzyme
sites to facilitate cloning into pVR1012, TA cloning was conducted with the
pcDNA vector (TOPO TA Cloning, Life Technologies).
2.3.5.1. Polymerase chain reaction
Oligonucleotide primers for PCR were obtained from MWG Biotech (Ebersberg,
Germany). All PCRs were conducted using a pre-prepared, commercially
available mastermix (High Fidelity PCR Master, Roche, U.K.) and thermal
cycling was conducted by a GeneAmp PCR System 9700 (Applied Biosystems,
Warrington, U.K.). A list of primers and conditions for specific PCRs is included
in Appendix 8.2.
2.3.5.2. Purification of PCR products
PCR products were electrophoresed on 0.8-1.5% agarose gels containing
ethidium bromide, generally at 100V for one hour in TBE buffer. Amplicons
were visualised under UV light and gel-excised using sterile scalpels. PCR
products were then purified from the agarose using the QIAquick Gel
Extraction kit (Qiagen) according to manufacturer’s instructions. This protocol
effectively precipitates DNA with isopropanol before binding it to a silica-
based membrane and repeated ethanol washing, prior to elution with water.
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2.3.5.3. Restriction enzyme digestion and ligation
When cloning inserts into specific vectors (for example, pVR1012) restriction
digests were conducted upon both the vector and PCR product to create ssDNA
overhangs to aid ligation. All restriction digests were conducted according to
manufacturer’s instructions, regarding the suitable buffer(s) and the presence
of bovine serum albumin in the reaction. Digestions were conducted at 37°C.
Adequate digestion was visualised by an alteration of the migration patterns of
the DNA upon gel electrophoresis (see above). DNA was purified from agarose
as previously described. Overnight ligation of DNA fragments was conducted
with T4 ligase (Life Technologies) at 16°C.
2.3.5.4. Transformation
DH5α Max Efficiency competent cells [genotype F- φ80lacZΔM15 Δ(lacZYA-
argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ- thi-1 gyrA96 relA1]
(Life Technologies) were transformed with ligation products according to the
manufacturer’s protocol. Briefly, 2µL of ligation products were added to 20µL
competent cells and incubated on ice for at least 30 minutes before being
heat-shocked at 42°C for 45 seconds. After further two minute incubation on
ice, 900µL SOC broth (Life Technologies) was added and cells were incubated
at 37°C for an hour whilst being shaken continuously. Cultures were spread on
to LB agar plates containing the desired antibiotic (kanamycin at 50µg/mL or
ampicillin 100µg/mL) and incubated overnight at 37°C. Positive transformants
(containing the desired insert within the vector) were identified by restriction
digest of DNA isolated from overnight cultures of individual bacterial colonies.
2.3.6. Preparation of plasmid DNA
A commercial kit was used to isolate small volumes of plasmid DNA, according
to manufacturer’s instructions (QIAquick Minikit, Qiagen). Glycerol stocks of
82
bacterial cultures were prepared by mixing 500µL of actively-growing culture
with 500µL sterile 60% glycerol, before being stored at -80°C. Large-scale
plasmid purification from up to 500mL of actively-growing culture was
conducted using commercial kits (HiPure Maxiprep Kit, Qiagen).
2.3.7. Genetic sequencing
All DNA was sequenced using the BigDye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems). Briefly, a PCR was conducted using specific primers and
the recommended conditions (1 cycle at 96°C, 1 minute; followed by 25 cycles
of (1) 96°C, 10 seconds; (2) 50°C, 5 seconds; (3) 60°C, 3 minutes). Sequencing
reaction products were precipitated using the ethanol/sodium acetate
method. 100µL of DNA was added to 1µL 3M sodium acetate and 200µL 100%
ethanol. After mixing the solution was stored at -80°C for at least 30 minutes.
DNA was precipitated by a 10 minute centrifugation at 13 000 rpm using a
benchtop microcentrifuge, then washed once with 200µL 70% ethanol. DNA
pellets were air-dried thoroughly before being re-suspended with 20µL highly-
deionised formamide (Applied Biosystems). Sequencing reaction products were
analysed using an ABI Prism 3130xl Genetic Analyser (Applied Biosystems).
2.3.8. Site-directed mutagenesis of plasmids
The QuickChange Lighting Mutagenesis kit (Agilent Technologies) was utilised
to enable accurate and efficient mutation of specific nucleotides within the
FeLV-A(Glasgow-1) molecular clone and the pVR1012 construct encoding the
FeLV-A(Glasgow-1) Env gene. The protocol was conducted according to
manufacturer’s instructions, however PCR products were precipitated with
ethanol/sodium acetate following Dpn1 treatment. They were then re-
suspended in a small volume of water prior to transformation into competent
cells.
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2.4 In silico and bioinformatics techniques
2.4.1. RNA structural models
RNA secondary structures were modelled using the programs RNAStructure
Version 5.3 (Reuter & Mathews, 2010), the mFold webserver (available online,
http://mfold.rna.albany.edu/?q=mfold) (Zuker, 2003) and the Alifold web-
server (available online, http://rna.tbi.univie.ac.at/cgi-bin/RNAalifold.cgi)
(Gruber, Lorenz, Bernhart, Neubock, & Hofacker, 2008) using default
parameters (pH 7.0, temperature of 37°C).
RNAStructure Version 5.3 predicts structures within nucleic acid sequences
based upon the minimal possible free energy of the structure(s). Although an
optimal structure is produced, this program also allows visualisation of
alternative structures with less optimal free energies. This program requires
the input of two distinct RNA sequences and allows modelling of both homo-
and hetero-dimers.
The mFold webserver predicts nucleotide secondary structures based upon the
thermodynamic stability, including free energy, of the resulting model(s).
Multiple predictions are produced for each input sequence; these often
contain conserved structural motifs which are predicted to be highly stable.
The Alifold webserver requires input of a multiple sequence alignment, within
which the individual sequences can be assumed to possess similar secondary
motifs (for example, as a ClustalW alignment or FASTA file). The output file is
a single structural prediction based upon the consensus sequence. The relative
colour coding of the individual nucleotides reflects their conservation within
the original alignment and/or their ability to base-pair (see Chapter 6 for
further details). This structural model takes into account the minimal free
energy as well as to the phylogenetic relationships between the input
sequences.
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Both the mFold and Alifold webservers model the secondary structures within
monomeric RNA. To model dimeric RNA, the two RNA sequences are arranged
consecutively with a string of >9 uridine bases separating them. This synthetic
“linker” forms a hairpin structure from which the monomeric sequences
extend, allowing interactions between them to be modelled.
2.4.2. Multiple sequence alignments
Genetic data was analysed with DNADynamo (Blue Tractor Software Ltd, U.K.).
Both protein and nucleotide multiple sequence alignments were created with
Seaview Version 4.3.2 (Galtier, Gouy, & Gautier, 1996; Gouy, Guindon, &
Gascuel, 2010). Seaview utilises the ClustalW2 program for maximum
alignment and parsimony (Larkin et al., 2007).
2.4.3. Transcription factor screens
MatInspector was used to screen LTRs for potential TF binding sites. This web-
based software is available from Genomatix Software (www.genomatix.de ).
This program analyses a genetic sequence (the input sequence, provided by
the user) for the presence of annotated transcription factor binding sites and
other promoter and enhancer elements (Cartharius et al., 2005; Quandt,
Frech, Karas, Wingender, & Werner, 1995). A quality rating is assigned to each
detected site; this is based upon the degree of similarity between the input
sequence and a matrix describing the TF family.
2.4.4. Graphs and statistics
Graphs were constructed using SigmaPlot 8.0. Error bars represent the
standard error of the mean (SEM). Statistical tests (paired and unpaired
Student’s T tests) were performed using SigmaPlot 8.0.
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3. Specific FeLV-A strains may be predisposed
towards conversion to FeLV-C
3.1 Introduction
There are three main subgroups of FeLV; FeLV-A, -B and –C, from which only
FeLV-A appears to be transmitted efficiently between hosts (W. D. Hardy, Jr., et
al., 1976; W. D. Hardy, Jr., Old, Hess, Essex, & Cotter, 1973). Despite FeLV-C
strains being fully replication competent in vitro (Riedel, et al., 1986),
replication in vivo is thought to require the continued presence of FeLV-A. Thus
the A subgroup is commonly referred to as a “helper” virus required for
transmission and dissemination of novel subgroups within the host. FeLV-A is
often mistakenly termed the “low-pathogenicity” variant (Donahue, et al., 1988)
as approximately 60% of exposed cats mount a competent immune response and
successfully clear infection following a transient viraemia (Hoover & Mullins,
1991; N. C. Pedersen et al., 1977). However, FeLV-A is pathogenic and in cats in
which a chronic infection is established a range of clinical signs may develop,
including immunosuppression, lymphoma and anaemia (Chandhasin, et al., 2005;
Mackey, et al., 1975; Reinacher, 1989).
The disease association and clinical prognosis of an infection is influenced by
both the genotype of the FeLV-A isolate and the presence of other subgroups
which arise in vivo (O. Jarrett, 1992). FeLV-C arises within the infected host
through the gradual acquisition of mutations within the viral genome (Rigby, et
al., 1992) and is thus frequently identified alongside a concurrent FeLV-A
infection (O. Jarrett, et al., 1978; O. Jarrett & Russell, 1978; Sarma & Log,
1973). FeLV-C is found in approximately 1-2% of chronically infected cats and its
emergence is associated with the development of PRCA (O. Jarrett, et al.,
1984; O. Jarrett, et al., 1978; Mackey, et al., 1975). This non-regenerative
anaemia is fatal within approximately 2-3 months of FeLV-C arising in the cat
(Onions, et al., 1982; Riedel, et al., 1986).
The development of FeLV-C infection from an initial infection with a FeLV-A
isolate is accompanied by an alteration in the receptor usage of the virus, from
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the thiamine transporter feTHTR1 utilised by FeLV-A (Mendoza, et al., 2006) to
the haem transporter, feFLVCR1 utilised by FeLV-C (Tailor, et al., 1999). The
binding of FeLV-C to feFLVCR1 impairs the normal cellular function of the
protein, preventing haem transport in erythroid cells and resulting in a depletion
of erythrocyte precursors (Quigley, et al., 2000; Quigley, et al., 2004). Although
the widespread cellular distribution of both feTHTR1 and feFLVCR1 means that
FeLV-A and –C are able to infect multiple lineages of haematopoietic cells
(lymphoid, erythroid and myeloid), the pathogenic potential of subgroup C
viruses appears to be conferred by the ability to interfere with the function of
feFLVCR1 on erythroid progenitor cells, rather than the widespread infection of
diverse cell types (Dean, Groshek, Mullins, & Hoover, 1992).
The development of FeLV–C is due to alterations within the SU domain of the Env
glycoprotein (Brojatsch, et al., 1992; Riedel, et al., 1988; Rigby, et al., 1992).
These mutations affect the RBD, the region that determines the cognate
receptor used for cellular entry. Accordingly, mutations within this region of Env
alter the cellular tropism of the virus and FeLV-C possesses an expanded in vitro
host range (Boomer, et al., 1997; W. D. Hardy, Jr., et al., 1976; O. Jarrett, et
al., 1969b; O. Jarrett, et al., 1973). Previous studies have demonstrated that a
241 amino acid region within the Env of prototype FeLV-C(Sarma) conferred the
ability to induce PRCA in experimental infections (Riedel, et al., 1988).
Subsequently, the primary determinant of this phenotype was mapped more
precisely to a string of 92 amino acids within the RBD of isolates of FeLV-C
cloned biologically (Brojatsch, et al., 1992; Rigby, et al., 1992). It was noted
that there was limited conservation between the sequence of individual isolates
of FeLV-C (Brojatsch, et al., 1992; Rigby, et al., 1992), supporting the assertion
that there is minimal inter-host transmission of FeLV-C and that each isolate
arises de novo within a unique host. Protein signatures or structures that are
conserved between all FeLV-C isolates have yet to be identified, and the critical
residues that are essential and sufficient to confer FLVCR binding upon Env have
not been elucidated.
It has been assumed that the acquisition of the Env mutations that define the C
subgroup would lead to the emergence of two distinct viral populations with
non-overlapping receptor tropisms within the host, resulting in the FeLV-A/FeLV-
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C co-infections observed in clinical cases. However, recent studies have
suggested that the evolution of FeLV-C in vivo may be a gradual process, with
viruses displaying intermediate phenotypes and receptor usages co-existing
within the infected host (Shalev, et al., 2009). Indeed, virus isolates have since
been identified that utilise both THTR1 and multiple FLVCR1 paralogues (Shalev,
et al., 2009). Presumably, these FeLV-A/C dual-tropic viruses would eventually
give rise to a FeLV-C isolate which would utilise feFLVCR1 solely.
Previous research conducted in our laboratory had used 7 primary FeLV field
isolates which had been confirmed previously to contain both subgroups A and C
by interference assays (Table 3.1) (Adema, 2003). Comparisons between the env
genes of these subgroup A strains with those of prototypic FeLV-A would allow
identification of mutations which may contribute to an initial interaction with
FLVCR1. Their presence would therefore enhance the possibility of FeLV-C
development occurring following genetic drift during subsequent cycles of
replication.
Table 3.1: Primary FeLV isolates.
FEA cells were infected with 7 primary FeLV isolates previously classified as
being either A/C or A/B/C co-infections through interference assays (Adema,
2003). Three isolates had been partially characterised previously.
FEA cells were chronically infected with the FeLV-A/C primary isolates and
proviral env genes were cloned from genomic DNA. The PCR conditions, “FeLV-
Env”, are detailed in Appendix 8.2. Consistent with their designations by
interference, multiple unique env sequences were obtained from each isolate,
Isolate
Subgroup
Classification
Previous
References
FA27 A/C
Onions, 1982;
Brojatsch, 1992;
Rigby 1992
FS246 A/C
Onions, 1982;
Brojatsch, 1992;
Rigby 1992
FZ215 A/B/C
Brojatsch, 1992;
Rigby 1992
FA621 A/C N/A
FX343 A/C N/A
L3128F A/C N/A
L3950F A/C N/A
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confirming the heterogeneity of the viral populations within these isolates. The
majority of variation between Envs was located within the region encoding the
RBD (Figure 3.1). These results indicated that primary isolates of FeLV-A/C
mixed infections contain semi-conserved polymorphisms. By comparing the
amino acid sequences of the novel variants with the prototypic FeLV-A(Glasgow-
1) (Stewart, et al., 1986) and FeLV-C(Sarma) (Riedel, et al., 1986) strains, each
Env was tentatively identified as either the subgroup A or subgroup C component
of the isolate. Criteria for classification as a likely FeLV-C Env were the presence
of substantial amino acid substitutions and/or length polymorphisms in the “Vr1”
region (Rigby, et al., 1992) of the RBD. Viral variants that appeared genetically
to be of the FeLV–B subgroup (present in isolates FY981 and FZ215) and which
showed characteristic evidence of recombination with endogenous FeLV
sequences were not included in subsequent analyses.
Figure 3.1: RBDs from the
FEA cells were infected with primary isolates of FeLV containing both subgroups
A and C from cats with anaemia.
genomic DNA and the nucleic acid sequences of multiple clones determined.
Sequences in blue were putatively assigned to subgroup A; sequences in red
were assigned to the FeLV
conservation with the prototype FeLV
included to maintain alignment conservation
terminal region are
envs of anaemogenic strains of FeLV
Env genes were amplified from purified
-C component/s of the isolate. Dots indicate
-A(Glasgow-1) sequence. Dashes are
. Residues 83 and 91 in the N
annotated. Figure adapted from (Adema, 2003
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The sequences of the FeLV-A components were highly conserved between
isolates, despite the lengthy interim between their isolation. It is widely
assumed that all retroviruses acquire significant levels of variation over time due
to the error prone enzymatic activity of reverse transcriptase, the actions of
cellular antiviral factors and the selective pressure from the host immune
response (Overbaugh & Bangham, 2001). However, while this is indeed the case
for HIV, and to a lesser extent FIV, most isolates of FeLV-A date are remarkably
similar (Donahue, et al., 1988). In comparison, FeLV-C is thought to be poorly
transmissible and each isolate arises independently within the infected cat. This
is reflected by the high degree of divergence observed in the RBD region of Env
between isolates. Despite this heterogeneity, no mutations were identified that
were conserved across all the FeLV-C env sequences.
Within the A/C mixtures Envs were identified that were ostensibly subgroup A by
sequence alignment and yet bore point mutations from the reference strain
FeLV-A(Glasgow-1) (Figure 3.1). It can be assumed that the FeLV-A Envs were
the parental viruses of the FeLV-C isolates within their respective hosts;
therefore these mutations may have affected the receptor utilisation of the
FeLV-A Env, increasing the likelihood of FeLV-C developing.
Within the FA27 isolate, variants were identified with an aspartate to asparagine
substitution D83N, a residue that varied in two of the novel FeLV-Cs. This non-
conservative mutation (D83N) was documented previously in the FY981 virus, a
variant that is able to utilise FLVCR1, FLVCR2 and THTR1 (Shalev, et al., 2009).
Similarly, as asparagine to aspartate substitutions (N91D) was present in three of
the novel FeLV-As (L3128F, FZ215 and FA27), ablating a potential site for N-
linked glycosylation and aligning with a region of FeLV-C Envs that is critical to
the determination of the subgroup C phenotype (Riedel, et al., 1986; Rigby, et
al., 1992). Asparagine-91 of FeLV-A(Glasgow-1) is replaced with a Serine (S91) in
both FeLV-A(3281) and FeLV-A(61E) (Donahue, et al., 1988). In contrast, FeLV-
A(Rickard) which has been shown to give rise to FeLV-C in vivo (Chen, et al.,
1998; Phipps, Chen, et al., 2000) contains an aspartate residue (D91). D91 is also
found in FeLV-C(Sarma) (Riedel, et al., 1986) and FeLV-A(945) (Levesque, et al.,
1990). As the D83N and N91D substitutions were localised to the primary
determinant of FeLV
evolution of FeLV-C from FeLV
The aims of this study were
mutations confer an expanded receptor tropism to the FeLV
a dual-tropic A/C virus). Alternatively, such mutations
influence its ability to e
an insight into the sequ
of a highly pathogenic retroviral variant.
3.2 Results
3.2.1.
(Glasgow
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directed mutagenesis,
were developed, designated FeLV
N83:N91 (NN). HEK293T cells were then transfected with
molecular clones and a chronic FeLV infection of each mutant virus was
established. Active infection was confirmed after two weeks in culture by
immunoblotting for both viral
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A(Glasgow-1) has the genotype D83:N91, the mutants DD, ND and NN were
D83:D91, N83:D91 and N83:N91 respectively. Viral supernatant was harvested 72
hours post-transfection, filtered and ultracentrifuged, separated by SDS-PAGE,
immunoblotted and probed with either anti-gp70 (SU) or anti-p27 (CA).
3.2.2. The N91D mutation increases viral entry through
THTR1
During the preparation of virus stocks of the four variants, it was noted that the
DD mutant appeared to grow more efficiently in HEK293T cells. This was unlikely
to be a reflection of transfection efficiency, as it was observed in multiple
independent experiments utilising a range of transfection volumes from
independently-derived DNA stocks. In order to measure the approximate titre of
the four virus preparations, serial dilutions of the HEK293T-derived viruses were
prepared, plated onto QN10 (S+L-) cells and the number of foci per µL
quantified. This S+L- assay is used widely to confirm the presence of an
infectious feline gammaretrovirus (Russell & Jarrett, 1976) and indicated that
despite transfection of matched inputs of the four molecular clones into
HEK293T cells, the four viruses displayed differences in infectious titre. DD
achieved a significantly higher titre than the reference FeLV-A(Glasgow-1) while
ND and NN achieved lower titres (Figure 3.3). These observations suggested that
the combination of residues D83 and D91 conferred an enhanced replicative
capacity upon FeLV-A.
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Figure 3.3: The DD mutant of FeLV-A(Glasgow-1) displays a higher viral titre.
FeLV-A(Glasgow-1) (A) or the DD, ND and NN mutants were transfected into
HEK293T cells and the supernatant recovered. Serial dilutions of each
supernatant were prepared and plated onto QN10 (S+L-) cells. 72 hours post-
infection, foci were scored manually; values represent the mean +/- SEM of two
independent experiments. The increase in titre between A(Glasgow) and the DD
mutation is statistically significant (Students t test, p value= 0.0474).
As QN10 assays were designed to detect infectious virus rather than quantify
viral entry, the Glasgow-1 (A), DD, ND and NN envs were subcloned into a
mammalian cellular expression vector in order to produce MLV(FeLV) lacZ
pseudotypes (murine leukaemia virus virions bearing the FeLV Envs and carrying
a lacZ marker gene), thus facilitating quantification of viral titre based solely on
viral entry. Following infection of HEK293T cells with matched inputs (equal RT
value) of the MLV(FeLV) lacZ pseudotypes, DD Env-bearing pseudotypes yielded a
higher titre than those bearing the parent FeLV-A(Glasgow-1) Env (Figure 3.4). In
contrast, ND Env-bearing pseudotypes achieved a lower titre than Glasgow-1
Env-bearing pseudotypes. As these pseudotypes undergo a single cycle of
infection, the data suggest that the DD mutation enhanced replication at the
stage of viral entry.
Figure 3.4: The DD Env supports more efficient infection of HEK293T cells
Matched inputs (RT activity) of MLV(FeLV) lacZ pseudotypes bearing the
Glasgow-1 (A), DD, ND or NN Envs, were plated onto HEK293T cells. 72 hours
post-infection, the cells were stained for expression of lacZ and counted
manually. Values are presented as in
of three independent experiments.
the decrease in titre of the ND mutant
with A (Glasgow-1) (unpaired T test, p=0.031 and
HEK293T cells are susceptible to all subgroups of FeLV
D. Hay, 1969a;
presumably express all the cognate receptors, although this has never been
confirmed directly
viral entry, this assay did not allow identification of the
utilised by the virus
accurate analysis of viral receptor tropism. MDTF
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manipulation of these cells to express specific receptors would allow accurate
assessment of virus-receptor binding and cellular entry.
Table 3.2: Receptors expressed in MDTF and 104C1 cells.
Cells were transduced to express a range of FeLV-A and-C receptors from Felis
catus, Sus scrofa and Homo sapiens.
Receptor WildtypeFunction
Species of
Origin
FeLV
Subgroup
Known Receptor
Functionality
feTHTR1 Thiaminetransporter
Felis catus FeLV-A Functional
huTHTR1 Thiaminetransporter
Homo sapiens FeLV-A Functional
poTHTR1 Thiaminetransporter
Sus scrofa FeLV-A Functional
huFLVCR1 Haemtransporter
Homo sapiens FeLV-C Functional
huFLVCR2
Putative
haem
transporter
Homo sapiens FeLV-C Limited functionality(selected isolates)
(A)
(B)
Figure 3.5: Stably transduced
MDTF (A) and 104C1 (B) c
pseudotypes, encoding retroviral receptor cDNA transcripts cloned into the pFB
Neo construct (kindly provided by C. Tailor, University of Toronto). After
selection with G418, immunofluorescence was conducted upon
paraformaldehyde-
tagged receptor proteins.
cells express a range of retroviral receptors
ells were transduced with VSV
fixed cell monolayers to detect surface expression of the HA
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The lacZ pseudotype assay was repeated using the MDTF cells, expressing a
range of FeLV receptors. Cells were infected with matched inputs (RT activity)
of MLV(FeLV) lacZ
results indicated that pseudotypes bearing the DD Env displayed a significant
increase in the usage of all three THTR1 orthologues in comparison with the
wildtype FeLV-A(Glasgow
pseudotypes displayed a marked preference for hFLVCR1
Figure 3.6: The DD Env confers enhanced utilisation of THTR1 homologues
MLV(FeLV) lacZ pseudotypes bearing the A (Glasgow
Envs were plated onto MDTF cells expressing the feline (fe), human (hu) or
porcine (po) THTR1 homologues, human FLVCR1 or human FLVCR2. 72 hours
post-infection, cells were stained f
Values represent the mean +/
increase in titre associated with the DD mutation upon feline, human or porcine
THTR1 is statistically significant in comparison with A
test, p=0.0063).
pseudotypes and the efficiency of infection quantified. The
-1) Env (Figure 3.6). In contrast, C(Sar
-expressing MDTF cells.
-1), C (Sarma), DD, ND or NN
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3.2.3.
receptors
In vitro studies with MLV(FeLV) pseudotypes had suggested that the combination
of D83 and D91 in Env conferred enhanced viral entry. This led to the question as
to whether this effect was mediated by increasing binding to the viral
receptor(s), THTR1 (FeLV
B receptor). The SU domains of the mutant FeLV Env proteins were cloned into
the pTORSTEN mammalian expression vector (PCR “FeLV SU”, details in
Appendix 8.2) and recombinant SU proteins were expressed
HEK293T cells as C
with anti-gp70 MAb
of the SU-Fc proteins respectively (Figure 3.7).
Figure 3.7: Expression of soluble Fc
HEK293T cells were transfected with the pTORSTEN vector into which the SU
domains of the Glasgow
Glasgow-1 mutants DD, ND and NN had been
supernatant were separated by SDS
immunoblotted for both gp70 (upper) and the human IgG Fc tag (lower).
SU-Fc binding to receptor
was then assessed by flow cytometry using matched inputs of SU
(informed by immunoblotting of the recombinant SU
from FeLV-A(Glasgow
(C) or the FeLV-A(Glasgow
(NN). The A, DD, ND and NN SU
Enhanced binding of FeLV D83:D91 SU to viral
-A receptor), FLVCR1 (FeLV-C receptor) and Pit1 (FeLV
-terminal fusions with human IgG-Fc. Immunoblot analysis
and anti-human IgG Fc confirmed the antigenicity and yield
-tagged FeLV SUs.
-1 (A), Gardner-Arnstein (B) and Sarma (C), or the
cloned. Matched volumes of
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human THTR1 with comparable efficiency and with a reduced efficiency to
porcine THTR1 (Figure 3.8). In contrast, B SU-Fc bound to huPit1 expressing
MDTF cells while C SU-Fc bound most efficiently to human FLVCR1-expressing
cells, confirming the specificity of the interactions. Of the four FeLV-A SU-Fcs,
the DD mutant appeared to display higher binding than the A, NN and ND SU-Fcs
to each of the THTR1s suggesting that the DD combination may enhance the Env-
receptor interaction, implicating a molecular basis for the enhanced replication
and viral entry.
These findings were mirrored using independently generated cell lines derived
from 104C1 cells (Figure 3.8). The binding studies with the 104C1 cells also
indicated that the NN and ND SU-Fc proteins bound less efficiently to 104C1-
expressed THTR1s than the parental A Su-Fc, suggesting that while mutations
such as DD may enhanced Su-Fc binding the converse may be true of NN and ND
mutations. Significant weak binding of all SU-Fcs was noted to control MDTF and
104C1 cells although it was notable that the A and B SU-Fcs had higher
background binding than the C Su-Fc protein, with the DD SU-Fc displaying the
highest binding to control cells. As THTR1 are expressed widely and MDTFs
express a murine THTR1, this background binding is most likely due to either
endogenously expressed murine THTR1 or a related protein. It is notable that
while the DD-SU Fc bound with a higher efficiency than the other A SU-Fcs to the
control MDTF cells, it bound with a similar efficiency to huFLVCR2-expressing
cells. As the A, NN, ND and DD SU-Fcs bound to huFLVCR2-expressing cells with
similar efficiencies (Figure 3.8, red lines) these data strongly suggest that the
enhanced binding of the DD SU-Fc to diverse receptors is a specific property of
the DD SU receptor binding domain and not a reflection of variations in the
amount of viable SU-Fc in the preparation. Given that the development of FeLV-
associated PRCA is marked by a shift in receptor usage from THTR1 to FLVCR,
the enhanced binding afforded by the DD mutation may be highly significant in
the spread of such variants into compartments expressing the FLVCR1 receptor;
this likely represents the first step towards the biological selection of subgroup C
viruses.
Figure 3.8: The DD mutations confer enhanced binding
Matched volumes of supernatant containing the Fc
Glasgow-1 (A), Gardner
were added to either MDTF or 104C1 cells expressing feline, human or porcine
THTR1, human FLVCR1 & 2, hum
binding was detected by flow cytometry with PE
Each histogram represents 10,000 events collected in LIST mode and are
representative of two independent analyses. Ordinate
while abscissa displays fluorescence intensity.
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has displayed a unique RBD sequence, suggesting that recombination with
endogenous env sequences is an unlikely source of the mutated RBD. In contrast,
the emergence of subgroup B viruses is associated with recombination between
exogenous and endogenous FeLV env sequences (Pandey, et al., 1991; Sheets, et
al., 1992; Stewart, et al., 1986). A more likely mechanism for the derivation of
subgroup C viruses would be the acquisition of mutations in vivo in response to a
selective pressure from the host, either through pressure to escape the adaptive
immune response or through receptor availability in the tissue in which the virus
replicates. Such a mechanism predicts the presence of variants with an
intermediate tropism; subgroup A viruses with point mutations in the RBD that
confer an enhanced or expanded receptor usage. Previous studies identified a
subgroup C virus, FY981 that had retained the ability to utilise the subgroup A
receptor THTR1 for infection (Shalev, et al., 2009), confirming that there are
indeed “dual-tropic” or “poly-tropic” viruses amongst primary isolates of
anaemogenic strains of virus. FY981 is actually a poly-tropic virus as it is able to
utilise a third receptor (FLVCR2) in addition to THTR1 and FLVCR1 (Shalev, et
al., 2009).
3.3.1. The D83:D91 motif enhances viral replication
Here, it was demonstrated that subtle variations in the RBD of subgroup A
viruses may have significant effects on the way the viruses interact with their
receptors, potentially predisposing the viruses to in vivo mutagenesis.
Accordingly, the presence of the combination of D83 and D91 in the background
of FeLV-A(Glasgow-1) was sufficient to enhance receptor binding, viral entry and
viral replication. Residue D91 is particularly intriguing as it is present in the
well-characterised Rickard strain of FeLV. In two separate studies examining
recombination in FeLV infection, it was noted that inoculation of cats with a
molecular clone (pFRA) of the Rickard strain of FeLV resulted in 1 of 3 (Phipps,
Chen, et al., 2000) and 1 of 5 (Chen, et al., 1998) cats developing an FeLV-C
associated anaemia. As FeLV-C is thought to arise in <1% of infected cats, the
high incidence of FeLV-C emergence following inoculation with FRA (33% and 20%
respectively) may suggest an enhanced propensity for the development of FeLV-
C. Mechanistically, a scenario can be envisaged whereby some subgroup A
viruses may be inherently more pathogenic than others due to an enhanced
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ability to infect and spread in the infected host, a feature determined largely by
the affinity of the Env for the viral receptor. Indeed, such a virus (FeLV-945) has
been described and shown to have a higher binding affinity for its receptor
(Bolin, et al., 2011). Mapping the determinants of the enhanced binding of the
FeLV-945 SU to feline cells suggested that the major determinant of the
enhanced binding of the 945 SU resided in variable region B (VRB) of gp70. FeLV-
945 is a D83:D91 virus, similar to the DD mutant examined in this study;
however, inserting the VRA of 945 in the background of FeLV-61E (an SU that
binds with a lower affinity to its receptor) did not confer an enhanced binding
upon the 61E SU, suggesting that multiple determinants in gp70 may contribute
to the receptor binding affinity. However, it should also be noted that the 61E
SU varies from the Glasgow-1 SU at a number of other residues across gp70; the
context in which D83:D91 is expressed may be critical to its effect on binding
affinity. Moreover, in this study, SU fusion proteins (dimeric) with a C-terminal
IgG Fc-tag were expressed and binding was assessed on both mouse and guinea-
pig cells expressing individual receptors, whereas the 945-SU proteins (Bolin, et
al., 2011) were expressed as C-terminal HA tagged proteins (monomers) and
binding assessed on the feline lymphosarcoma cell line 3201, a cell line that
produces a soluble 35kDa endogenous FeLV Env protein capable of viral
interference (McDougall, et al., 1994). Such experimental differences may
modulate both the affinity and the specificity of the Env-receptor interaction in
the two systems. For example, it has been shown that the context in which the
receptor THTR1 was expressed altered the efficiency of receptor usage by FeLV
(Shalev, et al., 2009) while soluble endogenous FeLV Env produced from 3201
cells conferred infectivity on the otherwise defective FeLV-T Env (Anderson, et
al., 2000). Irrespective of the differences in the experimental systems, the
enhanced binding of the Glasgow-1 DD mutant SU-Fc to THTR1 was consistent
with the enhanced entry and replication of the virus, while the high affinity
binding of the 945-SU was consistent with enhanced binding of intact virus
particles from FeLV-945 to the same cells (Bolin, et al., 2011).
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3.3.2. FeLV-A RBDs display promiscuous receptor
binding
The binding assays with Fc-tagged FeLV SUs suggest that all FeLV-A RBDs are
able to bind to both THTR1 and FLVCR1 homologues, an observation not
described previously. It is possible that both the affinity of the FeLV SU for the
receptor and its ability to induce fusion once bound combine to determine the
eventual route of viral entry. These data may predict that during FeLV-C
evolution, additional mutations accumulate during long-term viral replication
and that these mutations decrease SU affinity for THTR1 whilst increasing the
relative affinity for the FLVCR1 homologues. Such viral evolution would
eventually result in an Env capable of mediating fusion and entry via FLVCR1,
producing the FeLV-C phenotype and associated PRCA symptoms. This theory is
supported by the observation that FeLV-C (Sarma) displayed a severely limited
ability to bind to THTR1 despite possessing the D83:D91 motif. However this
altered binding affinity may be mediated by a range of mutations across the SU,
not comprising a single binding motif, explaining why individual FeLV-C Env
proteins are functionally but not genetically conserved. It is possible that the
overall final Env conformation, rather than specific individual residues, permits
FLVCR1-mediated membrane fusion and cellular entry. The deletions which were
observed in multiple FeLV-C env clones from the primary isolates may be
essential for decreasing the affinity of the THTR1-SU interaction and allowing
FLVCR1-mediated entry. This deletion may represent the final mutation in the
progression from FeLV-A to -C.
3.4 Conclusions
There are particular caveats which must be taken into account during
interpretation of these results. Specifically, the higher-affinity of DD-Env
proteins to receptors assumes this mutation does not alter the proportion of Env
incorporated within a virion. Similarly, RT enzyme activity was used to ensure
an equivalent amount of virus was utilised in the pseudotype assays; it was
assumed mutations would not influence RT protein packaging within virions. The
degree of receptor expression upon the surface of stably-transfected MDTFs was
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observed to be of a similar value; however small discrepancies in their
expression levels may have influenced results.
These studies indicate primary isolates of FeLV-A and C consist of heterogeneous
viral populations and the subgroup A components of these isolates display a
range of subtle mutations in Env. In the context of FeLV-A(Glasgow-1), the
combination of D83 and D91 in gp70 allowed increased binding to both THTR1
and FLVCR1 and enhanced both viral entry and replication. Such properties may
predispose viruses to evolution from subgroup A to subgroup C by enhancing
spread of the virus into cellular compartments where ability to use FLVCR1 is
selected preferentially. These data provide a first step towards elucidating why
FeLV-C emerges infrequently in infected animals and provide further evidence
that despite a high degree of genetic homogeneity, not all FeLV-As are equal.
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4. Investigation of potential factors which may
drive FeLV-A to -C evolution
4.1 Introduction
In the previous chapter, mutations were identified which may predispose
particular strains of FeLV-A isolates to evolve into subgroup C variants by
altering the receptor-binding properties of Env. Subsequent studies, described in
this chapter, aimed to model the process of FeLV-A to –C evolution in vitro. If,
as predicted, the acquisition of substitutions such as D83N and N91D render the
virus more likely to evolve from subgroup A to subgroup C, this evolutionary
process may be observable if a similar viral milieu to that observed in vivo could
be recreated in vitro. Unfortunately, the site of viral replication and evolution
in vivo remains unclear and therefore it can only be surmised that it is a site in
which both A and C receptors are expressed. Moreover, additional selective
pressures may be placed upon the evolution of the viral Env protein in vivo from
the adaptive (acquired) immune response of the host.
It was predicted that the FeLV-A genotype, host humoral immune response and
the relative availability of cognate receptors upon target cells would be the
main determinants of FeLV-C development. These factors are commonly
regarded as the two main selective pressures shaping the evolution of retroviral
variants (Overbaugh & Bangham, 2001). In vitro models mimicking these
pressures would allow accurate mapping of the viral mutations and receptor
usage alterations occurring in real time. As the presence of the D83:D91 motif
within Env enhanced SU binding to FLVCR1, indicating that these viral variants
may be predisposed towards FeLV-C conversion in vivo, the replication-
competent mutants of FeLV-A(Glasgow-1), D83:D91, N83:D91 and N83:N91 (DD,
ND and NN respectively) were included in the in vitro viral replication models.
This would allow comparison of the relative capacity of each Env to evolve
further towards a FLVCR-utilising variant.
The in vitro models also aimed to determine whether the presence of gp70-
specific antibodies during long-term FeLV-A replication would result in the
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accumulation of mutations previously associated with FeLV-C, and whether this
would be more likely to occur in the D83:D91 mutant compared to wildtype
FeLV-A(Glasgow-1). For many retroviruses, the host humoral immune response
exerts a pressure upon circulating virions which selects for those able to escape
virus neutralising antibodies (VNAs) (Manrique et al., 2007; Nakowitsch et al.,
2005; Rwambo, Issel, Hussain, & Montelaro, 1990). In the case of HIV, such
mutations additionally correlate with the development of a specific disease and
the acquisition of an extended cell tropism in a scenario parallel to that of FeLV-
C (Berger, Murphy, & Farber, 1999). It is possible that FeLV virions possessing
the DD Env are able to circumvent these antibodies more efficiently than
minimally-pathogenic FeLV-A strains, either by their heightened cell entry rates
or through alteration of neutralising epitopes. Alternatively, during replication in
the presence of gp70-specific antibodies FeLV-A may acquire specific mutations
to avoid neutralisation, which would then interact synergistically with residues
83 and 91. These mutations may induce the conformational changes presumably
required within the SU domain to enhance the preliminary FLVCR1-SU binding,
eventually allowing FLVCR1-mediated entry. The development of dual-tropic
viruses and eventual FeLV-C phenotype may therefore be a result of this
antibody-mediated escape.
In contrast, the development of viral variants with altered tropism may occur if
the novel receptor is the only such available protein (Overbaugh & Bangham,
2001). Subscribing to this theory, the presence of VNAs would have minimal
effect upon receptor usage without this additional pressure upon the virus.
Therefore in vitro assays in which virus was cultured within cells expressing
solely FLVCR homologues, both with and without prior growth on permissive FEA
cells, were also conducted. This would theoretically allow the expansion of low-
titre FeLV-C viral variants. This technique is similar to traditional methods of
purifying FeLV-B or –C from mixed subgroup primary isolates upon selective cell
lines (Adema, 2003). It must be highlighted that this is a less physiologically
relevant method of mapping the accumulation of Env mutations, as FLVCR1 is
not the receptor initially encountered by the virus in vivo. However these
additional studies would allow comparison of the extent to which both receptor
availability and the host humoral response influence viral evolution.
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The overall aims of these studies were therefore to characterise the relative
roles that VNAs, receptor availability and the initial FeLV-A genotype play in the
development of FeLV-C and dual-tropic viral variants, using in vitro models of
viral evolution.
4.2 Results
4.2.1. D83N and N91D Env mutations do not alter
neutralisation susceptibility
In order to investigate whether the humoral immune response played a role in
the evolution of FeLV-C, sera from FeLV-infected cats were pooled and screened
for reactivity with gp70. During recovery from infection, cats mount a
neutralising response that targets gp70. Accordingly, by pooling sera from
recovered cats, a polyclonal serum was generated which reacted with gp70 on
immunoblot (Figure 4.1A) and which neutralised infection with FeLV (Figure
4.1B). When the relative sensitivities of FeLV-A(Glasgow-1) and the DD, ND and
NN mutants to neutralisation by either the pooled cat serum or a monoclonal
antibody targeting gp70 were compared, no significant differences were
detected, suggesting that the substitutions in amino acids 83 and 91 did not
confer resistance to either of these neutralising antibodies. As it is likely that, in
individual cats, the response to gp70 may be epitope-specific and that the
specificity of the response will vary between cats, the possibility that N83D or
N91D-containing variants may have either a heightened or reduced sensitivity to
neutralisation in vivo cannot be discounted.
Figure 4.1: Neutralisation of FeLV by either pooled serum from FeLV
recovered cats or anti
(A) Purified FeLV-A (Glasgow
nitrocellulose membrane. Strips of membrane were probed with pooled FeLV
positive sera (lane 1), pooled FeLV
MAb (lane 3). (B) 100 I.U. of FeLV
mutants were incubated for two hours with serially
serum or anti-gp70 MAb
infection, foci were enumerated manually. Values represent the mean +/
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Figure 4.2: Replication of FeLV in the presence of sub
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A total of 59 mutations, 42 of which were non-synonymous, were identified
(Figure 4.3). Appendix 8.3 contains a multiple sequence alignment displaying the
nucleotide mutations. With rare exceptions, each mutation was identified in a
single individual clone. When comparing the mutations which arose to those
described previously or those observed in the original primary isolates (Figure
3.1), no evidence was seen for the selective expansion of variants with FeLV-C-
like sequences. The level of variation varied widely between viruses and while
nine non-synonymous substitutions were detected in variants amplified from the
culture infected with the ND mutant, in the presence of anti-gp70 MAb (D30G,
T49A, R263K, D305G, T336A, L476O, R482G, M591T, L608P), no substitutions
were detected in the culture infected with the NN mutant in the presence of
anti-FeLV polyclonal antibody. Mutations were dispersed across both SU (gp70)
and TM (p15E) and were not focussed within variable regions A and B (VRA and
VRB) or the proline rich region (PRR). The data indicate that under the culture
conditions utilised for this study, the four variants had equal propensities to
acquire mutations in vitro and that the combinations of either ND, DD, DN or NN
did not alter significantly the likelihood of the Env acquiring non-synonymous
mutations.
Figure 4.3: Acquisition of non
mutants following long
FEA cultures were infected with FeLV
mutants in the presence of pooled feline sera from FeLV
MAbs, or with no antibody (control). 50 days post
amplified from purified viral RNA and their nucleic acid sequ
Nucleic acid sequences are detailed within Appendix 8.3.
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4.2.3. Evolution of non-functional FeLV Env proteins
during long-term viral replication
Env proteins containing mutations between residues 220 to 400 were selected.
This Env section encompasses the proline rich region (PRR) and the C-terminal
“C domain” (Cdom) of gp70; both these motifs affect receptor usage (Rey,
Prasad, et al., 2008). It has been suggested that whilst the N terminal RBD
confers receptor specificity, the Cdom provides a secondary receptor binding
motif which binds to the viral receptor independently to that of the RBD (Rey,
Prasad, et al., 2008). This is based upon observations that the FeLV-A Cdom
binds weakly to FLVCR1; binding being dependent upon the SU C2 loop, a
disulphide bridge formed between C342 and C396. Specific mutations in this loop
therefore may also affect FLVCR1 usage. It was therefore hypothesised that
substitutions observed in either the C2 loop, Cdom or PRR may enhance SU-
FLVCR1 binding and potentially contribute to either the FeLV-C phenotype or
receptor dual-tropism.
In total, 12 mutations were located in this region (summarised in Table 4.1).
Two clones contained two mutations each; however, four env clones also
contained downstream frameshift mutations, caused by either the loss or gain of
a cytosine residue. As these occurred within a string of cytosines encoding
residues 337 to 400 of Env, these mutations may have been due to “slipping” of
the DNA polymerase during the cloning process. As these env clones would
produce nonsense proteins, they were not investigated further.
Table 4.1: Mutations arising within the PRR and Cdom during long-term viral
replication.
Parental Genotype Culture Conditions Mutation/s Functionality
D83:D91 MAB R263K Functional
N83:D91 AB-free V274A, frameshift N/A
D83:N91 (wildtype) MAB T297A, frameshift N/A
N83:D91 MAB D305G Non-functional
N83:D91 AB-free T309A, T364A Functional
N83:D91 AB-free D311G Functional
N83:D91 MAB L316R, T336A, frameshift N/A
D83:N91 (wildtype) Feline Sera S344P, frameshift N/A
D83:D91 AB-free P366L Non-functional
N83:D91 Feline Sera N374D Non-functional
MLV(FeLV) lacZ particles, pseudotyped with the six remaining FeLV Env mutants,
were produced by transient transfection of HEK293T cells. A
immunoblots were
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Figure 4.4: Mutant FeLV Env proteins display inconsistent levels of
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The long-term viral replication assay described above indicated that VNAs did
not drive the evolution of FeLV-C variants, regardless of the initial FeLV-A
genotype; it appeared that mutations arose through genetic drift rather than
antibody-mediated escape. Although some of these mutations abrogated
functionality, others enhanced viral entry through the THTR receptor.
4.2.5. FeLV-A culture within MDTF-huFLVCR1/2 cells
does not produce FeLV-C variants
The next aim was to investigate whether receptor availability contributed to the
evolution of FeLV-C or of dual-tropic viral variants. As FEA cells are susceptible
to FeLV-A,-B and -C, continued use of this cell line in the previous assay did not
exert a purifying effect upon the viral cultures. Therefore the long-term
replication assay was reproduced using MDTF cells expressing either huFLVCR1 or
huFLVCR2 proteins.
Initially, MDTF-huFLVCR1 cells were infected at a MOI of 0.01 with the four
FeLV-A(Glasgow-1) based viruses. After the first subculture (72 hours post-
infection), antibodies were included in the culture medium at sub-neutralising
concentration to aid development of neutralisation-escape mutants. The cells
were subcultured upon confluency for 50 days. Supernatants were regularly
harvested, concentrated by ultracentrifugation and screened by immunoblot for
the detection of the FeLV CA and Env proteins. However, replicating virus was
not detected in any of the cultures at any point, regardless of the presence of
antibodies.
The third long-term replication assay was conducted upon MDTF-huFLVCR2
expressing cells. Antibodies (either pooled sera or the Env MAb) were not
included in this assay as stocks of these preparations were limited. As described
previously, the four FeLV-A(Glasgow-1)-based mutant viruses were used to infect
MDTF-huFLVCR2 cells and cells were passaged for 50 days. Concentrated cellular
supernatant was tested regularly for the presence of viral particles by
immunoblots against both CA and gp70. However, after 50 days in culture no
virus replication was detected in any of these cultures.
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4.2.6. Expansion of FeLV-A subpopulations upon
MDTF-huFLVCR1/2 cells
Neither homologue of FLVCR is the initial receptor encountered by FeLV-A
virions, indicating that initial growth upon MDTF-huFLVCR1/2 cells is a
physiologically inaccurate model. A lack of active virus production during these
latter models was therefore partly expected. It must also be highlighted that a
pure culture of virus, produced from an infectious molecular clone, was used in
these assays which does not mirror the natural scenario. A natural isolate of
FeLV-A would contain a cloud of viral variants within the sample, some of which
may give rise to FeLV-C viruses after purification by growth on MDTF-huFLVCR1
cells. However, using a primary field isolate in an in vitro model would prevent
distinction between those mutations which arose during the purifying expansion
process and those which were initially present in the FeLV-A inoculum.
To more closely mimic the natural scenario whilst still utilising whole viral
molecular clones, both MDTF-huFLVCR1 and –huFLVCR2 cells were infected with
virus from the final passage of the FEA cells infected in the first long-term assay.
Although the final env analysis had not detected viral mutations potentially
leading to expanded receptor usage, the nature of the methods (PCR followed by
env cloning) was not exhaustive and did not provide a fully conclusive result. It
is possible that dual-tropic viruses were present in some cultures and had not
been detected during the cloning analysis. Further culture of the viruses on
both MDTF-huFLVCR1 and -huFLVCR2 cells would allow amplification and
purification of variants able to utilise these receptors.
MDTF-huFLVCR1 and –huFLVCR2 expressing cells were therefore infected with
concentrated viral preparations from the originally infected FEA cells, harvested
at 50 days post-infection. Viral supernatant had been stored at -80°C. Antibodies
(either pooled feline sera or the Env MAb) were not included in the media.
Cultures were passaged upon confluency for 50 days. Supernatant was harvested
regularly and concentrated by ultra-centrifugation before being screened by
immunoblotting for the detection of both CA and Env proteins. Virus production
was not detected in any of the cultures at any point throughout this assay. This
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was confirmed by a RT detection assay conducted upon cellular supernatant at
the conclusion of the experiment.
These studies indicated that if low levels of FeLV-C/dual tropic variants were
present at the conclusion of the FEA long-term replication assay, further culture
upon MDTF-huFLVCR1/2 cells did not allow selection and expansion of these
variants. It remains possible that FeLV-C progenitor viruses were present within
the FEA viral cultures at extremely low levels. To quantify the sensitivity of this
FeLV-C expansion method, a control experiment was performed to confirm the
length of passage required for an FeLV-A/C mixture to replicate to detectable
levels upon MDTF-huFLVCR1 cells. A preparation of replication-competent FeLV-
A (Glasgow-1) was prepared, and “spiked” with serial dilutions of FeLV-C
(FY981C). These viral preparations were then used to infect MDTF-huFLVCR1
cells. FeLV-A(Glasgow-1) alone was included as a control for viral genetic drift.
Cellular supernatant samples were taken daily and cells were subcultured upon
confluency. By 50 days post-infection, replicating FeLV-C could be detected
from an initial dilution of 1:10-3 (vol/vol) by RT detection assay (Figure 4.7). This
indicates that FeLV-C viruses initially contributed less than 0.1% of the viral
population during the long-term viral replication assays.
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Figure 4.6: A 1:103 dilution (vol/vol) of FeLV-C within a FeLV-A population is
detectable by RT detection assay after 50 days in culture upon MDTF-
huFLVCR1 cells.
10-fold dilutions of FeLV-C within a stock of FeLV-A were cultured in MDTF-
huFLVCR1 cells. RT activity, measured by absorbance at 405nm, was measured in
cell-free supernatant fifty days post-infection. FeLV-A (only) viruses and a
control sample of cell- and virus-free supernatant (Con) were included as
controls.
To summarise, the development of FeLV-C or dual-tropic viral variants from any
FeLV-A strain was not observed in any long-term viral replication models,
regardless of the presence of VNAs or cognate receptor availability. As these two
variables are thought to be the main influences upon viral subgroup evolution,
these results were unexpected. It may be that pressures other than antibody-
mediated escape and receptor availability are the determinants of FeLV-C
evolution, regardless of the genotype of the infectious FeLV-A strain.
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4.3 Discussion
Having established that subtle variations in the VRA of FeLV-A could have a
significant impact upon the biological properties of FeLV-A(Glasgow-1) (Chapter
3), the subsequent aim was to mimic the selective pressures exerted upon FeLV
in vivo. By culturing virus in the presence of sub-optimal concentrations of
either monoclonal anti-gp70 antibody or pooled serum from FeLV-infected cats,
the acquisition of non-synonymous mutations over time was observed, although a
shift from subgroup A (THTR1-using) to subgroup C (FLVCR1-using) viruses was
not demonstrated. Subgroup C viruses emerge in an estimated 1% of anaemic
cats, suggesting that a relatively rare set of circumstances combines to drive
their evolution. It is possible that the epitope specificity of the antibody
response elicited following infection may prove critical in determining the
composition of variants that evolve, and so serum from cats from which FeLV-C
had been isolated rather than a diverse pool of FeLV-infected cat sera would be
required to mimic this response in vitro. While the working hypothesis was that
the humoral immune response influences the likelihood of FeLV-C emerging in
infected cats, other factors may have a significant impact upon viral evolution;
for example VRA may constitute a T cell epitope in some cats and pressure to
escape a cellular immune response may play a role in driving variation in VRA.
4.3.1. The role of VNAs in viral evolution
It is possible the antibodies in this experiment were used at too low a
concentration to drive selection of escape mutants. The antibody concentrations
were calculated so as to neutralise the majority of virus present but allow a
continuous low level of replication. However, the clones from the viral cultures
containing each antibody preparation (either pooled feline sera or gp70-MAb) do
not contain mutations in common areas. Mutations did not localise to specific
areas; rather, they are randomly and evenly distributed throughout the env
gene. This indicates the antibody concentration in either preparation was not
sufficient to induce purifying selection; had this occurred the mutations would
have clustered within the targeted epitopes. It would then have been of
additional interest to investigate if the mutations which arose conferred
resistance to homologous and/or heterologous neutralisation. However the
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limited availability of the antibody preparations made this impossible in this
study. These results would have provided further evidence as to whether
antibody-mediated escape was occurring, regardless of the association of the
mutations with the FeLV-C subgroup.
It must be highlighted that the selective pressure provided by VNAs does not
alter the mutation rate of a virus, but rather exerts a purifying effect on the
circulating mutants and alters the spectrum of variants able to flourish
(Overbaugh & Bangham, 2001). The choice of antibodies would therefore have
been a major influence on the viral mutants detected in the final cloning
analysis; it is probable that an alternative antibody or sera combination would
have produced very different results. Utilising a MAb specific for a known gp70
epitope may have been more informative, as mutations within the targeted
epitope could be easily identified. The C11D8 MAb may have been a useful
choice; this neutralising MAb targets the MGPNL motif (Elder, et al., 1987). It is
not known which epitope was targeted by the gp70-MAb used in this study or
whether it was linear or conformational. As the mutations which arose in the
MAb-treated cultures are not confined to the one region, these results cannot be
reliably used for epitope-mapping. It is also possible that the mutations present
in natural FeLV-C isolates, potentially including D83N and/or N91D, alter Env T-
cell epitopes. If this were the case, the advantage these mutations conferred
would not be detectable in an antibody-based experimental study such as this.
The inclusion of VNAs in the long-term replication study was based upon the
assumption that FeLV-C evolution may be a result of the replicating virus
escaping antibody-mediated neutralisation. This hypothesis is not without
precedent as there are numerous instances of retroviral antigenic variation and
receptor usage alterations being driven by pressure from the host immune
response. VNA play a role in the selection and expansion of viral variants in both
simple and complex retroviruses, and this has been mimicked successfully in
vitro in numerous cases (Manrique, et al., 2007; Nakowitsch, et al., 2005;
Rwambo, et al., 1990). In the example of equine infectious anaemia virus (EIAV),
an in vitro model of viral evolution found that 13 viral passages were required to
obtain an antibody-escape mutant. This phenotype was conferred by only two
altered epitopes in the SU domain (Rwambo, et al., 1990). This is a similar
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timespan to that used in this study, indicating it was sufficient to observe
antibody-escape mutants. Despite the lack of FeLV-C-associated mutations in
these results, development of FeLV-C as a consequence of antibody escape
remains a plausible theory. There are numerous variables in this process which
could not be replicated in this model, including the broad range of antibodies
produced in a competent immune response. Before definitive conclusions can be
drawn about the role of VNAs in FeLV-C development, these studies should be
repeated using a more extensive range of both polyclonal and monoclonal
antibodies.
4.3.2. Analysis of mutations arising during long-term
viral replication
A detailed analysis of the mutations that arose during viral replication within
FEA cells allows several inferences to be made (Figure 4.3). Firstly, the rate of
mutation appeared consistent across all cultures, indicating viral genetic drift
occurred at similar rates regardless of the presence of VNAs. Additionally, few
mutations were identified more than once, indicating a single FeLV genome had
not emerged as the dominant viral subpopulation in any culture. However the
limited capacity of the env selection method (cloning as opposed to deep
sequencing) must be taken into account as it is possible that the amplification of
more env sequences, or the use of alternative techniques, may have produced
different results. Amplification and cloning of env genes may not provide a
sufficiently broad picture of the genomes present in the culture. It remains
possible that dual-tropic virus strains, or those containing mutations indicative
of a FeLV-C phenotype were present in some cultures but were not detected
during this analysis. The results presented herein therefore represent a
“snapshot” of the viral genomes present at 50 days post-infection. It was not
possible to determine whether specific viruses formed prominent subpopulations
during the course of infection, indicative of a species with a replicative
advantage expanding.
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4.3.3. Cell-to-cell transmission in FeLV replication
It was initially hypothesised that the mutations within FeLV Env which arose
during escape from antibody-neutralisation may correlate with usage of the
FLVCR1 receptor and a FeLV-C viral phenotype. However other mechanisms of
antibody avoidance, distinct from receptor-usage alteration, were not
investigated. It is possible that FeLV switches to spreading preferentially via
cell-to-cell transmission, as opposed to a cell-free infection route, to reduce
antibody-mediated neutralisation. It was recently suggested that MLV (and
presumably other gammaretroviruses) spreads predominantly via cell to cell
transmission, although this is a contentious issue (Jolly, 2011; Sherer et al.,
2007); nevertheless the ability or preference of FeLV to spread via these two
distinct mechanisms has not been investigated. Therefore the mutations
investigated herein were not studied for their effects on viral transmission
routes. A switch in the main route of viral transmission may allow the virus to
escape immune clearance without altering receptor usage. The concept that
cell-to-cell spread allows escape from VNAs has been suggested previously for
HIV-1 (Jolly, 2011; Martin & Sattentau, 2009). It is thought this transmission
route reduces the exposure of the virus to VNAs, both spatially due to increased
viral budding at cell-cell interfaces and temporally by reducing the timespan
viral antigens are exposed to circulating VNAs.
In further support of this hypothesis, a recent publication described a
neutralisation-resistant mutant of EIAV which had acquired enhanced rates of
cell-to-cell transmission (W. Wu et al., 2011). The escape mutant displayed
resistance to neutralisation by VNAs; however its cell-free viral titre was
significantly lower than that of the parental virus. Despite this, the two viruses
displayed similar rates of cell-to-cell transmission, indicating this route may
overcome the inefficient cell-free infection rate of the mutant and contribute to
its resistance to VNAs. As cell to cell transmission is rapidly being recognized as
a major factor in viral kinetics, it is possible that FeLV Env proteins which
appear less efficient in traditional receptor-binding or single-cycle pseudotype
assays may be successfully utilised for this method of viral expansion. Future
work may be directed towards investigating the effects of the D83N and N91D
mutations upon cell-to-cell transmission rates, and determining whether this
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route of viral infection is enhanced by the presence of the D83:D91 motif.
However this would require methods able to differentiate cell-to-cell and cell-
free viral spread which was out-with the scope of this project. Virions able to
bind receptors whilst displaying budding defects may potentially be used, as
they would be expected to be limited to a cell-to-cell route of transmission.
4.3.4. Additional factors influencing viral evolution
The experimental data presented here indicate that genetic drift, rather than
selective pressure provided by VNAs, induced the env mutations observed in
viruses from FEA cells. However there are numerous alternative mechanisms for
the observed mutations, for example some mutations may have arisen at sites as
a result of structural biochemistry. There is evidence that adenine-thymine
tracts (consisting of four consecutive A or T nucleotides) are associated with
“bends” in the nascent DNA strand, and are more likely to be mutated through
misincorporation (Svarovskaia, Cheslock, Zhang, Hu, & Pathak, 2003). As 13 of
the 59 mutations (~22%) observed in the FEA long-term replication study
occurred in AT-rich tracts (see Appendix 8.3 for nucleotide sequence data) it is
possible these are due to this phenomenon, rather than either neutralisation
escape or receptor tropism expansion as originally predicted. In addition, some
mutations may have arisen as the result of apolipoprotein B mRNA-editing
enzyme catalytic polypeptide (APOBEC) activity. APOBECs mutate retroviral
genomes by deaminating the cytosines during first-strand DNA synthesis,
eventually causing an accumulation of G to A mutations in the genome. However
there was minimal evidence of APOBEC activity in the env sequences analysed in
this study; of the 59 mutations identified only 7 were G-to-A transitions (~12%).
Additionally, only 3 (~5%) are found within likely targets for feline APOBECs
(AGG or GGG motifs) (Geret et al., 2011). This is in accordance with other
reports that APOBECs exhibit weak restriction of FeLV in natural infections
(Geret, et al., 2011; Munk et al., 2008).
In comparison, approximately 50% of the mutations which arose in this study are
A to G hypermutations. The causative factor for this unexpectedly high
occurrence is not known, however these nucleotide substitutions may be due to
double-stranded RNA adenosine deaminases (dsRADs). These cellular enzymes
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deaminate adenosine bases within dsRNA, producing an inosine which is then
converted to guanosine during reverse transcription (Polson, Crain, Pomerantz,
McCloskey, & Bass, 1991). However dsRADs tend to induce “strings” of such
transitions, altering approximately 50% of the adenosine bases within the
targeted region (Hajjar & Linial, 1995; Nishikura et al., 1991), rather than the
isolated single nucleotide polymorphisms which were observed in this study.
Although retroviruses do not produce a dsRNA complex at any point during their
replication cycle, hypermutation attributed to dsRADs has been reported in both
HIV-1 and simple avian retroviruses (Felder et al., 1994; Hajjar & Linial, 1995;
Sharmeen, Bass, Sonenberg, Weintraub, & Groudine, 1991).
Continuing viral replication past 50 days post-infection would be unlikely to have
produced different results; there were multiple reasons to limit the experiment
to this period. In practicality, there were time constraints and a limited amount
of each antibody preparation was available. Regardless of these factors, re-
infection of naïve cells only occurs until a cell line is chronically infected. At this
point, downregulation or masking of the cognate receptor would occur. Although
infectious virions would continually be released reinfection and proviral
integration would not occur, preventing the reverse transcription stage of the
retroviral life cycle during which the majority of mutations are incorporated.
Were the study to be continued after this point, the viruses sampled would have
been transcribed from established proviruses and would no longer represent a
differentiating population. Proviral replication, occurring during cellular mitosis,
plays only a minor role in retroviral mutation rates. It is therefore unlikely that
continuing the experiment for a longer duration would have altered the
experimental outcome.
4.3.5. In vivo models of FeLV-A to -C evolution
There have been no recent attempts to reproduce the FeLV-A to –C conversion
process using in vivo feline infections. However, a recent publication describes
an experimentally-infected cat which displayed FeLV reactivation after
approximately 8 years of clinical latency (A. K. Helfer-Hungerbuehler, et al.,
2010). As this cat was inoculated with FeLV-A(Glasgow-1) this is a fairly accurate
in vivo comparison to the studies presented in this chapter. The disease
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manifestation, being non-regenerative anaemia and multicentric B-cell
lymphoma, is indicative of FeLV-C development. Three variant viruses were
identified within this cat at the time of necropsy. Although the env genes were
predicted to be of subgroup A, receptor usage was not experimentally analysed.
As the determinants of FLVCR1 usage have not been elucidated it should not be
assumed these supposedly FeLV-A viruses could not utilise alternative receptors;
to claim that these strains are not FeLV-C due to a low genetic identity to FeLV-
Sarma is inaccurate.
Evidence that these variants are either FeLV-C or dual-tropic comes from an
analysis of the Env amino acid sequences (GenBank Accession numbers EU359303
to EU359305). This reveals the presence of polymorphisms conserved between
the FeLV-C components of the primary isolates detailed in Chapter 3 (Figure
3.1). These residues are S94, P102, P104, M132, Y138, and P177. Notably, one
Env variant also contains the D83N mutation. The presence of these mutations in
an in vivo study such as this supports the hypothesis that FeLV-C arises from an
FeLV-A isolate through the stepwise accumulation of mutations, gradually
altering the receptor-binding properties of the SU domain and eventually
resulting in a FeLV-C virus solely able to utilise FLVCR1.
4.3.6. The role of receptor availability in retroviral
evolution
The studies utilising MDTF-huFLVCR1/2 cells addressed the possibility that a
switch in retroviral receptor usage will only be induced if the novel receptor is
the solely functional protein available. This is the case for the pathogenic avian
leukosis virus, which acquires an expanded receptor tropism when cultured in
the presence of soluble non-functional receptors (Melder, Pankratz, &
Federspiel, 2003). This alters the subtype classification of the virus, in a manner
similar to FeLV. Therefore receptor availability represents a significant potential
driving force for retroviral evolution, indicating the use of FEA cells expressing
all 3 cognate receptors may have inadvertently decreased the likelihood of FeLV-
C evolving in the initial study. If receptor availability is the main determinant of
viral evolution, the presence of VNAs would also have had minimal effect on the
mutations identified in the study with FEA cells.
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It must also be noted that although evolution of novel receptor usage allows the
virus to access novel cellular niches and spread further throughout the host, in
the case of FeLV this represents an evolutionary cul-de-sac, as both FeLV-B and –
C do not transmit to naïve hosts in nature. The concept that receptors targeted
during chronic viraemia within a host may be distinct from those required for
transmission between hosts has been suggested for other retroviruses including
HIV (Overbaugh & Bangham, 2001). However, as HIV requires both a receptor
(CD4) and co-receptor (either CXCR4 or CCR5) for successful cell entry (reviewed
in (Philpott, 2003)), this allows the virus a higher level of variation regarding
receptor choices and binding affinities than FeLV, which is constrained by the
fact it must retain a threshold binding affinity to THTR1 until a chronic infection
is established.
4.4 Conclusions
The most significant drawback to these experiments was the inadequate length
of time available; as many retroviral-associated pathologies only arise after
years of infection it remains possible that either VNAs or receptor expression
play significant roles in FeLV-C evolution. Similarly, the VNA neutralisation
studies rely upon the breadth of antibodies present in the pooled feline serum,
which would be unique across individual hosts. Finally, it must be highlighted
that the cloning method utilised for assessing the Env proteins (isolated after
long-term viral culture) would heavily influence the results.
During these studies, an in vitro model of FeLV-A to –C evolution was utilised to
characterise the roles of both receptor availability and VNAs in this process.
FeLV-A mutant viruses displaying differential initial abilities to bind to THTR1
and FLVCR proteins were included, however no association between any one
FeLV-A genotype and the development of FeLV-C or dual-tropism was found.
Using feline cells permissive to FeLV-A, -B and –C in a long-term viral replication
assay, mutations were identified within the Cdom of SU which affected viral
titre and infection rates. However these arose through viral genetic drift and
were not associated with the presence of VNAs. Non-functional Env proteins
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which could not pseudotype gammaretroviral virions were also isolated, although
the cause of this non- functionality was not apparent.
Further studies with selective cell lines, which would expand low-titre viral
variants able to utilise FLVCR1/2, indicated these variants were either absent or
present at a concentration below 1:10-5 (vol/vol) within the FeLV-A virions.
These results indicate receptor availability plays a minimal role in the
development of FeLV-C in infected cats. Viruses appearing phenotypically as
FeLV-C did not arise under any of the experimental conditions, indicating either
extensive incubation periods (>50 days) or other unidentified pressures are
required for this to occur. Before any definitive conclusions can be drawn about
the role of VNAs in FeLV-C development, this study should be repeated using a
more extensive range of both polyclonal and monoclonal antibodies and a more
thorough approach to profiling the final env sequences should be utilised.
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5. Are endogenous feline leukaemia viruses really
endogenous?
5.1 Introduction
The aim of the studies detailed in this chapter was to characterise novel virus
isolates which appeared phenotypically to comprise solely FeLV-B infections.
This would allow investigation into whether inter-host transmission of FeLV-B
may occur without the presence of FeLV-A “helper” viruses. It was hypothesised
that such events may represent horizontal transmission of transcriptionally-
active endogenous FeLV proviruses, posing the question of whether such enFeLV
elements are truly endogenous. Further studies regarding horizontal enFeLV
transmission are discussed in Chapter 6.
Endogenous retroviruses (ERVs) arise after a proviral integration event occurs
within a germline cell or during early embryogenesis. The resultant provirus is
maintained at this locus in every cell of the adult host. “Ancient” ERVs are
therefore fixed Mendelian elements within the genome of the species, whereas
more recently integrated ERVs may display polymorphism between individuals.
There are numerous FeLV-related endogenous elements (enFeLV) within the
domestic cat genome (Benveniste & Todaro, 1975; Koshy, et al., 1980; Okabe, et
al., 1976; Soe, et al., 1983), most of which are polymorphic (Koshy, et al., 1980;
Roca, et al., 2005) and many have intact LTRs (Soe, et al., 1983; Soe, et al.,
1985). The U3 region of the LTRs differs significantly between endogenous and
exogenous FeLV genomes (Berry, et al., 1988; Casey, et al., 1981; Okabe, et al.,
1978), hence this domain is often analysed to determine the nature of FeLV
proviruses (Tandon, et al., 2008). As enFeLV elements are generally mutated and
non-functional, they do not form infectious virions (Soe, et al., 1985), although
expression of short transcripts has been observed (Busch, et al., 1983;
McDougall, et al., 1994; Niman, et al., 1980).
Recently, full length enFeLV elements with intact open reading frames (ORFs)
have been characterised (GenBank Accession numbers AY364318 and AY364319)
(Roca, et al., 2004). These endogenous elements possess identical 5’ and 3’ LTRs
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and are present in only 9 - 15% of domestic cats (Roca, et al., 2005) indicating
they are relatively recent additions to the feline genome. It was hypothesised
that if transcription and packaging of these full-length enFeLV genomes occurred
in vivo, then they may be transmitted between hosts.
FeLV-B arises through recombination events between the env genes of FeLV-A
and enFeLV transcripts (Neil, et al., 1991; Overbaugh, Riedel, et al., 1988;
Stewart, et al., 1986). The recombination event leading to FeLV-B formation is
hypothesised to take place within a virion that has co-packaged two distinct
FeLV transcripts, however to date this has not been observed directly. Thus
FeLV-B is always found alongside FeLV-A, which is generally regarded as the
“helper” virus required for FeLV-B transmission (O. Jarrett & Russell, 1978;
Sarma & Log, 1973). The recombination event leads to an alteration of the
receptor usage of the virus, as this is determined by the receptor-binding
domain (RBD) located within the translocated SU-encoding region (Bae, et al.,
1997; Rigby, et al., 1992). FeLV-A strains utilise a thiamine transporter protein
(feTHTR1) for cell entry (Mendoza, et al., 2006) whilst FeLV-B utilises an
inorganic phosphate-sodium symporter (fePit1) (Rudra-Ganguly, et al., 1998;
Takeuchi, et al., 1992). As the RBD of FeLV-B is encoded by an enFeLV region of
the recombinant genome, infections caused by transmission of enFeLV-encoded
virions would present as subgroup B only in interference assays. Interference
assays, a method of classifying viruses according to their receptor usage, rely
upon the fact that infection with a retrovirus leads to down-regulation or
masking of the receptor upon the cell surface, preventing re-infection by a virus
of the same interference group (R.A. Weiss, 1993).
In this study, a group of FeLV field isolates were examined for the presence of
variants that displayed the FeLV-B phenotype alone. Two isolates were
identified from the sera of naturally infected cats, and the viral genomes were
sequenced to identify their proviral origins. Although there was evidence for
recombination between endogenous and exogenous transcripts in the genomes of
both these isolates, viruses of purely endogenous origin were not identified.
Additionally, one isolate co-packaged a defective exogenous FeLV-A genome
alongside the functional recombinant. It is predicted that these ostensibly-FeLV-
B isolates may be transmitted between hosts without the presence of FeLV-A. It
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appears that enFeLV elements may contribute more to FeLV transmission and
pathogenesis than previously suspected, despite the lack of enFeLV horizontal
transmission.
The overall aim of the studies detailed in this chapter was to characterise novel
virus isolates which appeared phenotypically as purely FeLV-B infections. This
would allow investigation into whether inter-host transmission of FeLV-B may
occur without the presence of FeLV-A “helper” viruses and whether endogenous
FeLV proviruses were actively circulating within the host population.
5.2 Results
5.2.1. The field isolates FeLV-2518 and -4314 are
phenotypically subgroup B
FEA cells were infected with a panel of 300 FeLV field isolates, which were then
classified by interference assay (R.A. Weiss, 1993) into their respective
subgroups (initial assays conducted by Matthew Golder, University of Glasgow).
Two isolates, designated FeLV-2518 and FeLV-4314, displayed the FeLV-B
phenotype alone with no evidence of FeLV-A co-infection. Although FeLV-B
infection is highly associated with FeLV-induced lymphomas (Sheets, et al.,
1993; Tsatsanis, et al., 1994) and leukaemias (O. Jarrett, et al., 1978; Tzavaras,
et al., 1990), the clinical history and disease status of these hosts was not
available, therefore the disease manifestation of these FeLV-B isolates is
unknown.
To confirm these viruses were replication-competent, cell-free filtered
supernatant from the infected FEA cells was used to infect HEK293T cells.
Immunoblots of cell-free virions from both FEA and HEK293T cells were
conducted to detect both the p27 (CA) and gp70 (SU) proteins, confirming the
cells were persistently infected (Figure 5.1). These results indicated that both
isolates produced a full-length envelope glycoprotein.
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FeLV-B alone.
MLV (FeLV) lacZ pseudotypes were titrated upon a range of FEA cells infected
with the Glasgow-1 (A),
the novel strains -2518 and
infection. Values represent the mean +/
-regulation was provided
the FeLV-A, -B or –C Envs. A decrease in
surface expression of the respective cognate receptor.
es. Conversely, prior infection with FeLV
-B Env-bearing pseudotypes while FeLV
-C, but not FeLV
These assays confirmed the decrease of
observed previously in FeLV-2518 infect
-4314 displayed lowered expression of the Pit1
-2518 are resistant to both FeLV
-4314 infected cells are resistant to superinfection with
Gardner-Arnstein (B) and Sarma (C) strains of FeLV, or
-4314. Titres were calculated 72 hours post
- SEM of three independent experiments.
134
MLV(FeLV) lacZ
lacZ titre would
-A
-B and -C Env-
-B reduced the
-C
-A or –B Env
both Pit1 and
ed FEA cells (Figure
-A
-
The decreases in titre marked with asterisks are s
(p<0.001).
5.2.3.
enFeLV transcripts
As the FeLV-4314 and
5.1) and appeared to be solely of the FeLV
genes were of endogenous origin and the
transcriptionally active enFeLV provirus
endogenous env and U3 regions from cell
(“FeLV enEnv” and “FeLV en
However enFeLV env
cDNA, indicating an endogenous
detected earlier. In support of this, endogenous LTRs were only detected in
gDNA from feline cells, indicating transmission of an enFeLV provirus to the
HEK293T cells had not occur
(A)
Figure 5.5: EnFeLV transcripts are not present in FeLV
(A) Virus was pelleted from the supernatant of cells chronically infected with
FeLV-2518 and -4314 and used to prepare cDNA. cDNAs were then screened for
the presence of enFeLV transcripts by PCR with primers specific for enFeLV
Plasmids containing endoge
respectively) were included to confirm primer specificity. Con = no template
control. (B) Genomic DNA
FeLV-2518, -4314 and A (Glasgow
LTR sequences using PCR with enFeLV LTR
uninfected FEA (Con) and from FEA cells chronically infected with FeLV
tatistically significant
FeLV-4314 and -2518 are not encoded by
-2518 viruses contained full-length Env proteins (Figure
-B subgroup, it was predicted the
se isolates may
es. PCRs were conducted
-free virus and proviruses, respectively
-U3”, PCR details included i
could not be detected in either FeLV
env was not encoding the full
red.
(B)
-2518 and
nous and exogenous env clones (En
from HEK293T and FEA cells chronically infected
-1) were screened for the presence of enFeLV
-specific primers.
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-Env and Ex-Env,
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Genomic DNA from
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uninfected HEK293T (Con) were included to confirm
indicate the presence of enFeLV LTRs in feline gDNA only.
5.2.4.
within FeLV
The lack of evidence for the involvement of enFeLV in these isolates
an exogenous genome was present
indicate a functional subgroup A virus was present in either case.
conducted with exogenous FeLV
transcripts from viral cDNA (“FeLV Env”, PCR detailed in
could not be detected from FeLV
produced a ~1kB amplicon (Figure 5.
gDNA from both infected HEK293T and FEA cells
proviral form.
Figure 5.6: Exogenous
within FeLV-2518 virions, termed FeLV
Viral RNA was isolated from
and screened by RT
containing endogenous and exogenous
respectively) were included to confirm primer specificity.
Cloning and sequence analysis of the ~1kB amplicon revealed it to be an
exogenous FeLV env
SU/TM cleavage site, hydrophobic membrane anchor and the majority of the TM
primer specificity. Products
A defective exogenous FeLV env gene is present
-2518
, despite the fact earl
-specific primers, to amplify exogenous
Appendix
-4314 templates; however FeLV
6). This could be reproduced using cellular
, indicating it was also present in
env PCR reveals a truncated FeLV
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chronically infected and uninfected (
-PCR to detect exogenous FeLV env
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transcript, with an internal ~900bp deletion
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transcripts. Plasmids
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domain (see Figure 5.11 for a s
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2518(A); the Env amino acid sequence is detailed in Appendix
the absence of a hydrophobic TM region suggests this peptide would be soluble,
it was not detected within supernatant from FeLV
However the FeLV-
downregulation of THTR1 that was observed in FeLV
be speculated that this peptide binds to immature THTR1 proteins within the
cell and prevents display of the functional receptor upon the cell surface.
5.2.5.
To confirm the presence of this exogenous FeLV genome in the virions of FeLV
2518, a PCR to specifically amplify the U3 region of exogenous FeLV LTRs was
conducted upon genomic DNA from both FEA and HEK293T cells
detailed in Appendix
were observed from both Fe
analysis confirmed these were integrated exogenous FeLV U3 motifs.
Figure 5.7: Exogenous LTRs are present in
Genomic DNA was isolated
PCR for the detection of
infected and uninfected
specificity. A water
chematic of the defective genome)
ed. This defective exogenous FeLV genome was termed FeLV
-2518
A RBD within this peptide was intact. Given the unexpected
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Although exogenous LTRs
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indicated RD-114 was not involved in the transmission or replication of these
novel isolates (Figure 5.8).
Figure 5.8: The endogenous virus
4314.
Cell-free supernatant from
HEK293T and FEA cells was
separated by SDS-
capsid protein (upper panel). V
PCR for the presence of RD114
samples were obtained by transfection of HEK293T cells with the RD
infectious molecular clone
In addition to RD-
functional retrovirus terme
Non-FeLV retroelements are not present in either
were present in both virus isolates, the lack of
FeLV env transcripts
retrovirus may be contributing to
involvement of the endogenous feline retrovirus, RD
the RD-114 capsid protein and a PCR to detect RD
(“RD-114 Env”, PCR detailed in
RD114 is not present in FeLV
chronically infected and uninfected (control)
harvested, concentrated by ultracentrifugation and
PAGE before being probed for the presence of the RD114
iral RNA was also isolated and screened by RT
env transcripts (lower pa
, pS3C3 (Reeves, et al., 1985).
114, there exists in the domestic cat genome a putatively
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Figure 5.9: FcEV transcripts
Genomic DNA was isolated
HEK293T and FEA cells
env sequences. Amplicons were not observed in FeLV
non-feline cell lines.
5.2.7.
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not present in FeLV
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conserved region within the U3 of both enFeLV and exogenous FeLV
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Appendix 8.2). Amplicons were sequenced to
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-2518 or
FeLV-4314 and -2518 possess recombinant
retroviral elements (enFeLV,
-2518 or -4314 isolates, it was conclude
however the isolation of this subgroup
-A virus has not been documented previously
env genes from the gDNA of
(“FeLV-Recombinant”, PCR details i
Figure 5.10). Cloning and sequence analysis
env sequences with exogenous FeLV LTR
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Figure 5.10: FeLV-
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sequences of FeLV
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(encoding the SISALEK motif within TM), conserved between both the prototype
FeLV-A(Glasgow-1) and enFeLV viral genomes. Upstream there were 12
randomly-distributed mutations, encoding 7 amino acid substitutions, which
distinguish this from the full-length enFeLV genome AY364318 (Roca, et al.,
2004). This indicated that although the contributing enFeLV locus is not
definitively known it is likely to be a recently-endogenised retrovirus. It is
hypothesised that the majority of the TM domain, and the accompanying U3
region of the 3’ LTR, are derived from an exogenous FeLV-A genome that is no
longer present within the isolate.
In comparison, the 3’ recombination breakpoint of the FeLV-2518 genome is an
18 nucleotide stretch encoding the WTSDFC motif, ~100bp upstream of the
SU/TM cleavage site. This recombination site has been identified previously in
FeLV-B isolates (Boomer, Gasper, Whalen, & Overbaugh, 1994) indicating it may
be a preferential region for RT strand transfer during DNA synthesis. Within the
endogenously-derived region of FeLV-2518, there is only one nucleotide
difference (causing a K to I substitution) when compared to the AY364318
genome, again indicating a recently-endogenised provirus is the most probable
source of this region. Sequence comparison of FeLV-2518 and the defective
FeLV-2518(A) env gene revealed homologous stretches both within the 3’ region
of env and across U3. This provides evidence for FeLV-2518(A) being the source
of the exogenous regions within the functional FeLV-2518 genome. However
numerous mutations were observed clustered within the region immediately
downstream of the stop codon of FeLV-2518(A). This genetic drift may have
occurred since the recombination event that formed the functional FeLV-2518
viral genome, as there was no longer selective pressure upon the exogenous
genome to retain functionality.
Using a series of oligonucleotides conserved between exogenous and endogenous
FeLV sequences, the whole viral genome of both FeLV-2518 and -4314 was
sequenced from viral cDNA. Genome sequence contigs were created for each
virus (Appendix 8.4 (A)). This allowed identification of the 5’ recombination
breakpoints, identified by the alteration from an exogenous sequence to that of
an endogenous FeLV element (Figure 5.11 for a schematic of the overall genome
structures).
Figure 5.11: The genomes of FeLV
Viral RNA was isolated from chronically infected HEK293T cells and
of FeLV-2518 and
multiple contigs, resulting from overlapping PCRs.
between endogenous and exogenous transcripts were identified and compared to
the previously-described FeLV
are detailed in Appendix 8.4..
FeLV-2518 contains
env, whereas the 5’ recombination site of
gene, specifically within the RT ORF.
identified within the
possesses an identical sequence to that of FeLV
hence the two genomes could not be disting
that the now-defective FeLV
recombinant FeLV-
-2518 and -4314.
-4314 were determined and annotated
Recombination breakpoints
-B isolates. Nucleotide and a
a 5’ recombination breakpoint within
FeLV-4314 is found within the
The fact that multiple transcripts were not
FeLV-2518 viral cDNA at any point suggests
-2518 outside the
uished. This supports th
-2518(A) is the parental virus
2518.
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5.2.8. Alteration of the LTRs may alter the pathogenic
potential of enFeLV
As the Gag and Pol polyproteins of endogenous and exogenous FeLV genomes are
highly conserved (Berry, et al., 1988; Roca, et al., 2004), substituting the
majority of the env gene of FeLV-A with that of enFeLV would exert a similar
phenotypic effect as the transmission of a wholly endogenous enFeLV to a novel
host. It is not known whether this event would be detrimental; as ERVs rarely
display pathogenicity towards their wildtype host (Miyazawa et al., 2010;
Wilson, 2008) an adverse effect would be unlikely. The most commonly-cited
example of pathogenic endogenously-derived retroviruses is that of AKR mice,
which are not a naturally-occurring breed (Fan, 1997). However the acquisition
of exogenous LTRs to an otherwise-endogenous FeLV genome would be expected
to significantly alter the pathogenic potential of the isolate, as these regions
contain differential promoter and enhancer elements (Berry, et al., 1988).
To support this theory, bioinformatics software MatInspector (Genomatix)
(Cartharius, et al., 2005; Quandt, et al., 1995) was used to screen the exogenous
and endogenous FeLV LTRs for potential transcription factor (TF) binding sites.
This program has been used previously to accurately map regulatory elements of
retroviral U3 regions (Kwon, Lee, Greenhalgh, & Cho, 2011). Parameters were
set to detect only those transcription factor binding sites which displayed
maximum conservation between the input sequence/s and the prototype binding
sequence (matrix similarity of 1.00). Although this increases the accuracy of the
predictions, this method also increases the probability that additional TF binding
sites will remain undetected. The results (summarised in Table 5.1) indicated
that the LTRs would be recognised by different TFs and therefore may be
differentially expressed in vivo. Three potential TF binding sites were predicted
within the enFeLV U3 region, whereas 5 and 6 sites were predicted for FeLV-
2518 and -4314, respectively. Additionally, only one TF binding site was
conserved between all three motifs (myeloid zinc-finger protein MZF1).
Table 5.1: The U3 regions of endogenous and exogenous LTRs contain
differential TF binding sites
The MatInspector program
used to screen U3 domains for potential TF binding sites with a matrix similarity
value of 1.00. The sequence described is the motif possessing TF binding
potential; capital letters indicate the core binding sequence.
.
(Cartharius, et al., 2005; Quandt, et al., 1995)
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In support of these results, a manual comparison of the known TF binding sites
present in the FeLV-A U3 region (Fulton, Plumb, Shield, & Neil, 1990; A. K.
Helfer-Hungerbuehler, et al., 2010) also indicates the endogenous counterpart
possesses differential TF binding capacities. Although the leukaemia virus factor
B (LVb) site, CAT and TATA boxes are intact in both endogenous and exogenous
LTRs, in contrast the simian virus 40 core enhancer (CORE), nuclear factor 1
(NF1), glucocorticoid response element (GRE) and FeLV-specific binding motif
(FLV1) domains are highly mutated in endogenous sequences (Figure 5.12).
Figure 5.12: The U3 regions of endogenous and exogenous FeLV proviruses
display differential TF binding motifs
A multiple sequence alignment of the U3 motifs from
recently-endogenised enFeLV elements was screened for elements of the
enhancer framework previously described in FeLV LTRs.
.
FeLV
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-2518, -4314 and two
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Although this analysis cannot be extrapolated without supportive experimental
data, it does provide preliminary evidence that the acquisition of novel
exogenous LTRs would significantly alter the transcriptional activity and
pathogenic potential of a full-length enFeLV provirus. The switch in LTRs may
have allowed FeLV-4314 to outgrow the exogenous FeLV-A which was presumably
present originally in the host. Given time, this may also occur with FeLV-2518, as
there is no evidence that the defective FeLV-2518(A) genome is required for
transmission or replication of this recombinant variant.
5.2.9. The RNA structure of the RBD displays increased
propensity for recombination
According to the published literature, FeLV-4314 is both the first strain of FeLV-
B isolated without the presence of a FeLV-A “helper” virus, and the first
described recombinant FeLV possessing a 5’ recombination breakpoint within the
RT ORF. However the majority of FeLV-B isolates described to date contain
recombination sites within a central region of the SU domain (Ahmad & Levy,
2010; Sheets, et al., 1992). To investigate why this region appears preferentially
subject to such high rates of recombination, bioinformatics software programs
mFold (Zuker, 2003; Zuker & Jacobson, 1998), Alifold (Hofacker, Fekete, &
Stadler, 2002) and RNAStructure Version 5.3 (Reuter & Mathews, 2010) were
used to model the secondary structures within FeLV env RNA. This aimed to
identify potential recombination “hotspots” which may exist in either the
endogenous or exogenous env genes. Apart from the 5’ leader sequences,
retroviral dimeric RNA is not thought to form interstrand structures within
virions (Murti, Bondurant, & Tereba, 1981; Paillart, Marquet, Skripkin,
Ehresmann, & Ehresmann, 1996), therefore monomeric sequences were used in
these analyses. The original structural predictions are included in Appendix 8.5;
Figure 5.13 displays schematics of the resulting models, redrawn for ease of
reference.
(A)
(B)
Figure 5.13: The predicted RNA secondary structures
(B) endogenous FeLV
Schematics are based upon the predicted structures from the mFold and
RNAstructure webservers.
This bioinformatics analysis indicated that the overall RNA secondary structure
was conserved between exogenous and endogenous
region upstream of the RBD forms a helix which is structu
between exogenous and endogenous
to stall at the termini of RNA helices to facilitate RNA “unwinding”, hence such
regions are common site
The presence of this conserved helix immediately prio
may therefore contribute to the high incidence of recombination sites with
5’ sequence of the RBD. In comparison
RBDs form highly divergent
the more conserved
in (A) exogenous and
env transcripts.
Original files are included in Appendix 8.5.
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RNA in this region would decrease the probability of further recombination
occurring within this sequence. This supports observations that the majority of
FeLV-B env genes described to date bear RBDs from enFeLV envs.
The sequence downstream of the RBD is once again highly conserved between
exogenous and endogenous FeLV. This results in almost identical predicted
secondary structures forming in the regions encoding the TM of both enFeLV and
FeLV-A env. As there are numerous stable helices within this region,
recombination may occur and remain undetected due to the high primary
sequence conservation.
This preliminary in silico analysis suggests that the high rate of recombination
within the 5’ region of env is due to secondary structures within the RNA which
facilitate increased RT strand transfer within this region. It would be of interest
to determine accurately the frequency of recombination and whether it
additionally occurs in the highly conserved TM domain; however time and
resource limitations made this impossible at this point.
5.3 Discussion
The results presented within this chapter provide evidence that strains of FeLV
appearing phenotypically as purely subgroup B may be circulating in the
domestic cat population. Two strains of this nature were isolated and found to
be replication-competent in multiple cell lines, without the required presence of
a viable FeLV-A helper virus. Genetic characterisation of these field isolates
revealed they are both recombinant viruses, possessing mostly endogenously-
derived env gene sequences and in the case of FeLV-4314, a significant portion
of an endogenous pol gene. FeLV-2518 also packaged a defective exogenous
genome. The expression of an Env-related peptide from this genome appeared to
induce downregulation of THTR1 within cells, presumably by intracellular
peptide-receptor binding prior to display on the cell surface.
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5.3.1. FeLV-4314 and -2518 represent distinct
recombination events
There are 12 nucleotide differences between the exogenous U3 domains of FeLV-
2518 and -4314, making it unlikely that they arose from a conserved parental
virus. Thus a recombination event resulting in a mostly-endogenous viral env
gene with exogenous LTRs appears to have occurred separately on at least two
occasions in naturally infected hosts, and manifests as an FeLV-B infection
without a co-infection of FeLV-A. This is the first reported identification of a 3’
recombination breakpoint being identified within a FeLV-B TM domain, and a 5’
site identified within RT, as the majority of recombination sites span a central
250bp region of SU (Sheets, et al., 1992). There are rare reports of
recombination sites being identified in the pol gene, although these are further
downstream than the position described here (Overbaugh, Riedel, et al., 1988;
Pandey, et al., 1991).
The high sequence identity of the endogenous portions of both FeLV-2518 and -
4314 to the recently-endogenised enFeLV proviruses (Roca, et al., 2004)
indicates that retroelements such as these are transcriptionally active and
contribute to FeLV-B formation. Additional evidence for this comes from the fact
that both FeLV-2518 and -4314, as well as the full-length enFeLV genomes (Roca,
et al., 2004) contain the central-SU C11D8 epitope (MGPNL) (Elder, et al., 1987;
Nunberg, Rodgers, et al., 1984) which is not found in defective enFeLV elements
such as CFE-6 (McDougall, et al., 1994; Sheets, et al., 1993). Thus the CFE-6
provirus and other previously-described enFeLV may no longer be suitable
choices for FeLV-B genetic comparisons. For example, it was recently stated that
geographically diverse FeLV-B isolates display a range of identical non-
synonymous substitutions when compared to CFE-6, providing evidence they are
preferentially selected for during FeLV-B generation (Ahmad & Levy, 2010). A
more probable scenario exists wherein recently-endogenised enFeLV loci are
more likely to be transcriptionally active and thus are the main contributors to
FeLV-B genomes.
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5.3.2. RNA recombination in gammaretroviruses
Recombination occurs during reverse transcription when the RT enzyme switches
from the initially reverse-transcribed “donor” template to an alternative
“acceptor” RNA strand (Worobey & Holmes, 1999). Synthesis of the nascent DNA
strand continues, resulting in a novel recombinant product. Thus two cycles of
infection are required for recombination between exogenous genomes to occur:
(1) the initial infection of a cell by two distinct viruses, the transcripts from
which are later co-packaged, and (2) the subsequent infection of a naïve target
cell by the heterozygous virions, at which point reverse transcription produces
the recombinant genome and subsequent provirus. In the example of FeLV-B
formation, it is endogenous expression of enFeLV transcripts that contributes the
second genome, rather than a distinct secondary viral particle.
It is not known which enFeLV loci contribute to FeLV-B formation or whether this
varies between hosts. As the intact full-length enFeLV elements are polymorphic
between domestic cat genomes (Roca, et al., 2005), it is probable that defective
mutated elements contribute in some cases of FeLV-B development. Early
studies upon enFeLV gag genes indicated they were highly mutated and thus
assumed to be defective; however both the packaging signal and leader
sequences were intact (Berry, et al., 1988). It is therefore feasible that co-
packaging of defective endogenous RNA transcripts alongside exogenous
genomes may occur even in host cats lacking the full-length, putatively-
functional enFeLV loci. It must be noted that co-packaging of this nature has not
been observed directly, although co-packaging of both FeLV and MLV RNAs has
been observed in vitro and results in novel recombinant genomes (Pandey, et
al., 1991; Yin & Hu, 1997). There is also the notable case of AKR mice, which
develop leukaemia following development of a replication-competent virus from
recombination events between three endogenous elements. Interestingly, in this
case a specific locus (Bxv-1) contributes the LTRs which directly influence the
pathogenic potential of the final virus (Coffin, Stoye, & Frankel, 1989).
Therefore the formation of FeLV-B, arising through recombination between
exogenous and endogenous transcripts in infected animals, is not without
parallels.
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HIV has an estimated recombination rate of approximately 1.4 x 10-5 per site per
generation (Neher & Leitner, 2010) whereas MLV recombines at least 10-fold less
(Simon-Loriere & Holmes, 2011). Therefore the frequency of recombination
varies significantly across the retroviral genera, and is influenced by both the
processivity and fidelity of the RT enzyme and the presence of structural motifs
within viral RNA (Simon-Loriere & Holmes, 2011). RT pause sites include highly
stable structures such as the termini of dsRNA helices. These aid strand transfer
events, inducing recombination, by stalling the RT enzyme and increasing the
probability strand transfer will occur during synthesis of the antisense DNA
strand (Lanciault & Champoux, 2006; Simon-Loriere & Holmes, 2011). This
pausing is also thought to allow the RNaseH function of the RT enzyme to further
degrade the donor strand, thereby increasing interactions between the acceptor
RNA and the nascent DNA (Roda et al., 2002).
There are conflicting opinions as to whether RNA recombination offers
advantages to retroviruses. It is often assumed to allow generation of functional
viruses from potentially nicked and damaged genomes, and therefore heightens
replication fidelity by effectively purging deleterious mutations which would
otherwise render the genome non-functional (Temin, 1991). In the case of HIV,
intergenic domains tends to possess highly stable RNA structures, thus
decreasing the probability that recombination will produce deleterious viral
progeny by nucleotide misincorporation and the introduction of frame-shift
mutations (Simon-Loriere, Martin, Weeks, & Negroni, 2010). In contrast,
recombination allows complementation between functional and defective viral
genomes, which decreases the overall fitness of the viral population. It has been
suggested that recombination may merely be a “mechanistic by-product” arising
due to the nature of the retroviral life cycle (Simon-Loriere & Holmes, 2011); as
two strand transfer events are required for a successful infection, the RT
enzyme may have evolved to possess low processivity and template affinity
(Temin, 1993). In the case of FeLV, recombination producing a novel subgroup
(FeLV-B) may increase viral fitness by expanding receptor tropism and allowing
continued viraemia.
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5.3.3. Exogenous LTRs may alter the properties of
enFeLV viral strains
The 3’ LTR is often a contributing factor in the virulence and oncogenic
potential of retroviruses. Promoter and enhancer-like elements, including the
CCAAT (Grosschedl & Birnstiel, 1980) and Goldberg-Hogness boxes (Corden, et
al., 1980; Proudfoot, 1979), are located within the U3 region and may activate
proto-oncogenes downstream of the site of insertion (Fan, 1997; L. S. Levy,
Lobelle-Rich, & Overbaugh, 1993). There are numerous examples of specific
FeLV U3 domains, usually containing short repeats either upstream or within the
enhancer regions, being associated with heightened pathogenesis. In some cases,
the repeats form novel TF binding sites, leading to higher rates of viral
replication and an accelerated disease progression (Finstad, Prabhu, Rulli, &
Levy, 2004; Prabhu, et al., 1999). These include cases of FeLV-related
multicentric lymphoma (Athas, Choi, Prabhu, Lobelle-Rich, & Levy, 1995;
Chandhasin, et al., 2004) and acute myeloid leukaemia (Hisasue et al., 2009;
Matsumoto et al., 1992; Nishigaki et al., 1997). These repeated motifs are not
found in the LTRs detailed within this study; however it would be of interest to
determine the clinical manifestation of FeLV-2518 and -4314 infection and
characterise how this is influenced by the exogenous LTRs they contain.
There is also recent evidence that the U3 region may be directly involved in
FeLV pathogenesis; a short positive-sense RNA transcript is produced from the
FeLV U3 region in vitro and is thought to activate the NFκB signalling pathway 
(Abujamra et al., 2006; Forman, Pal-Ghosh, Spanjaard, Faller, & Ghosh, 2009). It
is not known if this pathway and/or the transcript itself contribute to FeLV-
induced diseases, although the NFκB pathway is associated with cancer 
progression (Okamoto, Sanda, & Asamitsu, 2007). The stimulation of this
pathway may increase cell proliferation and therefore heighten the opportunity
for retroviral activation of proto-oncogenes (Forman, et al., 2009). Supporting
evidence for a direct role of gammaretroviral LTRs in disease progression comes
from the fact that the U3 domain activates the AP-1 signalling pathway
(Abujamra, Faller, & Ghosh, 2003; S. K. Ghosh & Faller, 1999; Weng, Choi, &
Faller, 1995). Notably enFeLV LTR expression does not exert these effects (S. K.
Ghosh, Roy-Burman, & Faller, 2000). Therefore the effective replacement of
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endogenous LTRs with those from an exogenous viral strain would almost
certainly alter the pathogenic potential of the virus. Similar effects have been
described in MLV, wherein a switch in LTR sequences between distinct strains
predictably alters the resulting disease spectrum (Chatis, Holland, Hartley,
Rowe, & Hopkins, 1983; Fan, 1997).
5.3.4. The potential roles of the defective FeLV-2518(A)
genome
It is not known if the truncated exogenous Env peptide encoded by FeLV-2518(A)
plays a role in the transmission and/or replication of FeLV-2518. Were this
protein secreted, it may either prevent FeLV-A infection through competitive
receptor-binding, or enhance infection with other viruses in a similar manner to
that of FeLIX. However gp70-specific immunoblots did not indicate it was
present in cell-free supernatant. The fact that decreased surface expression of
feTHTR1 in FeLV-2518-infected cells was observed with two distinct techniques
(reverse interference assays and lacZ-pseudotype infection) indicates binding
between the 2518(A) Env peptide and the receptor occurs intracellularly and
prevents both peptide secretion and feTHTR1 display. Thus the predicted
behaviour of 2518(A) Env is similar to that of the described protective enFeLV
Env peptide (McDougall, et al., 1994), in that it may reduce cellular
susceptibility to superinfection by downregulating surface expression of FeLV
cognate receptors. A similar mechanism is seen in mice wherein endogenously
expressed polytropic and xenotropic MLVs (the Rmcf and Rmcf2 resistance
genes) interact with the XPR1 receptor (Jung, et al., 2002; T. Wu, et al., 2005).
However it remains possible that low levels of the 2518(A) Env peptide are
secreted and were not detectable. As it would be predicted to form soluble RBD-
like proteins, it was initially suggested that it would possess similar properties to
FeLIX, an endogenously-encoded Env peptide required for FeLV-T infection of T-
lymphocytes (Anderson, et al., 2000; Lauring, et al., 2001). FeLIX consists of the
N-terminal 273 residues of the Pit1-RBD; comparatively the 2518(A) Env peptide
possesses the initial 295 residues of FeLV-A RBD. FeLIX is thought to restore
infectivity to non-infectious gammaretroviruses by “priming” the otherwise non-
functional SU proteins, allowing fusion of the viral and cellular membranes to
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occur. The ability of other soluble gammaretroviral RBDs to restore infectivity to
mutant viruses has also been characterised (Lavillette, et al., 2001; Lavillette,
Ruggieri, Russell, & Cosset, 2000). However the amino acid sequence of FeLV-
2518 Env is predicted to be wholly functional, therefore the 2518(A) Env peptide
would presumably not be required to induce fusion. More importantly, 2518(A)
Env does not possess a functional N-terminal fusion motif. This motif, consisting
of a SPHQ sequence, couples the receptor-binding properties to the fusion
machinery of gammaretroviral Env proteins. Proteins with mutations in the
fusion motif are able to bind receptors but cannot mediate cellular entry
(Barnett & Cunningham, 2001); this is likely to be the case concerning 2518(A)
Env which contains a SPPQ motif. Comparatively, the full-length FeLV-2518
genome encodes a presumably-functional SPHQ, indicating 2518(A) Env is likely
to be obsolete for fusion mediation even if it binds to feTHTR1.
It can therefore be presumed that the lack of a fusion motif in 2518(A) Env
peptides would make it unable to aid infection by defective virions. Conversely,
it may be able to bind THTR1 intracellularly and prevent future FeLV-A
superinfection. Finally, it is not known whether 2518(A) Env forms part of the
Env trimer complex present on released FeLV-2518 virions. Heterodimerisation
of gammaretroviral Env proteins has been observed in vitro (Dewannieux &
Collins, 2008) and results in decreased infectivity of the released virions. Thus it
is possible FeLV-2518 virions contain heterotrimeric Env complexes, although the
lack of a conjugated TM domain makes it difficult to predict the stability of
2518(A) Env peptides. Future experiments may be directed towards unravelling
the respective contributions of the FeLV-2518 and 2518(A) Env proteins to the
receptor-binding and cellular entry processes.
5.4 Conclusions
It must be noted that the interference assays detailed in this Chapter do not
directly measure downregulation of receptor expression upon a cell surface;
rather these are indirect measurements of viral entry which is assumed to be a
consequence of altered receptor availability. As in Chapter 3, MDTF receptor
expression levels were assumed to be approximately equivalent and therefore
156
would not restrict infection by either of the novel viruses studied. Equally, Env
incorporation in the pseudotype virions was assumed to be equivalent.
Although enFeLV horizontal transmission events were not identified, two FeLV
field isolates (FeLV-2518 and -4314) were isolated which presented as FeLV-B
without FeLV-A co-infection. These viral genomes are recombinants possessing
unusual recombination breakpoints. It is hypothesised that in the case of FeLV-
4314, the acquisition of an exogenous LTR allowed the recombinant virus to
achieve higher rates of transcription due to the U3 promoter and enhancer
elements, possibly contributing to it outgrowing the exogenous virus that was
originally present. In the case of FeLV-2518, a defective FeLV-A genome is also
packaged and maintained throughout infection of naïve cells, potentially causing
a decrease in functional THTR1 expression.
These studies describe the first isolation of FeLV viruses displaying the B
subgroup phenotype without the presence of a fully functional helper FeLV-A
virus. These results may shed some light upon the biology of FeLV-B formation.
Since both of these ostensibly subgroup B viruses occurred naturally, it is likely
that enFeLV expression contributes to FeLV pathogenesis more than was
assumed previously.
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6. The functionality of endogenous FeLV elements
6.1 Introduction
An ERV is a heritable retroviral element present at fixed loci within the genomes
of all individuals within a species. Therefore all retroelements, including solo
LTRs and defective retroviral genetic relics, represent ancient retroviral
infections by a once-functional exogenous virus which may or may not have a
related viral descendant currently circulating within the host community. In
recent years, advancements in genomics and bioinformatics have resulted in a
significant increase in the identification of recently-endogenised ERVs; these
elements are recognised by their high degree of polymorphism between
individuals of the species and the presence of intact retroviral motifs within the
endogenous provirus. Although the acquisition of mutations and deletions
ensures “ancient” ERVs are defective, in the case of these recent genomic
integration events insufficient evolutionary periods have elapsed for this to be
the case. This leads to the question of whether recently-endogenised proviruses
possess the capacity to function as replication-competent exogenous viruses. It
can be assumed their expression would not exert a pathogenic effect, as natural
selection would ensure a highly pathogenic retrovirus would not become an
established retroelement within its host germline. In contrast, although there
are examples of retroviral genes being co-opted by the host for their beneficial
effects (Varela, Spencer, Palmarini, & Arnaud, 2009), the polymorphic nature of
these retroelements indicates they do not perform an essential role in the hosts’
biology. Such recent endogenisation events have been described in diverse
species, including koalas (Tarlinton, Meers, & Young, 2006), mule deer (Elleder
et al., 2012), laboratory-derived mice strains (Kwon, et al., 2011; Lee, Horiuchi,
Itoh, Greenhalgh, & Cho, 2011; Ribet et al., 2008) and significantly, in particular
breeds of the domestic cat (Roca, et al., 2005; Roca, et al., 2004).
The description of intact enFeLV proviruses, identified within a feline genomic
library, indicates that FeLV is continually invading the host genome. As
exogenous FeLV infection has pathogenic consequences for the host, the study of
these proviruses represents an opportunity to investigate the mechanisms
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involved in the endogenisation process, which would be expected to attenuate
the virus and allow it to become an established genetic element as opposed to a
horizontally transmissible, pathogenic retrovirus (Oliveira, Satija, Kouwenhoven,
& Eiden, 2007). Alternatively, if these endogenous elements are transcriptionally
active and have retained their ability to transmit horizontally, this leads to the
question of how they are being maintained in the genome considering their
pathogenic potential.
The two genomic regions which differ significantly between endogenous and
exogenous FeLV are the env gene and the U3 domain within the LTRs. It can
therefore be predicted that differences in the functionality of enFeLV compared
to exogenous FeLV-A would be ascribed to either of these regions. Given the
essential function of Env in mediating retroviral infection and the large extent to
which exogenous FeLV Env proteins have been studied, the initial studies
described in this chapter were aimed towards characterising potential
functionality of enFeLV Env. However the presence of a functional env gene
would not automatically indicate an endogenous provirus was truly replication-
competent; the provirus must additionally be transcriptionally active. Although
published descriptions of enFeLV expression in host tissues have provided
inconclusive results to date (Busch, et al., 1983; Kidney, Ellis, Haines, &
Jackson, 2001; McDougall, et al., 1994; Niman, et al., 1980), the presence of a
tentatively endogenous functional RT enzyme in FeLV-4314 (Chapter 5)
displaying high nucleotide conservation with the AY364318 and AY364319
proviruses (Roca, et al., 2004) indicates these enFeLV genomes are
transcriptionally active, although the tissue specificity and level of transcription
is unknown.
Finally, it must be noted that for a complete viral replication cycle to occur an
intact gag-pol ORF such as that found in AY364318 and AY364319 would not
suffice. Genomic retroviral RNA is present in a dimeric form which binds to the
nucleocapsid (NC) component of the Gag polyprotein, driving construction of the
viral core. The dimerisation and packaging signals (Ψ) are found within cis-acting
secondary structures within the 5’ region of the viral RNA (Prats, et al., 1990).
As these elements encompass the 5’ LTR and overlap with the gag ORF, the
primary nucleotide sequence of this region will have a significant effect upon
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the transmission potential of a virus by potentially altering the intramolecular
structures which the RNA is able to attain. Notably, subgenomic mRNA is not
selectively packaged as the Ψ packaging signal is located downstream of the 
splice donor site (Maurel & Mougel, 2010). Therefore env-encoding spliced
transcripts would not suffice for enFeLV transmission despite potentially
encoding functional glycoproteins; an intact leader and 5’ gag sequence is
essential for this process.
The aims of the studies discussed in this chapter were to assess endogenous Env
protein functionality and conduct an in silico analysis of 5’ RNA structural motifs
of enFeLV elements. This would identify potential factors which may restrict
horizontal transmission of otherwise-intact enFeLV elements.
6.2 Results
The primary block to horizontal transmission of whole enFeLV proviruses would
be expected to be the lack of a functional Env protein. Despite possessing an
intact env, the enFeLV provirus AY364318 was identified within a feline genomic
library (Roca, et al., 2005; Roca, et al., 2004) and experimental expression has
not been described. The ability of wholly enFeLV Env proteins to pseudotype
viral cores and/or mediate cellular entry has therefore not been elucidated,
partly due to the lack of a cloned enFeLV env construct. Initial experiments
aimed to clone full-length env genes from the feline embryonic fibroblast (FEA)
cell line.
6.2.1. Multiple intact enFeLV env genes are present in
the feline genome
A PCR was conducted to specifically amplify enFeLV env genes from both
uninfected FEA cells and those infected with FeLV-2518 and -4314 (“FeLV enEnv”
PCR, detailed in Appendix 8.2). Amplicons were cloned into the pVR1012
expression vector and amino acid sequences were determined. Five full-length
env genes with intact ORFs were identified (clones Env-1 to -5). An additional
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two env genes were isolated by the method described above by other laboratory
members and are included in subsequent analyses (Env-6 and-7, Figure 6.1).
1
AY364318 MEGPTHPKPS KDKTFSWDLM ILVGVLLRLD VGMANPSPHQ VYNVTWTITN LVTGTKANAT SMLGTLTDAF
enFeLV-1 .......... .......... .......... .......... .......... .......... ..........
enFeLV-2 .......... .......... .......... .......... .......... .......... ..........
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 .......... .......... .......... .......... .......... ....A..... ..........
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .......... .......... .......... .......... .......... ..........
enFeLV-7 .......... .......... .......... .......... .......... .......... ..........
71
AY364318 PTMYFDLCDI IGNTWNPSDQ EPFPGYGCDQ PMRRWQQRNT PFYVCPGHAN RKQCGGPQDG FCAVWGCETT
enFeLV-1 .......... .......... .......... .......... .......... .......... ..T.......
enFeLV-2 .......... .......... .......... .......... .......... .......... ...A......
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 ..I....... .......... ....R..... .......... .......... .......... ..........
enFeLV-5 .......... .......... .......... .......... .......... Q......... ..........
enFeLV-6 .......... .......... .......... .......... .......... .......... ..........
enFeLV-7 .......... .......... .......... .......... .......... .......... ..........
141
AY364318 GETYWRPTSS WDYITVKKGV TQGIYQCSGG GWCGPCYDKA VHSSKTGASE GGRCNPLILQ FTQKGRQTSW
enFeLV-1 .......... .......... .......... .......... ....I..... .......... ..........
enFeLV-2 .......... .......... .......... .......... ....I..... .......... ..........
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 .....K.... .......... .......... .......... ....I..... .......... ..........
enFeLV-5 .......... .......... .......... .......... ....I..... .......... ..........
enFeLV-6 .......... .......... .......... .......... ....I..... .......... ..........
enFeLV-7 .......... .......... .......... .......... ....I..... .......... ..........
211
AY364318 DGPKSWGLRL YRSGYDPIAL FSVSRQVMTI TPPQAMGPNL VLPDQKPPSR QSQIESRVTP HHSQGNGGTP
enFeLV-1 .......... .......... .........V .......... .......... .......... ..........
enFeLV-2 .......... .......... .......... .......... .......... .......... ..........
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 .......... .......... .......... .........P .......... ........I. ..P.......
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .H........ .......... .......... .......... .......... ..........
enFeLV-7 V......... .......... .......... .......... .......... .......... ..........
281
AY364318 GITLVNASIA PLSTPVTPAS PKRIGTGNRL INLVQGTYLA LNVTNPNKTK DCWLCLVSRP PYYEGIAVLG
enFeLV-1 .......... .......... .......... .......... .......... .......... ....E.....
enFeLV-2 .......... .......... .......... .......... .......... .......... ....E.....
enFeLV-3 .......... .......... .......... .......... .......... .......... ....E.....
enFeLV-4 .......... .......... .......... .......... .......... .......... ..........
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .......... .......... .......... F......... .......... ....E.....
enFeLV-7 .......... .......... .......... .......... .......... .......... ..........
351
AY364318 NYSNQTNPPP SCLSDPQHKL TISEVSGQGL CIGTVPKTHQ ALCKKTQKGH KGTHYLAAPS GTYWACNTGL
enFeLV-1 .......... .......... .......... .......... ...N...... .......... ..........
enFeLV-2 .......... .......... .......... .......... ...N...... .......... ..........
enFeLV-3 .......... .......... .......... .......... ...N...... .......... ..........
enFeLV-4 .......... ..A....... .......... .......... ...N...... .........N ..........
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .......... .......... .......... .......... .......... ..........
enFeLV-7 .......... .......... ......R... .......... ...N...... .......... ..........
421
AY364318 TPCISMAVLN WTSDFCVLIE LWPRVTYHEP EYIYSHFENK PRFKRDPISL TVALMLGGIT VGGMAAGIGT
enFeLV-1 .......... .......... .......... .......... ......S... .......... ..........
enFeLV-2 .......... .......... .......... .......... .......... .......... ..........
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 .......... ........T. .......... .......... .......... .....Q.... ..........
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .......... .......... .......... .......... .......... ..........
enFeLV-7 .......... .......... .......... .......... .......... .......... ..........
491
AY364318 GTAALLETAQ FRQLQMAMHT DIQALEESIS ALEKSLTSLS EVVLQNRRGL DILFLQEGGL CAALKEECCF
enFeLV-1 .......... .......... .......... .......... .......... .......... ..........
enFeLV-2 .......... .......... .......... .......... .......... .......... ..........
161
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 .......... .......... .......... .......... .......... .......... .T........
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .......... .......... .......... ...F...... .......... ..........
enFeLV-7 ........V. .......... .......... .......... .......Q.. .......... ..........
561
AY364318 YADHTGLVRD NMAKLRERLK QRQQLFDSQQ GWFEGWFNKS PWFTTLISSI MGPLMILLLI LLFGPCILNR
enFeLV-1 .......... ......G... .......... .......... .......... .......... .F........
enFeLV-2 .......... .......... .......... .......... .......... .......... .F........
enFeLV-3 .......... .......... .......... .......... .......... .......... ..........
enFeLV-4 .......... .......... .......... .......... .......... .......... .........Q
enFeLV-5 .......... .......... .......... .......... .......... .......... ..........
enFeLV-6 .......... .......... .......... .......... .......... .......... ..........
enFeLV-7 .......... .......... ..K....... .......... .......... .......... ..........
631
AY364318 LVQFVKDRIS VVQTLVLTQQ HQRLGQCDSD QPYHPSZ
enFeLV-1 .......... .......... .......... .......
enFeLV-2 .......... .......... .......... .......
enFeLV-3 .......... .........L .......... .......
enFeLV-4 .......... .......... Y......... .......
enFeLV-5 .......... .......... .......... .......
enFeLV-6 .......... .......... .......... .......
enFeLV-7 .......... .......... .......... .......
Figure 6.1: The feline genome contains multiple intact enFeLV env genes.
A multiple protein sequence alignment of the seven intact enFeLV env genes
cloned from gDNA of FEA cells was constructed using the ClustalW algorithm.
Provirus AY364318 was used as the reference sequence (Roca, et al., 2004). Dots
indicate conserved sites.
Comparisons between the predicted amino acid sequences of the 7 cloned
enFeLV Env and the published intact Env AY364318 revealed multiple non-
synonymous mutations in each ORF, although the overall sequence conservation
was extremely high. This supports previous observations that FeLV retroelements
are highly polymorphic within the feline genome (Koshy, et al., 1980; Roca, et
al., 2005). Although Env-1, -2, and -5 were isolated from FEA cells infected with
FeLV-4314 and -2518, none of the Envs possessed 100% sequence identity to the
endogenous portions of these viruses, indicating the parental enFeLV element
had not been identified. This was expected as these recombinant viruses arose
within naturally hosts, which would possess a genome distinct from that of FEA
cells.
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The RBD, fusion motif, fusion peptide and R peptide are intact within all seven
ORFs, therefore virions possessing these glycoproteins would be predicted to be
infectious. To further investigate the functionality of these novel proteins,
pseudotypes were corrected for equivalent RT activity and titrated upon the
range of receptor-expressing MDTF cells described earlier. The results indicated
only one of the seven enFeLV Env proteins (Env-5) was able to mediate cellular
entry (Figure 6.3). This supports observations that this was the sole
endogenously-encoded glycoprotein incorporated into virions. As expected,
enFeLV Env-5 utilised the hPit1 receptor, thus appearing phenotypically as a
FeLV-B strain.
Figure 6.3: enFeLV Env-5 utilises hPit1 for infection.
HEK293T cells were used to prepare MLV (FeLV) lacZ pseudotypes bearing the
seven enFeLV Envs or reference subgroup A (Glasgow-1), B (Gardner-Arnstein) or
C (Sarma) Envs. The viral pseudotypes were then titrated upon MDTF cells
expressing huPit1, feTHTR1, huFLVCR1 or vector only. 72 hours post-infection,
cells were stained for lacZ expression and counted manually. Values represent
the mean +/- SEM of three independent experiments.
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The lack of incorporation of the remaining six enFeLV Env proteins could not be
explained, as they possessed all the motifs and domains required for a functional
gammaretroviral Env protein. It is possible these proteins are translated within
the cell and are either degraded or incorrectly trafficked, preventing budding of
intact virions. To investigate this possibility, immunofluorescence using the anti-
gp70 MAb was performed to detect intracellular Env. HEK293T cells were
transiently transfected to produce MLV(FeLV) lacZ pseudotypes, before being
treated with both methanol and paraformaldehyde to allow visualisation of
intracellular and membrane-associated proteins. The results indicated enFeLV
Env-2, -3, -5, -6, and -7 were translated within cells (Figure 6.4). In contrast,
enFeLV Env -1 and -4 could not be detected, indicating an unidentified block to
translation exists for these proteins. As the gp70-MAb was of the same
preparation as that used for the previously-described immunoblots, this
experiment also confirmed the specificity of the antibody and hence the lack of
incorporation of the Env proteins into viral particles (excluding Env-5).
Figure 6.4: enFeLV Envs
HEK293T cells transfected with enFeLV expression vectors (enFeLV
processed for immunofluorescence using an anti
and cells transfected with vector only (N
background fluorescence, while FeLV
controls for antibody specificity.
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be attributed to any single specific residue. At this point it is not known what
difference(s) between the Env proteins prevent synthesis of Env-1 and -4, nor
what causes the subsequent lack of incorporation of Env-2, -3, -6 and -7 into
virions.
These studies indicate that intact enFeLV env genes are present in the domestic
cat genome at a higher copy number than previously assumed, and a minority of
these genes encode functional glycoproteins able to pseudotype gammaretroviral
virions. It is possible that retroviral env genes of low infectivity are able to form
endogenous elements preferentially, a possibility which has been raised
previously (Oliveira, et al., 2007). However if env genes such as that encoding
Env-5 were located within a full-length transcriptionally active enFeLV provirus,
they may be able to mediate cellular infection through the fePit1 receptor and
be transmitted horizontally between hosts as an exogenous FeLV-B infection.
The assumption that such env genes are located within full-length enFeLV
genomes is highly plausible. The high degree of sequence conservation between
the intact env genes described herein and those described in the literature
(Roca, et al., 2004) indicates they are likely to be recent endogenisation events.
6.2.3. EnFeLV env transcripts are not detectable in
feline tissues
There are numerous examples of host-mediated silencing of ERVs through
methylation of the proviral DNA (Feenstra, Fewell, Lueders, & Kuff, 1986;
Gimenez et al., 2009; Groudine, Eisenman, & Weintraub, 1981; Harbers,
Schnieke, Stuhlmann, Jahner, & Jaenisch, 1981; Hsieh & Weinstein, 1990), an
effect which is ablated during the in vitro cloning process. Therefore the
presence of a replication-competent provirus does not necessarily indicate
transcription will occur in host tissues. Such epigenetic methods of retroviral
silencing are especially relevant when considering genomically intact proviruses
resulting from recent integration events (Lee, et al., 2011), however a genome-
wide analysis of the methylation status of ERVs within the domestic cat has not
been conducted. Although expression of full-length genomic enFeLV mRNA has
also not been investigated, short enFeLV env-derived transcripts have been
identified previously in lymphoid and placental tissues (Busch, et al., 1983;
McDougall, et al., 1994
enFeLV env genes, whole RNA was extracted from numerous tissue samples from
3 domestic cats (referred to as cats 623, 624 and 625). These cats had been
negative control animals for a previous experimental study and were confirmed
to be retrovirus-negative. Tissue samples had been snap
during necropsy and maintained at
DNase-treated to remove potential gDNA contamination.
then conducted to
in Appendix 8.2) (Figure 6.5). A PCR for the detection of GAPDH transcripts was
conducted to confirm the integrity of the RNA (“GAPDH”, PCR detailed in
Appendix 8.2).
Although the RNA was of a high quality in the majority of samples, enFeLV
transcripts could not be detected in any sample using this method.
Unfortunately a positive control tissue, such as placenta, was not available for
comparison; however
earlier assays upon gDNA, it is highly probable
case is indicative of a lack of transcripts
present at levels below the detection sensitivit
been detectable using either nested or quantitative PCR techniques.
Alternatively, they may be expressed
were not studied here, such as peripheral blood monocytes.
Figure 6.5: enFeLV
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studied included popliteal lymph node (PLN), mesenteric lymph node (MLN),
thymus (Thy), spleen (Spl), ovarian tract (OVT), bone marrow (BM), tonsils
(Ton), submandibular lymph node (SLN), and synovial membrane (SM).
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6.2.4. In silico modelling of MLV RNA structural
elements
The fact that enFeLV env transcripts were not detected in this study does not
necessarily indicate enFeLV horizontal transmission is prevented by a lack of
genomic mRNA expression. Transcription of whole enFeLV genomes in certain
tissues is required for recombinant FeLV-B genomes to form, a process which
occurs in approximately 40% of chronic FeLV-A infections (O. Jarrett, et al.,
1978). A currently unidentified block may exist which prevents transmission of
full-length enFeLV viral transcripts in the absence of an exogenous genome. As
the LTRs and env gene are the main genomic regions differing between
endogenous and exogenous FeLV, and the studies described herein had
confirmed specific enFeLV Env proteins were functional (Env-5), it was inferred
that the enFeLV LTRs act to restrict the horizontal transmission of enFeLV
genomes.
The 5’ LTR and adjoining leader sequence of the gag ORF forms RNA secondary
structures (collectively referred to as the packaging signal, Ψ), which allow both 
dimerisation of the RNA monomers and encapsidation of the genomic RNA by the
viral structural proteins. Production of a recombinant FeLV-B genome during
reverse transcription would require the formation of a heterodimeric RNA
genome composed of an exogenous and endogenous FeLV transcript. It can
therefore be assumed that the respective Ψ elements of these viral genomes are 
able to interact. However transmission of a wholly enFeLV virion in the absence
of an exogenous counterpart would require formation of an enFeLV RNA
homodimer.
Ideally, in vitro dimerisation assays would be utilised to quantify the ability of
enFeLV and FeLV-A RNA to form both homo- and heterodimers. However the lack
of a full-length enFeLV molecular clone made this impossible. In silico modelling
of RNA secondary structures was therefore performed to investigate the
dimerisation and packaging potential of both enFeLV and exogenous FeLV-A
leader sequences. Although early studies of enFeLV LTRs indicated that they
possessed intact packaging signals within the U5 region (Berry, et al., 1988), the
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importance of RNA secondary structure conservation during successful RNA
packaging has since been recognised. Given the high degree of divergence
between exogenous and enFeLV genomes in the neighbouring U3 region, it
cannot be assumed that enFeLV forms a functional packaging signal despite
possessing a conserved U5 domain.
The minimal dimerisation active sequence (MiDAS) of murine sarcoma virus is
composed of a stretch of 170 nucleotides within the 5’ LTR (Badorrek & Weeks,
2005). The RNAStructure, mFold and Alifold programs were used to produce
models of the RNA secondary structures in both monomeric and dimeric forms of
this RNA domain (see Chapter 2 for details of these programs). The ability of a
program to accurately predict the known structural elements of importance
within MLV RNA was the determining factor for the use of that program for the
subsequent FeLV models.
The original models produced by the Alifold program are included in Appendix
8.6. This program produced a highly accurate replication of the structures which
contribute to MLV packaging and dimerisation (Badorrek & Weeks, 2005;
Miyazaki, Irobalieva, et al., 2010) (Figure 6.6). These include two hairpins
culminating with GACG “tetraloops” within each monomer (Stem 1 and 2). In the
dimeric RNA genome, these stems form intermolecular “kissing-loops” via
hydrogen bonds which form between the unpaired cytosine and guanosine bases
of the two genomes. These then stabilise the tertiary structure of the dimeric
RNA. MLV also possesses palindromic sequences (Pal-1 and -2) which form loose
stem-loops in the RNA monomer. This region undergoes a structural
rearrangement during dimerisation to form an extended intermolecular RNA
helix (Badorrek, Gherghe, & Weeks, 2006; Badorrek & Weeks, 2005; De Tapia,
Metzler, Mougel, Ehresmann, & Ehresmann, 1998; Miyazaki, Garcia, et al.,
2010). Although the primary nucleotide sequences of MLV and FeLV packaging
signals are not highly conserved, their ability to cross-package alternative
gammaretroviral genomes indicates that these secondary structural elements are
conserved throughout the genus and are able to interact functionally (Doty,
Sabo, Chen, Miller, & Abkowitz, 2010; Metais et al., 2010).
(A)
(B)
Figure 6.6: The Alifold program accurately reproduces the known structural
elements within the MLV leader sequence
The Alifold webserver was used to predict the RNA secondary structures within
the minimal dimerisat
.
ion activation sites (MiDAS) of (A) monomeric MLV RNA and
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(B) dimeric MLV RNA genomes. All structures are conserved with those described
in the literature with consideration to both dimerisation (Badorrek & Weeks,
2005) and NC binding elements (Miyazaki, Garcia, et al., 2010). The second
genome in (B) is presented in red for ease of reference.
Given the accuracy of the MLV models, the Alifold program appeared likely to
produce accurate models of FeLV RNA, for which structures that are
experimentally-verified are not available for comparison. Additionally, Alifold
includes phylogenetic relationships of input sequences in the resulting models
(Gruber, et al., 2008), a factor which is not considered in the mFold or
RNAStructure servers. It has been estimated that algorithms for prediction of
RNA structures correctly identify only 60% of helices when a single input
sequence is used (Dowell & Eddy, 2004; Mathews et al., 2004), therefore the
capacity of Alifold to uptake multiple sequences in the form of a FASTA
alignment would drastically increase the accuracy of resulting models.
6.2.5. RNA structural elements are intact in FeLV-A RNA
homodimers
Predicted RNA secondary structures were generated using the Alifold webserver
(Gruber, et al., 2008). In each case a 800bp region was modelled, consisting of
the 5’ LTR and the gag leader sequence from both the FeLV-A(Rickard) and
FeLV-FAIDS genomes. Although the large amount of research upon MLV has led to
the MiDAS being accurately mapped to a short 170bp region, it cannot be
assumed that sequences external to this motif do not contribute to dimerisation
and packaging in FeLV, therefore the entire LTR was included in these analyses.
Models of both monomeric and dimeric exogenous RNA were produced (Figure
6.7). The resulting dimeric structure was highly symmetric and contained four
GACG tetraloops, indicating “kissing” loops would be able to form during tertiary
folding via intermolecular hydrogen bonds. A structural rearrangement was also
predicted to occur during dimerisation; a lengthy 5’ region which formed
numerous intramolecular stem-loops in the monomer formed multiple
intermolecular helices and short stem-loops in the dimer. This is similar to the
events concerning the palindromic sequences within the MLV models, although
the primary sequences
prototypic NC binding domains (consisting of an unbound 5’ U
identified in the RNA dimer. Collectively, the presence of these predicted
structures in the models supports
functional homodimeric RNA genomes
(A)
(B)
Figure 6.7: The leader sequence of FeLV
form the required structural elements for viral replication
are not conserved between the two viruses
indirect observations
during viral replication
-A RNA homodimers is predicted to
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. Four
CUG 3’ motif) were
that FeLV-A forms
.
.
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Models were produced of the structures within (A) FeLV-A monomeric RNA (free
energy of -316 kcal/mol) and (B) homodimeric RNA genomes (free energy of -
987.7 kcal/mol). The second genome in (B) is presented in blue for ease of
reference.
6.2.6. EnFeLV RNA homodimers may be non-functional
The RNA secondary structures within the 5’ LTR and leader sequences of intact
enFeLV proviruses, AY364319 and AY364318 were then modelled. Importantly,
the free energy predicted for these structures is similar to that of the exogenous
models (approximately -990 kcal/mol for the dimeric form), indicating they are
equally likely to form in a physiological environment and are of similar stability.
The monomeric form of enFeLV RNA was predicted to contain only a single GACG
tetraloop, as the nucleotides correlating to Stem 2 form a short loose stem with
an extended loop. However within the homodimeric form, one of the two
genomes was rearranged at this region into the prototypic 2-stem loop structures
(presented in black in Figure 6.8[B]). Although it is possible weak “kissing” loops
may form between the partial Stem 1 in genome A and full-length Stem 1 in
genome B, the significant disruption in Stem 1 of A as well as the lack of overall
symmetry would sterically hinder this conformation. Additionally, only three NC-
binding motifs are present in the enFeLV homodimeric RNA. Together these
findings indicate that there is likely to be differential exposure of the predicted
functional elements required for packaging of endogenous homodimeric RNA into
nascent virions.
(A)
(B)
Figure 6.8: The enFeLV RNA leader sequence is not predicted to form the
structures required for viral packaging
Models were produced of the secondary structures within (A) enFeLV monomeric
RNA (free energy of
(free energy of -988 kcal/mol).
for ease of reference.
.
-256.3 kcal/mol) and (B) enFeLV homodimeric RNA genomes
The second genome in (B) is presente
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6.2.7. Heterodimeric RNA genomes have regained
functionality
A model was produced of the structures within a heterodimeric RNA genome.
This was composed of a single exogenous FeLV-A (presented in black in Figure
6.9) and an accompanying endogenous FeLV leader sequence (presented in blue
in Figure 6.9). This model possessed a similar free energy to both the dimeric
structures described above. In this heterodimeric genome, a significant
rearrangement of both monomeric RNAs had occurred. Firstly, the exogenous
RNA presented only a single GACG tetraloop (Stem 1). Although this was
composed of a different primary sequence to the Stem 1 in the monomer, it was
of a similar length and stability indicating it would be able to partake in kissing
loop formation. The endogenous RNA strand had also undergone structural
alterations and presented in the heterodimer with two complete stem-loops, in
contrast to both the monomeric and homodimeric forms. Similarly to the
exogenous homodimeric RNA, this heterodimer also contained four NC binding
motifs.
Figure 6.9: Heterodimeric RNA genomes are predicted to contain the
structural elements
A model of the secondary structures within an exogenous/endogenous
heterodimeric RNA genome
Similar to the exogenous homodimer, and in contrast to the endogenous
homodimer, this genomi
exogenous RNA sequence is presented in black, whereas the endogenous
sequence is presented in blue.
Together these results support a model wherein recently
proviruses, although possessing intact ORFs and encoding potentially functional
Env proteins, are unable to spread in a horizontal manner due to their inability
to efficiently dimer
mediated by the presence of a significantly non
their 5’ LTR, despite the primary sequence of both the U5 region and
being conserved with that of the functiona
required for packaging.
was produced (free energy of
c RNA would be packaged into nascent virions.
ise and be packaged by viral NC proteins. This restriction is
-conserved U3 domain within
l exogenous virus
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-988.5 kcal/mol).
The
-endogenised enFeLV
gag ORF
es. During FeLV-A
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infection, in silico models predict that the presence of the exogenous genome
alongside the expression of an endogenous transcript causes a rearrangement of
the secondary structures within the RNA leader sequences. This leads to the
formation of a stable heterodimeric RNA genome, within which accessible stem-
loop structures required for tertiary RNA folding have been restored. The
transmission of this genomic RNA to a naïve cell, during which recombination
events may occur throughout reverse transcription, leads to the prototypic FeLV-
B infection seen in domestic cats.
6.3 Discussion
With the advancement of molecular biology techniques, the decreasing cost of
whole genome sequencing and increasing power of bioinformatics software there
are now examples of full-length ERVs in the genomes of multiple species that are
predicted to be functional. The presence of retroelements such as the proviruses
AY364318 and AY364319, thought to have become endogenised recently (Roca,
et al., 2005; Roca, et al., 2004), is therefore not unique to the genome of the
domestic cat, however FeLV represents one of few currently-circulating
retroviruses which exist in both endogenous and exogenous replication-
competent forms. Yet pathogenicity and the ability to vertically transmit
throughout multiple generations are presumably mutually exclusive properties,
suggesting a degree of viral attenuation must accompany the endogenisation
process (Oliveira, et al., 2007). As recent genomic integration events are marked
by a high degree of conservation between the novel endogenous provirus and the
exogenous counterpart, the study of these elements allows accurate
identification of the mutations contributing to this process.
6.3.1. The majority of intact enFeLV Env proteins are
non-functional
In the case of FeLV, there are two main regions which are significantly non-
conserved between endogenous and exogenous genomes; the env gene and U3
region of the LTR. In the studies described in this chapter, both regions were
analysed for their effects upon the transmission potential and functionality of
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enFeLV proviruses. The results indicate that although intact env ORFs are
present within the feline genome, only a minority of the corresponding proteins
are able to pseudotype viral cores. Non-conserved mutations within the
remaining Env proteins prevent either protein translation or correct trafficking
and incorporation into viral particles.
It is possible FeLV genomes encoding non-functional Env proteins preferentially
endogenise within the feline genome, although a potential mechanism for this
selection process is not clear. A gene encoding a defective Env protein may
require less host-mediated silencing, as transcripts will have a limited capacity
for successful translation. Additionally, recombinant FeLV-B Env proteins arising
from these transcripts may possess lowered infectivity and be unable to spread
easily. In this case even an enFeLV transcript that is expressed widely will not
necessarily contribute to pathogenic FeLV-B genomes. However this hypothesis
suggests the functionality of Env-5 is acquired through a gain-of-function
mutation. As there is only one mutation unique to Env-5 (R121Q), it would be of
interest to specifically back-mutate this residue and assay its effect upon both
Env incorporation and receptor usage.
Alternatively, rather than selection for the endogenisation of already-defective
enFeLV env genes, a more probable scenario is that the non-functional enFeLV
ORFs independently acquired a range of non-conserved mutations which
depleted their respective infectivity after the integration event. The
comparative prevalence of intact env ORFs encoding defective Env proteins may
therefore be evidence for attenuation of otherwise-functional enFeLV, a process
which would increase the probability of the retroelement becoming established
within the species genome. In the case of Env-1 and -4, the extent of mutations
prevent initial protein synthesis, however expression of Env-2, -3, -6 and -7
could be detected within transfected cells. It is possible these proteins are not
present upon virions due to a lack of association with the gag-encoded structural
proteins; this correlates to their presence within the cytoplasm but not in the
secreted virus preparations. Successful recruitment of Env glycoproteins by the
gammaretroviral Gag polyprotein requires an intermediate stage during which
the proteins colocalise within cytoplasmic vesicles, prior to the final virus
assembly (Sandrin, Muriaux, Darlix, & Cosset, 2004). It is possible these Env
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proteins each possess distinct mutations which alter their intracellular
trafficking and prevent successful association with Gag. However mutations
conferring this phenotype are generally mapped to the cytoplasmic tail (Sandrin,
et al., 2004). Although the blocked Env proteins -2, -3, -6 and -7 do not contain
excessive mutations in this region, there are scattered mutations throughout this
domain which are not present in the functional Env-5. Future work should be
aimed towards assessing the impact of these mutations upon protein trafficking
and Env incorporation.
It is possible that these apparently non-functional enFeLV Env proteins were
present within virions at extremely low levels, below the detection sensitivity of
either the anti-gp70 immunoblot or the pseudotyping system. If this is the case,
this indicates that they are either incorporated at too low a level to initiate
cellular entry via hPit1, or utilise a distinct cognate receptor. Given the high
degree of conservation these proteins displayed with the functional Env-5 (which
utilised hPit1), this is unlikely. However specific FeLV-B isolates may utilise
either hPit1 or the orthologue hPit2, and it has been suggested that the
proportion of endogenously-derived residues within FeLV-B Env affects the
ability of the protein to utilise Pit2 (Boomer, et al., 1997; Nunberg, Williams, et
al., 1984). The determinants for hPit2 usage were tentatively mapped to the
VRB region within the SU domain, whereas hPit1 usage maps to the VRA motif
(Boomer, et al., 1997). Although the ability to utilise hPit2 was not directly
investigated in these studies, it is unlikely that the non-functional Envs are able
to utilise this receptor as MDTF wildtype cells express the murine homologue of
Pit2 (mPit2) and these cells were not susceptible to infection with any enFeLV
pseudotypes. It remains possible that these proteins are synthesised at levels
undetectable with a standard immunoblot, and are able to utilise the feline
homologues of Pit which were not included in these analyses. If cloned
constructs encoding these receptors were available, it would be of interest to
target the mutations present within the VRB motif of these Env proteins and
screen for an altered ability to bind to fePit1 and -2.
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6.3.2. Non-functional packaging signals may prevent
horizontal transmission of enFeLV
The interpretation of the RNA structural in silico models produced in this
analysis relies upon the assumption that the conserved 2-stem-loop structure is
the primary determinant of RNA dimer functionality; i.e., whether the correct
tertiary structure can be obtained and is subsequently recognised by the viral
structural proteins. The validity of this assumption is supported by the fact that
gammaretroviral RNAs are packaged by heterologous viral proteins
promiscuously, despite the fact that the primary sequence of their
corresponding leader motifs are not necessarily conserved (Doty, et al., 2010;
Metais, et al., 2010; Patience, Takeuchi, Cosset, & Weiss, 1998; Suling, Quinn,
Wood, & Patience, 2003; Torrent, Gabus, & Darlix, 1994). The final hypothesis
that enFeLV RNA homodimers are restricted from inclusion in nascent virions due
to their inability to form functional “kissing” loops is therefore highly plausible.
Although it remains possible that the partial stem-loop observed in the enFeLV
homodimeric RNA is able to participate in intermolecular binding, further
support for this interpretation is provided by the observation that although each
“kissing” loop supports dimerisation individually, maximum stability of the RNA
dimer requires the presence of both kissing loops (Ly & Parslow, 2002; Oroudjev,
Kang, & Kohlstaedt, 1999). This suggests exogenous homodimeric RNA genomes
will preferentially be formed, regardless of the presence of endogenous
transcripts, as this was the only dimeric structure which possessed four complete
GACG tetraloops. Combined with the low levels of enFeLV transcription (Busch,
et al., 1983; Kidney, et al., 2001; McDougall, et al., 1994; Niman, et al., 1980),
this presumably contributes to the prevention of FeLV-B developing in all
domestic cats chronically infected with FeLV-A.
Once a dimeric RNA genome has undergone tertiary folding, it must then
interact with the NC proteins to ensure selectivity is maintained during the
packaging process. This occurs prior to the protease-mediated cleavage of NC
from the Gag polyprotein and is distinct from the subsequent “coating” of the
RNA with NC, which eventually forms the viral core particle (Rein, 1994). In the
prototype gammaretrovirus MLV, NC proteins bind to eight exposed UCUG motifs
with high affinity in the dimeric RNA genome. However these motifs are
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sequestered within intramolecular helices in RNA monomers, preventing
monomeric RNA encapsidation (D'Souza & Summers, 2004; Dey, York, Smalls-
Mantey, & Summers, 2005; Gherghe & Weeks, 2006; S. F. Johnson & Telesnitsky,
2010). Mutations of the guanosine within these motifs reduces packaging 100-
fold, therefore the loss of a single NC-binding site may significantly alter the
rate of genome encapsidation and final infectious viral titre (Gherghe et al.,
2010). As the enFeLV homodimeric RNA genome contains only 3 exposed UCUG
motifs this would be expected to exhibit decreased packaging titres compared to
either the exogenous homodimeric or heterodimeric RNA, both of which present
with four unpaired UCUG motifs. Additionally, the overall secondary structure
and long-range tertiary interactions of viral RNA also contribute to the
specificity of NC recognition; it is not merely due to the presence of exposed
UCUG motifs (Gherghe, et al., 2010). Thus the combined effect of the altered
stem-loop structures and the decrease in potential NC-binding sites in enFeLV
homodimeric RNA may significantly decrease the transmission potential of
virions containing this genome.
It must be highlighted that co-packaging and dimerisation of heterogeneous FeLV
genomes has not been directly observed, although this has been documented in
numerous other gammaretroviruses (Mikkelsen, Rasmussen, & Pedersen, 2004; S.
V. Rasmussen, Mikkelsen, & Pedersen, 2002; Suling, et al., 2003; Villanueva,
Campbell, & Roth, 2003). Alternative mechanisms must therefore be considered
for both the lack of enFeLV horizontal transmission and FeLV-B formation. For
example, the degree of epigenetic silencing of retroviral elements within the
feline genome has not been investigated and may prevent expression of
otherwise functional ERVs. During processes involving demethylation (such as
cellular differentiation) a low level of enFeLV transcription may occur, leading
to temporal and spatial determination of FeLV-B formation. Equally, FeLV-B
genomes may arise through homologous recombination of host DNA rather than
through strand-transfer events during reverse transcription. However viral
genetic recombination is more likely to occur during the packaging of two unique
genomes within a single virion, rather than during homologous recombination
within host DNA after infection by two distinct particles (Katz & Skalka, 1990).
Thus if chimaeric viral genomes are routinely observed, such as that which
occurs during FeLV-B formation, this provides indirect evidence for genomic
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dimerisation of the two parental viruses. It can therefore be assumed FeLV-B
arises after dimerisation of two heterogeneous RNA transcripts and a subsequent
RT strand transfer event during reverse transcription. In the absence of an
exogenous FeLV-A genome, the enFeLV genomic RNA monomers may form
homodimers which these models indicate are unable to form stable “kissing”
loops and achieve the tertiary structure required for virion packaging.
6.4 Conclusions
The conclusions which can be drawn from these experimental results
(specifically describing the expression and functionality of enFeLV Env proteins)
have a central caveat which assumes the reactivity of each Env with the gp70
antibody is e qual and consistent. As described within the text, it is unlikely that
any Env has lost the epitope in question, however it cannot be ruled out. The
lack of positive control reagents also means that only preliminary interpretation
of these results is possible (for example, placenta was not available for RT-PCR
studies and this is the only tissue definitely established to routinely express
enFeLV env transcripts). Regarding the in silico RNA structural analysis, although
the results are intriguing it must be stressed that definitive conclusions cannot
be drawn until corresponding experimental data has been obtained.
The results presented in this chapter suggest a novel mechanism of viral
restriction, wherein intact proviral genomes are unable to transmit in an
exogenous manner due to the inability of their dimerisation and packaging
signals to form the required RNA secondary structures. In the case of FeLV, these
ERVs are rescued by the presence of an FeLV-A transcript which initiates
refolding of the RNA and formation of a heterodimeric genome, eventually
resulting in FeLV-B formation. As an increasing number of putatively replication-
competent ERVs are currently being isolated from numerous species, this
mechanism may be relevant to other retroviruses in addition to FeLV.
As this hypothesis is primarily supported by simulations of RNA folding, these
results are preliminary and require validation with experimental data before any
final conclusions can be drawn. The possibility that enFeLV full-length
transcripts are transmitted between hosts at extremely low levels, presenting as
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FeLV-B sole infections, cannot be excluded at this stage. Ideally, in vitro RNA
binding assays using a range of transcripts, including both the leader sequences
alone and whole viral genomes, should be conducted to accurately assess the
dimerisation potential of these viral genomes.
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7. Concluding Remarks
Although protective vaccines have been developed for FeLV, this virus remains a
serious pathogen both for domestic and wild felids. The pathogenic mechanisms
of infection remain poorly understood and treatment options for those hosts
which display chronic viraemia and FeLV-associated disease are limited. In
addition to these unresolved issues, the relevance of FeLV as a model for human
diseases, including HIV-AIDS and cancer progression, means that significant
further research is required to understand this intriguing retrovirus. Although
many aspects of FeLV have been previously investigated, the recent
advancements of molecular biology now allow these areas to be revisited and
viewed from a renewed perspective. The studies discussed in this thesis focussed
broadly upon the evolution of novel subgroups FeLV-B and –C which tend to
display heightened pathogenicity from their parental FeLV-A virus.
There are many aspects which determine collectively whether a FeLV infection
is significantly pathogenic and whether novel subgroups arise within the host.
The majority of studies to date, including those discussed herein, have focussed
upon the LTRs and the Env protein as both these elements play a significant role
in determining whether a productive infection occurs within a host. Whether the
resulting chronic infection proves to be significantly pathogenic over time
depends upon additional factors including the integration site, degree of
resulting immunosuppression (which were not investigated within this research)
and the ability of Env to utilise alternative receptors. Finally, it must also be
considered whether virus binding to the cognate receptor depletes the wildtype
function of that cellular protein, such as in the case of PRCA arising during FeLV-
C infection (Quigley, et al., 2004). Therefore additional research into a number
of areas is required before the development of novel FeLV subgroups can be fully
understood. The studies described within this thesis had four main research
aims: (1) to identify Env determinants which predispose FeLV-A to FeLV-C
conversion; (2) to investigate the potential role of the host humoral response in
FeLV-C evolution; (3) to determine the potential for inter-host FeLV-B
transmission without the additional presence of FeLV-A; and (4) to characterise
the functionality of enFeLV elements and the possibility of enFeLV horizontal
185
transmission between hosts. The results, although intriguing and informative,
highlight the degree of further research required in this field before definitive
conclusions can be reached.
As the protective correlates of vaccination have not been definitively
established and no currently-available vaccine provide sterilising immunity, the
development of FeLV-C remains a possibility in all domestic cats. Given the
severe mortality and morbidity of this subgroup, it is of utmost importance to
ascertain which subgroups of FeLV-A may preferentially evolve into FeLV-C and
which factors contribute to this process. These results support a model wherein
FeLV-A isolates containing the D83:D91 motif possess heightened replication
rates and an increased ability to bind to both THTR1 and FLVCR1, compared to
the prototype FeLV-A strains not known to lead to FeLV-C (Chapter 3). Over
time, it is predicted that viral subpopulations would arise as the virus acquires
mutations through genetic drift. These would gradually increase the SU-FLVCR1
binding affinity, eventually resulting in dual-tropic “intermediate” viruses able
to mediate cellular entry through a range of receptors (Shalev, et al., 2009).
Prototype FeLV-C isolates would eventually develop, at which point the virus
would be predicted to have lost THTR-binding ability and rely solely upon
FLVCR1 for entry. This model supports previous observations that the primary
sequences of FeLV-C isolates display low conservation, reflecting their
independent evolution from different FeLV-A isolates despite inducing the
prototypic PRCA disease symptoms (Brojatsch, et al., 1992).
In a parallel scenario to the development of FeLV-C, alterations in receptor
usage induced by the gradual acquisition of mutations has been observed for
HIV-1; this may reflect a common mechanism of evolution for retroviruses. This
further highlights the relevance of FeLV research and its applications to general
retrovirology. However in the case of HIV-1 this switch in receptor usage is
partially due to an escape from host immunity; this could not be replicated in in
vitro models (Chapter 4). The ability of the virus to continuously replicate in the
face of an immune response determines whether FeLV is able to infect bone
marrow cells, resulting in the secondary viraemia and a subsequent chronic
infection. It is therefore logical that a virus able to circumvent this immunity
would display an increased probability of inducing disease and potentially
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developing into FeLV-C. Although these studies did not indicate that the
presence of VNAs increased the appearance of mutations associated with FeLV-
C, this remains a plausible theory given the numerous other examples of
retroviral evolution mediating antibody-escape.
The fact that the mutations studied in Chapter 3 were detected in multiple
independent FeLV isolates indicates an epitope in this region may be commonly
targeted by the host immune response. However these mutations did not confer
neutralisation resistance (Chapter 4), although this should be interpreted with
caution as the use of a broader range of antibodies may have produced different
results. A hypothesis not investigated herein is that these mutations alter a T-
cell epitope. As T cell epitope recognition differs broadly between individuals,
escape from CTL responses by a viral variant is unlikely to result in a viral strain
which has a replicative advantage in a secondary host (Overbaugh & Bangham,
2001). This explanation supports the observations that FeLV-C cannot be
transmitted between hosts, however it does not explain why these mutations
occurred in multiple independent field samples from presumably unrelated
hosts. As B cell epitopes are broadly recognised between individuals of a species,
it is more probable these mutations play a role in immune evasion through this
mechanism.
These results also indicated that a selective pressure in the form of receptor-
availability does not drive evolution of FeLV-C. This is in direct contrast to the
opinion that VNAs and receptor availability on target cells are the main forces
acting during retroviral evolution (Overbaugh & Bangham, 2001). However it
must be noted that the broad expression profile of THTR1 makes it unlikely that
a virion would encounter a cell which solely expresses FLVCR1. This theory may
be physiologically irrelevant to FeLV, whilst holding true for other retroviruses
which utilise receptors with non-overlapping expression profiles.
The low amino acid conservation between Env proteins of individual FeLV-C
isolates, documented in these studies and those of others (Adema, 2003;
Brojatsch, et al., 1992), indicates it may be the overall structure rather than the
acquisition of a defined RBD which determines the success of FLVCR1-SU binding.
This model is applicable to other retroviruses; gibbon ape leukaemia virus
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(GALV), amphotropic MLV and FeLV-B all utilise Pit homologues and yet do not
display high amino acid conservation between their Env proteins, indicating their
tertiary structures may be analogous (L. Pedersen, Johann, van Zeijl, Pedersen,
& O'Hara, 1995; Tailor & Kabat, 1997; Tailor, Nouri, & Kabat, 2000; Tailor et al.,
1993). These results therefore support suggestions that the SU binding site
within a receptor is not a predetermined invariable factor in retroviral cellular
entry (Tailor, et al., 1993). Future work should be aimed towards determining
the relative binding positions of FeLV-A and–C Env proteins to both THTR1 and
FLVCR1. The increase in affinity of SU for FLVCR1 predicted to occur during
FeLV-C evolution may be accompanied by a switch in the receptor domains
involved in binding.
Similar to FeLV-C, FeLV-B development in a host significantly alters the disease
association. The development of lymphomas and/or leukaemias in a domestic
cat confers an increased rate of mortality and morbidity and limited treatments
are available. Although FeLV-B is not thought to occur in endangered wild felids
due to their lack of enFeLV elements, it appears that FeLV-B isolates may be
transmissible between hosts without co-transmission of FeLV-A (Chapter 5). The
isolates FeLV-2518 and -4314 are therefore of significant interest and may
represent a novel pathogen for endangered felids, previously assumed to only be
at risk of FeLV-A infection. Had time and resources allowed, it would have been
of interest to investigate the clinical implications of FeLV-2518 and/or -4314 and
compare these to a prototypic FeLV-A/B infection. It has been previously noted
that FeLV-B variants associated with thymic lymphoma possess further upstream
3’ recombination junctions than those associated with other diseases (Ahmad &
Levy, 2010). Thus the proportion of the viral genome originating from an
endogenous element appears to influence the disease progression during
infection, supporting the notion that ERVs are preferentially selected for their
altered virulence (Oliveira, et al., 2007).
Instances of enFeLV horizontal transmission were not identified in these studies,
despite the prediction that it would be these infections presenting as FeLV-B
alone. Given that FeLV-4314 contains the majority of enFeLV-derived env and
pol genes and the gag ORF is highly conserved between enFeLV and exogenous
genomes, the only remaining portion of the FeLV-4314 genome which remains
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ostensibly exogenous are the LTRs. The analysis of the transcription factor
binding sites contained within the respective LTRs indicates that enFeLV virions
would not exert similar pathogenic effects to FeLV-4314 or -2518, as exogenous
LTRs contain significantly more intact promoter elements.
The in silico analysis of recombination sites within FeLV-B genomes (Chapter 5)
may also have implications for other viral research. Given that FeLV-2518 and -
4314 were produced during natural infections, these results provide an in vivo
comparative model for observations regarding increased recombination at the
termini of RNA helices in vitro. Retroviral recombination contributes
significantly to genetic variation in all retroviruses and may alter neutralisation
susceptibility, receptor-utilisation or replication kinetics (Simon-Loriere &
Holmes, 2011). However accurate identification of recombination breakpoints
may prove difficult within a highly homogeneous viral population; FeLV-B
therefore provides a unique model wherein the contributing genomes differ
significantly in two distinct areas (U3 and env). This allows accurate
recombination-site mapping and the subsequent correlation between predicted
RNA secondary structures. To the best of our knowledge, this analysis is the first
to link RNA structural elements with specific phenotypically-distinct subgroups
of FeLV.
The investigations into the functionality of enFeLV proviruses (Chapter 6) raise
some intriguing propositions. The discovery that full-length intact Env ORFs are
more prevalent than previously observed was partially expected, given the lack
of feline genomic research conducted to date and the knowledge that enFeLV
elements are polymorphic (McDougall, et al., 1994; Roca, et al., 2004). However
the inability of these proteins to express in vitro indicate an intact ORF may not
be indicative of a functional Env. Only one of seven proteins identified was able
to pseudotype viral cores and mediates cellular entry (enFeLV Env-5). The
remaining proteins displayed differential levels of expression within the cellular
cytoplasm; mutations conferring these properties could not be identified. Had
time allowed, it would have been of interest to identify which mutation/s within
each Env was responsible for the respective defects observed.
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These preliminary results also provide further evidence as to the conservation of
RNA secondary structures in the packaging and dimerisation domains of
gammaretroviruses. As the majority of gammaretroviral RNA structural work
conducted to date is concerned with MLV, the study of another virus such as
FeLV would complement these results and highlight similarities and differences.
However in vitro analyses of both the dimerisation and packaging abilities of
enFeLV RNA homodimers and FeLV-A/enFeLV heterodimers are required to
provide definitive answers to whether this is the block preventing enFeLV
horizontal transmission.
The novel suggestion that altered RNA structures provide a mechanism of
restriction for potentially-functional endogenous retroelements supports the
general theory that endogenous retroviral elements are by their nature
inoffensive to the host (Lower, 1999; Oliveira, et al., 2007). An actively
pathogenic endogenous retrovirus would by its very nature be purged from the
host over evolutionary time, although a relic such as a solo LTR may remain. The
exception to this premise is the example of FeLIX. Despite being endogenously
encoded, this peptide rescues defective FeLV-T strains and allows infection of T
lymphocytes (Anderson, et al., 2000). However given the fact that FeLV-T is only
rarely reported, it is probable that the majority of enFeLV peptides confer a
protective advantage to hosts. This is the alternative explanation for the
maintenance of their functionality and expression (McDougall, et al., 1994). In
contrast, it has also been suggested that the likelihood of persistence versus
deletion or inactivation of the retroelement (through, for example,
recombinational deletion during meiosis, resulting in a solo LTR genomic relic)
may simply reflect the gene density and recombination rate of the genomic area
in which it is integrated (Katzourakis, Pereira, & Tristem, 2007). Nonetheless,
the general observation that ERVs are non-pathogenic and display lowered
infectivity compared to their exogenous counterparts is supported by these
results, which indicate apparently-functional enFeLV elements may be restricted
by their inability to form the required RNA structures for efficient viral
transmission.
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Overall, the studies discussed in this thesis raise intriguing hypotheses applicable
to both FeLV and general retrovirology, and highlight the necessity of further
research upon this significant feline pathogen.
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8. Appendices
8.1 Buffers and solutions
Bromophenol Blue Protein Loading Buffer
0.25M Tris-HCl; 2.5% (w/v) SDS; 10% (w/v) glycerol, 1% (1/v) 2-mercaptoethanol;
0.02% (w/v) bromophenol blue; pH 6.8.
Phosphate-Buffered Saline
137mM NaCl; 2.7mM KCl; 8mM Na2HPO4; 2mM KH2PO4; pH 7.3.
DNA Electrophoresis Loading Buffer (10x concentration)
0.1M EDTA; 15% (w/v) glycerol; 0.05% (w/v) bromophenol blue; 0.25% (w/v)
xylene cyanol.
Tris-Borate EDTA (TBE) Buffer (10x concentration)
890mM Tris Base; 2mM di-sodium EDTA; pH 8.3.
Tris-Glycine Buffer
25mM Tris Base (7.9); 192mM glycine; 0.1% (w/v) SDS; pH 8.3.
Luria Broth (LB)
10% (w/v) bactotryptone; 5% (w/v) yeast extract; 85mM NaCl; pH 7.0.
1.5% agarose included for LB agar plates.
Super Optimal Broth for Catabolite Repression (SOC Broth)
20mM glucose, 10mM MgCl2, 10mM MgSO4; 2.5mM KCl; 10mM NaCl; 2% (w/v)
bactotrypone; 0.5% (w/v) yeast extract.
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8.2 List of Primers
FeLV Env Sense: 5’ GGTCGACATGGAAGGTCCAACGCACCCAAAA 3’
Antisense: 5’ GGGGTCGACTGGAATCATACATTTAATTGGAAAT 3’
FeLV SU Sense: 5’ CGATCTAGAATGGAAAGTCCAACGCACCCAAAA 3’
Antisense: 5’ CATGGATCCGCTGTGTACACATATTCGGGTTGATG 3’
FeLV enEnv Sense: 5’ GGTCGACATGGAAGGTCCAACGCACCCAAAA 3’
Antisense: 5’ CGCGGCCGCTTAGCTGGGGTGATACGGTTGGT 3’
FeLV en-U3 Sense: 5’ GAGCTAGCAATGCGACTCAGACCAACCGTATCA 3’
Antisense: 5’ GGTACCCGGGGCGGTCAAGTCTCGGCAAAG 3’
FeLV ex-U3 Sense: 5’ GAGCTAGCAATACGATCCGGACCGACCATG 3’
Antisense: 5’ GGTACCCGGGGCGGTCAAGTCTCGGCAAAG 3’
RD-114 Env Sense: 5’ GTTTGACGACCCCCGCAAGGCTAT 3’
Antisense: 5’ GGGCCAGCACCATGGCATGTACAACA 3’
FcEV Env Sense: 5’ ATTCCACCCTCACACCAGAATC 3’
Antisense: 5’ TTGAGTTAGGACCAAGGCCTG 3’
GAPDH Sense: 5’ CCTTCATTGACCTCAACTACAT 3’
Antisense: 5’ CCAAAGTTGTCATGGATGACC 3’
FeLV-Recombinant Sense: 5’ AAGACTAGACGTGGGAATGGCC 3’
Antisense: 5’ AATTTTCCATACCTTGTGAAATGG 3’
All PCRs were conducted using a high-fidelity commercially prepared mastermix
(Roche), which included 200uM of each dNTP and 0.2U/uL of polymerase
enzyme. Primers were added to a final concentration of 0.5uM each, with 50ng
(plasmid) or 200ng (genomic DNA) of template DNA per reaction. Cycling
parameters consisted of an initial denaturation (94°C, 2 minutes), followed by
35 cycles of denaturation-annealing-extension (94°C, 30 seconds; 50°C, 30
seconds; 72°C, 1 minute/kB of template DNA). A final extension period of 5-10
minutes at 72°C was included before reactions were stored at 4°C. In some
cases the annealing temperature was altered to increase reaction specificity.
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8.3 Nucleotide mutations arising in long-term FeLV
cultures
1
FeLV-A ATGGAAAGTC CAACGCACCC AAAACCCTCT AAAGATAAGA CTCTCTCGTG GAACTTAGCG TTTCTGGTGG
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
71
FeLV-A GGATCTTATT TACAATAGAC ATAGGAATGG CCAATCCTAG TCCACACCAA ATATATAATG TAACTTGGGT
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... ........G. .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
141
FeLV-A AATAACCAAT GTACAAACTA ACACCCAAGC TAACGCCACC TCTATGTTAG GAACCTTAAC CGATGCCTAC
FeLV-A Sera ..G....... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB ....G..... .......... .......... .......... ........C. .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
211
FeLV-A CCTACCCTAC ATGTTGACTT ATGTGACCTA GTGGGAGACA CCTGGGAACC TATAGTCCTA AACCCAACCA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... G.........
D83:D91 MAB .......... .......... .......... .......... .......... .......... G.........
D83:D91 Sera .......... ...CG..... .......... .......... .......... .......... G.........
N83:D91 .......... .......... .......... ......A... .......... .......... G.........
N83:D91 MAB .......... .......... .......... ......A... .......... .......... G.........
N83:N91 Sera .......... .......... .......... ......A... .......... .......... ..........
N83:N91 .......... .......... .......... ......A... .......... .......... ..........
N83:D91 Sera .......... .......... .......... ......A... .......... .......... G...G.....
N83:N91 MAB .......... .......... .......... ......A... .......... .......... ..........
281
FeLV-A ATGTAAAACA CGGGGCACGT TACTCCTCCT CAAAATATGG ATGTAAAACT ACAGATAGAA AAAAACAGCA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .........C .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......A.. ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
351
FeLV-A ACAGACATAC CCCTTTTACG TCTGCCCCGG ACATGCCCCC TCGTTGGGGC CAAAGGGAAC ACATTGTGGA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
194
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera ..G....... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
421
FeLV-A GGGGCACAAG ATGGGTTTTG TGCCGCATGG GGATGTGAGA CCACCGGAGA AGCTTGGTGG AAGCCCACCT
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... ......G... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
491
FeLV-A CCTCATGGGA CTATATCACA GTAAAAAGAG GGAGTAGTCA GGACAATAGC TGTGAGGGAA AATGCAACCC
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
561
FeLV-A CCTGGTTTTG CAGTTCACCC AGAAGGGAAG ACAAGCCTCT TGGGACGGAC CTAAGATGTG GGGATTGCGA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......C.. .......... .......... ..........
D83:D91 Sera .........A .....T.... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... ..G....... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
631
FeLV-A CTATACCGTA CAGGATATGA CCCTATCGCT TTATTCACGG TGTCCCGGCA GGTATCAACC ATTACGCCGC
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB ....G..... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
701
FeLV-A CTCAGGCAAT GGGACCAAAC CTAGTCTTAC CTGATCAAAA ACCCCCATCC CGACAATCTC AAACAGGGTC
FeLV-A Sera ....A..... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......C.. .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
195
771
FeLV-A CAAAGTGGCG ACCCAGAGGC CCCAAACGAA TGAAAGCGCC CCAAGGTCTG TTGCCCCCAC CACCATGGGT
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......A.. .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... C......... ..........
N83:D91 MAB .......... ......G... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
841
FeLV-A CCCAAACGGA TTGGGACCGG AGATAGGTTA ATAAATTTAG TACAAGGGAC ATACCTAGCC TTAAATGCCA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... ........G. .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
911
FeLV-A CCGACCCCAA CAAAACTAAA GACTGTTGGC TCTGCCTGGT TTCTCGACCA CCCTATTACG AAGGGATTGC
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... ....G..... .G........ .......... .......... .......... ..........
N83:D91 MAB ...G...... .......... .......... ......G... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
981
FeLV-A AATCTTAGGT AACTACAGCA ACCAAACAAA CCCCCCCCCA TCCTGCCTAT CTACTCCGCA ACACAAACTA
FeLV-A Sera .......... .......... .......... .......... .........C .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .....G.... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .T........ .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1051
FeLV-A ACTATATCTG AAGTATCAGG GCAAGGAATG TGCATAGGGA CTGTTCCTAA AACCCACCAG GCTTTGTGCA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... ......T... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .........G .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... .........G
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1121
FeLV-A ATAAGACACA ACAGGGACAT ACAGGGGCGC ACTATCTAGC CGCCCCCAAC GGCACCTATT GGGCCTGTAA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
196
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... G......... .......... ..........
1191
FeLV-A CACTGGACTC ACCCCATGCA TTTCCATGGC GGTGCTCAAT TGGACCTCTG ATTTTTGTGT CTTAATCGAA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .C........ ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... ........T. .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... ........G. .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .A........ .......... .......... ..........
1261
FeLV-A TTATGGCCCA GAGTGACTTA CCATCAACCC GAATATGTGT ACACACATTT TGCCAAAGCT GTCAGGTTCC
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ....C.....
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1331
FeLV-A GAAGAGAACC AATATCACTA ACGGTTGCCC TTATGTTGGG AGGACTTACT GTAGGGGGCA TAGCCTCGGG
FeLV-A Sera .......... .......... .......... .......... .......... .......... .....G....
FeLV-A MAB .......... .......... .......... .......... .....G.... .......... .....G....
D83:D91 .......... .......... .......... .......... .......... .......... .....G....
D83:D91 MAB .......... .......... .......... .......... .......... .......... .....G....
D83:D91 Sera .......... .......... .......... .......... .......... .......... .....G....
N83:D91 .......... .......... .......... .......... .......... .......... .....G....
N83:D91 MAB .......... .......... .......... .......... .......... .......... .....G....
N83:N91 Sera .......... .......... .......... .......... .......... .......... .....G....
N83:N91 .......... .......... .......... .......... .......... A......... .....G....
N83:D91 Sera .......... .......... .......... .......... .......... .......... .....G....
N83:N91 MAB .......... .......... .......... .......... .......... .......... .....G....
1401
FeLV-A GGTCGGAACA GGGACTAAAG CCCTCCTTGA AACAGCCCAG TTCAGACAAC TACAAATGGC CATGCACACA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... ...C...... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... ......C... .......... ...G...... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .G........ .......... .......... ..........
1471
FeLV-A GACATCCAGG CCCTAGAAGA ATCAATTAGT GCCTTAGAAA AGTCCCTGAC CTCCCTTTCT GAAGTAGTCT
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .....C.... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1541
FeLV-A TACAAAACAG ACGGGGCCTA GATATTCTAT TCTTACAAGA GGGAGGGCTC TGTGCCGCAT TGAAAGAAGA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
197
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......G.. .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1611
FeLV-A ATGTTGCTTC TATGCGGATC ACACCGGACT CGTCCGAGAC AATATGGCCA AATTAAGAGA AAGACTAAAA
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera ..A....... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1681
FeLV-A CAGCGGCAAC AACTGTTTGA CTCCCAACAG GGATGGTTTG AAGGATGGTT CAACAAGTCC CCCTGGTTTA
FeLV-A Sera .......... .....G.... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .G........ .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... A......... .......... .......... ..........
N83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1751
FeLV-A CAACCCTAAT TTCCTCCATT ATGGGCCCCT TACTAATCCT ACTCCTAATT CTCCTCTTCG GCCCATGCAT
FeLV-A Sera .......... .......... .........G .......T.. .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .........C .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .....G.... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB .......... .......... .C........ .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... .........C
1821
FeLV-A CCTTAACCGA TTAGTACAAT TCGTAAAAGA CAGAATATCT GTGGTACAGG CTTTAATTTT AACCCAACAG
FeLV-A Sera .......... .......... .......... .......... .......... .......... ..........
FeLV-A MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 .......... .......... .......... .......... .......... .......... ..........
D83:D91 MAB .......... .......... .......... .......... .......... .......... ..........
D83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:D91 .......... .......... .......... .......... .......... .......... ..........
N83:D91 MAB ..C....... .......... .......... .......... .......... .......... ..........
N83:N91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 .G........ .......... .......... .......... .......... .......... ..........
N83:D91 Sera .......... .......... .......... .......... .......... .......... ..........
N83:N91 MAB .......... .......... .......... .......... .......... .......... ..........
1891
FeLV-A TACCAACAGA TAAAGCAATA CGATCCGGAC CGACCATGA
FeLV-A Sera .......... .......... .......... .........
FeLV-A MAB .......... .......... .......... .........
D83:D91 .......... .......... .......... .........
D83:D91 MAB .......... .......... .......... .........
D83:D91 Sera .......... .......... .......... .........
N83:D91 .......... .......... .......... .........
N83:D91 MAB .......... .......... .......... .........
N83:N91 Sera .......... .......... .......... .........
N83:N91 .......... .......... .......... .........
N83:D91 Sera .......... .......... .......... .........
N83:N91 MAB .......... .......... .......... .........
198
8.4 Genome sequences of FeLV-2518 and -4314
(A) Whole genome nucleotide alignment
enFeLV genomic flanking Region
FeLV-A ---------- ---------- ---------- ---------- ---------- ---------- ----------
AY364318 TGAAAGACCC CTTCCCCTTG TTTTGACCCC CTGTCATAAT ATGCTTAGCA ATAGTAACGC CATTTGCAAG
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
71 Start of 5’ LTR
FeLV-A ---------- -----TGAAA GACCCCCTAC CCCAAAATTT AGCCAGCTAC TGCAGTGGTG CCATTTCACA
AY364318 ACAGCACCAA GAAGT.C.GG .GT.TTA.C. TAAGTCCACC GTTT....G. CAA.CA..AT ATC.G.GGTC
FeLV-2518 .......... .....----- ---------- ---------- ---------- ---------- ----------
FeLV-4314 .......... .....----- ---------- ---------- ---------- ---------- ----------
141
FeLV-A AGGCATGGAA AATTACTCAA GTA---TGTT CCCATGAGAT ACAAGGAAGT TAGAGGCTAA AACAGGATAT
AY364318 ..C..CCCGG CCC..AGAT. .CCACC..GC ..T.A..TGG GA.T....AG ..CT.A..CC .C.C.ATAGA
FeLV-2518 ---------- ---------- ---...---- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---...---- ---------- ---------- ---------- ----------
211
FeLV-A CTGTGGTTAA GCACCTGGGC CCCGGCTTGA GGCCAAGAAC AGTTAAACCC CGGATATAGC TGAAACAGCA
AY364318 .CC.A.AG.T .AG...A.T. AG.CA.CCAT .TTTTTC--. CCC.C.TT.T G...A..C.. CCTC.G.AA.
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
281
FeLV-A GAAGTTTCAA GGCCGCTACC AGCAGTCTCC AGGCTCCCCA GTTGACCAGG GTTCGACCTT CCGCCTCATT
AY364318 ...AAGAA.. A.AAAAA.AA .AA.AAAAAA .AAAAAA... .CCTCATTTA AC.G....AA TAAGAC.CCG
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
351
FeLV-A TAAACTAACC AATCCCCACG CCTCTCGCTT CTGTGCGCGC GCTTTCTGCT ATAAAACGAG CCATCAGCCC
AY364318 ...CTATG.T TC..G.TT.T GTAAC...GC T.C...-.A. T.CAA.C-.. ......A.TC T.CC......
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
421
FeLV-A C-CAACGGGC GCGCAAGTCT TTGCTGAGAC TTGACCGCCC CGGGTACCCG TGTACGAATA AACCTCTTGC
AY364318 AA...GA... .......... .......... .......... .......... .......... ..........
FeLV-2518 -.-------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 -.-------- ---------- ---------- ---------- ---------- ---------- ----------
491
FeLV-A TGATTGCATC TGACTCGTGG TCTCGGTGTT CTGTGGGCGC GGGGTCTCAT CGCCGAGGAA GACCTAGTTC
AY364318 ..T....... .......... .......... .C......A. .......... .......... .........A
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
561
FeLV-A AGGGGTCTTT CATTTGGGGG CTCGTCCGGG ATCGAGACCC CCGACCCCCG GGACCACCGA CCCACCATCA
AY364318 G......... .......... .......... ..A....... ..A....... .......... ..........
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
631
FeLV-A GGAGGTAAGC TGGCCGGCGA CCATACCTGT TGTCCTTGTA TAAGTGTCTC TGTCAATTGA TCTGATTTTG
AY364318 .......... .......... .....T.... .......... .G........ .....T.... ..........
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
701
FeLV-A GCGGTGGGAT CGAAGGAGCT GACGAGCTCG TACTTCGCCC CCGCAACCCT GGAAGACGTT CCACGGGTGT
AY364318 .......AGC .......... .......... A......... .......... .......... ..........
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
Gag-Pol Polyprotein Start Codon
FeLV-A CTGATGTCTG GAGCCTCTAG TGGGACAGCC ATTGGGGCTC ATCTGTTTGG GGTCTCACC- --------TG
AY364318 .......... .......... .......... .........A GAT....... .A.....T.C GTATTAGG..
FeLV-2518 ---------- ---------- -......... .......... .......... ......C... ..........
FeLV-4314 ---------- --------.T G......... .......... .......... .......... ..........
199
841
FeLV-A AATACAGGGT GTTGATCGGA GACGAGGGAG CCGGACCCTC AAAGTCTCTT TCTGAGGTTT CATTTTCGGT
AY364318 .......... .......... .......... .......... ..G.....C. .......... ..........
FeLV-2518 .......... .......... .......... .......... ..G....... .......... ..........
FeLV-4314 .......... .......... .......... .......... ........C. .......... ..........
911
FeLV-A TTGGTACCGA AGCCGCGCGG CACGTCTTGT CATTTTTTGT CTGGTTGCGT CTTTTCTTGT CCCTTGTCTA
AY364318 ......T... .......... .......... ....C..... ..T....... ....C..... ...C......
FeLV-2518 ........A. .......... .......... .........C .......... .......... ..........
FeLV-4314 ........A. .......... .......... .......... .......... .......... T.........
981
FeLV-A ACCTTTTTAA TTGCAGAAAC CGTCATGGGC CAAACTATAA CTACCCCCTT AAGCCTCACC CTTGATCACT
AY364318 .......... ........G. .......... ......G... .......... G......... ..CA.C....
FeLV-2518 .......... .......... .......... ..G....... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
1051
FeLV-A GGTCTGAAGT CCGGGCACGA GCCCATAACC AAGGTGTCGA GGTCCGGAAA AAGAAATGGA TTACCTTATG
AY364318 .......G.. ..A......G ....G...T. .G........ A......... .......... ....AC.G..
FeLV-2518 .......... .......... ........T. ....G..... .......... .......... ..........
FeLV-4314 .......... .......... ........T. .......... .......... .......... ..........
1121
FeLV-A TGAGGCCGAA TGGGTGATGA TGAATGTGGG CTGGCCCCGA GAGGGAACTT TTTCTCTTGA TAACATTTCC
AY364318 ...A...... .....A.... .......A.. T......... ..A....... .CA.CA.... C..T.....A
FeLV-2518 .......... .......... .......... .......... ..A....... .......... ..........
FeLV-4314 .......... .......... .......... .........G ..A....... .......... ..G.......
1191
FeLV-A CAGGTTGAGA AAAAGATCTT CGCCCCGGGA CCGTATGGAC ACCCCGACCA GGTTCCTTAC ATTACCACAT
AY364318 .....C...G .G.GA..... .........G ..A....... ....A..T.. AA.C.....T ........G.
FeLV-2518 .......... .......... .......... ..A....... .......... A......... ..........
FeLV-4314 .......... .......... .......... ..A....... .......... A......... ........G.
1261
FeLV-A GGAGATCCTT AGCCACAGAC CCCCCTTCGT GGGTTCGGCC GTTCCTACCC CCTCCCAAAC CTCCCACGCC
AY364318 ........C. .......... ......C.A. .......C.. A.....G... .....T..G. A.....G.A.
FeLV-2518 .......... .......... .......... .......T.. .......... .......... .......A..
FeLV-4314 .......... .......... .......... .......T.. .......... .......... .......A..
1331
FeLV-A ---CCTCCCT CAACCTCTCT CGCCGCAGCC CTCCGCCCCT CTTACCTCTT CCCTCTACCC CGTCCTCCCC
AY364318 AGAT.CT..C G.G.....T. .......A.. ...A.....C .CC.T...C. .......... ...T......
FeLV-2518 .......... ........T. .......... .........C .......... .......... ...T.....T
FeLV-4314 .......... ........T. .......... .......... .......... .......... ...T......
1401
FeLV-A AAGTCAGACC CTCCCAAACC GCCTGTGTTA CCGCCTGATC CTTCTTCCCC TTTAATAGAT CTCTTAACAG
AY364318 ..AC...... .C.....GG. ......A... ..A..CA... .......... ......T... ..........
FeLV-2518 .......... .C........ .......... .......... .......... ......T... ..........
FeLV-4314 ...C...G.. .C........ .......... .......... ....C..... ......T... ..........
1471
FeLV-A AAGAGCCACC TCCCTATCCG GGAGGTCACG GGCCA---CC GCCGTCAGGT CCTAGGACCC CAACCGCTTC
AY364318 .......... .........T ..G....... .....ACA.. .........C .....A.... ....T..C..
FeLV-2518 .......... .......... ..G....... .......... ...A...... .......... ..........
FeLV-4314 .......... .......... ..G....... .......... ...A...... .......... ..........
1541
FeLV-A CCCGATTGCA AGCCGGCTAA GGGAACGACG AGAAAACCCT GCTGAAGAAT CTCAAGCCCT CCCCTTGAGG
AY364318 .........C ........GC .A........ ......T..A .....GA... .......... ......A...
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
1611
FeLV-A GAGGGCCCCA ACAACCGACC CCAGTATTGG CCATTCTCAG CCTCAGACCT GTATAACTGG AAGTCGCATA
AY364318 ..A.....A. .....A.... ......C... ........G. ....T..... ...C..T... ..A.T.....
FeLV-2518 ..A....... .......... .......... .......... .T........ .......... ..........
FeLV-4314 ..A....... .......... .......... .......... .T......T. .......... ..........
1681
FeLV-A ACCCCCCTTT CTCCCAAGAC CCAGTGGCCC TAACTAACCT AATTGAGTCC ATTTTAGTGA CGCATCAACC
AY364318 .......... ......G... .......... .......... .......... .......... .A.....G..
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... .A........
1751
FeLV-A AACCTGGGAC GACTGCCAGC AGCTCTTGCA GGCACTCCTG ACAGGCGAAG AAAGGCAAAG GGTCCTTCTT
200
AY364318 .......... ........A. .......A.. ...T...... ..G.CA..G. .G..A..... ......C...
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
1821
FeLV-A GAGGCCCGAA AGCAGGTTCC AGGCGAGGAC GGACGGCCAA CCCAACTACC CAATGTCATT GATGAGACTT
AY364318 ..A....... ....A..... .......... .......... ....G..G.. .......G.. ..C...G...
FeLV-2518 .......... .......... .......... .......... .......... .......... ..C.......
FeLV-4314 .......... .......... .......... .......... .......... .......... ..C...G...
1891
FeLV-A TCCCCTTGAC CCGTCCCAAC TGGGATTTTG CTACGCCGGC AGGTAGGGAG CACCTACGCC TTTATCGCCA
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .T........ .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
1961
FeLV-A GTTGCTATTA GCGGGTCTCC GCGGGGCTGC AAGACGCCCC ACTAATTTGG CACAGGTAAA GCAGGTTGTA
AY364318 ......G... .......... .......... .......... .......... .......... ...A......
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... T......... .......... .......... ..........
2031
FeLV-A CAAGGGAAAG AGGAAACGCC AGCAGCATTT TTAGAAAGAT TAAAAGAGGC TTACAGAATG TACACTCCCT
AY364318 .......... .......... ...CT....C .......... .......... .......... ..........
FeLV-2518 .C........ .......... .......... .......... .......... .......... ..........
FeLV-4314 .....A.... .......... .......... .......... .......... .......... ..........
2101
FeLV-A ATGACCCTGA GGACCCAGGG CAAGCAGCTA GTGTTATACT ATCCTTTATA TACCAGTCTA GCCCAGATAT
AY364318 .......... .......... ..G..T.... .......C.. G........C .......... ....G..C..
FeLV-2518 .C........ .......... .....G.... .......T.. ...T..C... .......... ..........
FeLV-4314 .......... .......... .....G.... .......C.. ......C... .......... ..........
2171
FeLV-A AAGAAATAAG TTACAAAGGC TAGAAGGTCT ACAAGGGTTC ACCCTATCTG ATCTGCTAAA AGAGGCAGAA
AY364318 .......... .......... .......C.. ...G...... ..A..G.... ..T....... ..........
FeLV-2518 .......... ........A. .......C.. .......... .......... .......... ..........
FeLV-4314 .......... .......... .......C.. .......... .......... .......... ..........
2241
FeLV-A AAGATATACA ACAAAAGGGA GACCCCAGAG GAAAGGGAAG AAAGATTATG GCAGCGGCAA GAAGAAAGAG
AY364318 .......... .......... .......... .......... .......... .........G ..........
FeLV-2518 .......... .......... .......... .......... .......... .........G ..........
FeLV-4314 .......... .......... .......... ..G....... .......... .........G ..........
2311
FeLV-A ATAAAAAGCG CCACAAGGAG ATGACTAAAG TTCTGGCCAC AGTAGTTGCT CAGAATAGAG ATAAAGATAG
AY364318 .......... ...T...... .......... .......... .......... .......... ....G.....
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
2381
FeLV-A AGAAGAAAGT AAACTGGGGG ATCAAAGGAA AATACCTCTG GGAAAGGACC AGTGTGCCTA TTGCAAGGAA
AY364318 ...G...... ........A. .......... .......... ..G..A.... .......... ..........
FeLV-2518 ......G... .......... .......... .......... ..G..A.... .......... ..........
FeLV-4314 .......... ........A. .......... .......... ..G..A.... .......... ..........
2451
FeLV-A AAGGGGCATT GGGTTCGCGA TTGCCCCAAA CGACCCCGGA AGAAACCCGC CAACTCCACT CTCCTCAACT
AY364318 .....A.... .......... ......G... .......... .......... AG........ .........C
FeLV-2518 .G........ .......... .......... .......... .......... .......... ........T.
FeLV-4314 .......... .......... .......... ......AA.. .......... .......... ..........
2521
FeLV-A TAGGAGATTA GGAGAGTCAG GGCCAGGACC CCCCCCCTGA GCCCAGGATA ACCTTAAAAA TAGGGGGGCA
AY364318 ...A...... .......... .......... .......... .......... ...C.....G ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
2591
FeLV-A ACCGGTGACT TTCCTGGTGG ACACGGGAGC CCAGCACTCA GTACTAACTC GACCAGATGG ACCTCTCAGT
AY364318 ...A.....C ..T....... .T........ .........G .....G.... .......... ..........
FeLV-2518 .......... ..T....... .......... .......... .....G.... .......... ..........
FeLV-4314 .......... ..T....... .......... .......... .....G.... .......... ..........
2661
FeLV-A GACCGCACAG CCCTGGTGCA AGGAGCCACG GGAAGCAAAA ACTACCGGTG GACCACCGAC AGGAGGGTAC
AY364318 ......T... .......... .........A .......... .......A.. .......... ........G.
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
201
2731
FeLV-A AACTGGCAAC CGGTAAGGTG ACTCATTCTT TTTTATATGT ACCTGAATGT CCCTACCCGT TATTAGGGAG
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... ........C. .......... .......... .......... .......A..
2801
FeLV-A AGACCTATTA ACTAAACTTA AGGCCCAAAT CCATTTTACC GGAGAAGGGG CTAATGTTGT TGGGCCCAAG
AY364318 .......... ..C.....C. .......G.. ......C... ........A. .......... ...A....T.
FeLV-2518 .......... .......... .......... .......... .......... .......... ........G.
FeLV-4314 .......... .......... .......... .......... .......... .......... ........G.
2871
FeLV-A GGTTTACCCC TACAAGTCCT TACTTTACAA TTAGAAGAGG AGTATCGGCT ATTTGAGCCC GAAAGTACAC
AY364318 ..C....... .......... C..C..G... C.......A. .......... .........G ......GA..
FeLV-2518 .......... .......... .......... .......... .......... .........A ..........
FeLV-4314 .......... .......... .......... .......... .......... .........A ..........
2941
FeLV-A AAAAACAGGA GATGGACATT TGGCTTAAAA ACTTTCCCCA GGCGTGGGCA GAAACAGGAG GTATGGGAAC
AY364318 T......A.G T.......G. .......... .......... ...A...... .......... ....A....T
FeLV-2518 .......... .......... .......... .......... .......... .......... .........T
FeLV-4314 .......... ........C. .......... .......... .......... .......... .........T
3011
FeLV-A GGCTCATTGT CAAGCCCCCG TTCTCATTCA ACTTAAGGCT ACTGCCACTC CAATCTCCAT CCGACAGTAT
AY364318 .........C .........A .C........ ......A... ........C. .......... ...G.....C
FeLV-2518 .......... .........A .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......C.. .......... .......... .......... ..........
3081 RT Start Codon
FeLV-A CCTATGCCCC ATGAAGCATA CCAGGGAATT AAGCCTCATA TAAGAAGAAT GCTAGATCAA GGCATCCTCA
AY364318 ..C....... .......T.. ...A...... ..A..C.... ....G..... ...G..C... ..........
FeLV-2518 .......... .......G.. .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... ..C....... .......... ..........
3151
FeLV-A AGCCCTGCCA GTCCCCATGG AATACACCCT TATTACCTGT TAAGAAGCCA GGGACCGAGG ATTACAGACC
AY364318 .......... .......... .........C .......... C..A...... ..A....G.. ..........
FeLV-2518 .......... .......... .......... .......... A......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
3221
FeLV-A AGTGCAGGAC TTAAGAGAAG TAAACAAAAG AGTGGAAGAC ATCCATCCTA CTGTGCCAAA TCCATATAAC
AY364318 .......... .......... .......... G..A...... ........C. .......... C.....C...
FeLV-2518 ...A...... .......... .......... ...A...... .......... .......... ..........
FeLV-4314 .......... .......... .......... ...A...... .......... .......... ..........
3291
FeLV-A CTCCTTAGCA CCCTCCCGCC GTCTCACCCT TGGTACACTG TCCTAGATTT AAAAGACGCT TTTTTCTGCC
AY364318 .......... .......A.. T......... ........C. ........C. ......T... .........T
FeLV-2518 .......... .......... .......... .......... .......... ...G...... ..........
FeLV-4314 .......... .......... .......... .......... .......... ...G...... ..........
3361
FeLV-A TGCGACTACA CTCTGAGAGT CAATTACTTT TTGCATTTGA ATGGAGAGAT CCAGAAATAG GACTGTCAGG
AY364318 .......... .C.......C ........C. .......... .....A.... .....G.... .G........
FeLV-2518 .......... .C.......C .......... .C........ .......... .......... ..........
FeLV-4314 .......... .......... ..G....... .......... .......... .......... ..........
3431
FeLV-A GCAGCTAACC TGGACACGCC TTCCTCAAGG GTTCAAGAAT AGCCCCACCC TATTTGATGA GGCCCTGCAC
AY364318 ...A..G... .....T.... ....A..... .......... .......... .......... ......A...
FeLV-2518 .......... .......... ....A..G.. .......... ......G... .......... ..........
FeLV-4314 ...A...... .......... .......G.. .......... .......... .......... ..........
3501
FeLV-A TCAGACCTGG CCGATTTCAG GGTAAGGTAC CCGGCTCTAG TCCTCCTACA ATATGTAGAT GACCTCTTGC
AY364318 .......... .A........ ...G.....T ..A...T... .......... ...C...... ........A.
FeLV-2518 ..G....... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
3571
FeLV-A TGGCTGCGGC AACCAGGACT GAATGCCTGG AAGGGACTAA GGCACTCCTT GAGACTTTGG GCAATAAGGG
AY364318 .......... .....A...C ........A. .......... A......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
3641
FeLV-A GTACCGAGCC TCTGCAAAGA AGGCCCAAAT TTGCCTGCAA GAAGTCACAT ACCTGGGGTA CTCTTTAAAA
202
AY364318 T......... .......... .......... .......... A......... ....A..... .......G.G
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
3711
FeLV-A GATGGCCAAA GGTGGCTTAC CAAAGCTCGC AAGGAAGCCA TCCTATCCAT CCCTGTGCCT AAAAACTCAC
AY364318 .....T.... .A........ .........G ..A....... .T..C..... .......... ......C...
FeLV-2518 .......... .......... .........G ..A....... .......... .......... ......C...
FeLV-4314 .......... .......... .........G ..A....... .......... .......... ......C...
3781
FeLV-A GACAAGTAAG AGAGTTCCTT GGAACTGCAG GTTACTGCCG GCTGTGGATT CCCGGTTTTG CCGAGCTCGC
AY364318 .G.....G.. .......... .......... .C........ .......... .......... ..........
FeLV-2518 .T.....G.. .......... .......... .......... .......... .......... ..........
FeLV-4314 .......G.. .......... .......... .......... .......... .......... ..........
3851 FeLV-4314 5’ Recomb. Site
FeLV-A AGCCCCGCTA TACCCTCTCA CTCGACCAGG AACTCTGTTC CAGTGGGGAA CAGAGCAACA ATTGGCCTTC
AY364318 T......... ..T....... .......... .........T .......... ....A..... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......G.. .......... .......... .......... ..........
3921
FeLV-A GAGGACATTA AAAAAGCCCT CTTGAGTTCC CCTGCCCTGG GGTTGCCAGA TATCACCAAA CCCTTTGAAT
AY364318 ..AA...... .......... ......C... .......... .......... .........G ..........
FeLV-2518 ...A...... .......... ......C... .......... .......... .........G ..........
FeLV-4314 ...A...... .......... ......C... .......... .......... .........G ..........
3991
FeLV-A TATTTATTGA TGAGAACTCA GGATTTGCAA AGGGGGTGTT AGTCCAAAAA CTGGGACCCT GGAAAAGACC
AY364318 .......... .....G.... ..G.....G. .......... .......... .......... ..........
FeLV-2518 .......... .....G.... ........G. .......... .A........ .......... ..........
FeLV-4314 .G........ .....G.... .....C..G. .......... .......... .......... ..........
4061
FeLV-A AGTTGCCTAC CTATCAAAAA AGCTGGATAC AGTGGCATCT GGATGGCCCC CTTGTTTACG CATGGTTGCA
AY364318 .......... .......... .A........ .......... .......... .......... ..........
FeLV-2518 .......... .......... .A........ .........C .......... .......... ..........
FeLV-4314 .......... .......... .A........ .......... .......... .......... ..........
4131
FeLV-A GCCATCGCCA TCCTAGTCAA GGATGCAGGG AAGCTAACCC TAGGACAGCC GCTAACTATC CTGACCTCCC
AY364318 .......... .......... .......... ........T. .......... .......G.. ..........
FeLV-2518 .......... .......... .......... .....G.... .......... .......... ..........
FeLV-4314 .......... .......... .......... ........T. .......... .......G.. ..........
4201
FeLV-A ACCCAGTTGA GGCACTTGTC CGACAGCCTC CAAATAAATG GCTCTCTAAT GCTAGAATGA CTCATTACCA
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
4271
FeLV-A AGCTATGCTC CTCGATGCAG AGCGAGTCCA TTTCGGGCCG ACAGTCTCCC TTAACCCTGC TACCTTGCTC
AY364318 .......... .......... .......... .........A .......... .......... C........T
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .........A .......... .......... C........T
4341
FeLV-A CCCCTCCCCA GCGGGGGAAA CCACCACGAC TGTCTCCAGA TTTTAGCCGA GACCCATGGC ACCAGACCCG
AY364318 .......... A..A...... .......... ..C....... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ......A...
FeLV-4314 .......... A..A...... .......... ..C....... .......... .......... ..........
4411
FeLV-A ACTTAACTGA CCAGCCGTTG CCGGATGCAG ACCTGACCTG GTACACAGAT GGTAGCAGCT TCATCCGTAA
AY364318 .......... .......... .......... .......... ......G... .......... ..........
FeLV-2518 .......... .......... .......... .......... ......G... .......... ..........
FeLV-4314 .......... .......... .......... .......... ......G... .......... ..........
4481
FeLV-A TGGCGAGAGA GAGGCCGGAG CCGCAGTAAC AACCGAATCT GAGGTAATCT GGGCTGCTCC CCTCCCACCC
AY364318 C..A...... A......... .......... .......... .......... ........T. ..........
FeLV-2518 C......... A........A .......... .......... .......... ........T. ..........
FeLV-4314 C......... A..-...... .......... .......... .......... ........T. ..........
4551
FeLV-A GGAACGTCAG CCCAGCGAGC CGAACTGATT GCCCTGACCC AGGCACTAAA GATGGCAGAA GGTAAGAAGC
AY364318 .......... .......... .......... .......... .......G.. .......A.. ..........
FeLV-2518 .......... .......... .......G.. .......... .......... .......A.. ..........
FeLV-4314 .......... .......... .......... .......... .......G.. .......A.. ..........
203
4621
FeLV-A TAACTGTCTA TACGGACAGC CGATATGCCT TTGCTACAAC TCATGTACAC GGGGAAATCT ACAGGCGGCG
AY364318 .......... .......... .......... ........G. .......... .......... ..........
FeLV-2518 .......... .......... .......... ........G. .......... .......... ..........
FeLV-4314 .......... .......... .......... ........G. .......... .......... ..........
4691
FeLV-A GGGCCTACTA ACTTCAGAAG GAAAAGAAAT TAAAAATAAA AATGAAATCC TCGCCCTACT AGAGGCGTTA
AY364318 ......G... .......... .......... .......... .......... ........T. ..........
FeLV-2518 .......... .......... .......... .......... .......... ........T. ..........
FeLV-4314 ......G... .......... .......... .......... .......... ........T. ..........
4761
FeLV-A TTCTTACCCA AAAGACTGAG CATCATCCAT TGCCCGGGAC ACCAAAAAGG TGATAGTCCC CAGGCAAAAG
AY364318 .......... .......... T......... .....T.... .......... .......... .....G....
FeLV-2518 .......... .......... T......... .......... .......... .......... .....G....
FeLV-4314 .......... .......... T......... ..T..A.... .......... .......... .....G....
4831
FeLV-A GAAACAGATT AGCTGATGAT ACAGCAAAGA AAGCCGCCAC AGAGACTCAT TCATCACTAA CCGTCTTACC
AY364318 .......... ...C...... .......... .......... .........A .......... ..A.......
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... ...C...... .......... .......... .........A .......... ..A.......
4901
FeLV-A CACTGAACTT ATAGAGGGTC CCAAAAGGCC TCCATGGGAA TATGATGACA GTGATTTAGA CCTTGTGCAA
AY364318 .......... .......... .......... .......... .......... .......... .........G
FeLV-2518 .......... .......... .......... .......... .......... .......... .........G
FeLV-4314 .......... .....A.... ......A... .......... ...A...... .......... .........G
4971
FeLV-A AAACTCGAAG CTCATTATGA GCCAAAGAGA GGTACCTGGG AGTACCGAGG AAAAACTATC ATGCCTGAAA
AY364318 .....T.... .......... ......A... .......... ......A... G........A ..........
FeLV-2518 .....T.... .......... ......A... .......... .......... .......... ..........
FeLV-4314 .....T.... .......... ......A... .......... ......A... G........A ..........
5041
FeLV-A AATACGCAAA AGAGTTGATT AGCCATCTGC ATAAGTTAAC ACACCTCAGT GCTAGGAAAA TGAAAACTTT
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
5111
FeLV-A ACTAGAAAGA GAAGAAACTG GGTTTTACCT CCCTAACAGA GACTTACACC TCCGGCAAGT AACAGAGAGC
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... ......A... .......... .......... ..........
FeLV-4314 .......... ..G....... .......... .......... .......... .......... ..........
5181
FeLV-A TGCCGGGCAT GTGCTCAAAT CAACGCCGGA AAGATAAAGT TTGGACCTGA TGTAAGGGCC CGAGGCCGCC
AY364318 .......... .......... ......A..G ..A....... .......... .......... .......A..
FeLV-2518 .......... .......... ......A... .......... .......... .......... ..........
FeLV-4314 ....A..... ........G. ......A..G ..A....... .......... .......... .......A..
5251
FeLV-A GGCCCGGAAC ACATTGGGAA GTAGACTTCA CTGAAATCAA GCCAGGAATG TATGGATATA AATACCTCTT
AY364318 .........T .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .........T .......... .......... .......... .......... .......... ..........
5321
FeLV-A GGTGTTCATA GATACCTTCT CTGGCTGGGC CGAAGCTTAC CCCGCCAAAC ATGAAACAGC AAAAGTTGTT
AY364318 .......... ..C....... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
5391
FeLV-A GCCAAGAAAC TCTTAGAAGA AATTTTTCCC CGCTACGGGA TCCCTCAGGT ATTGGGTTCA GATAATGGAC
AY364318 .......... .......... G........T ..T....... .......... .......... ..........
FeLV-2518 .......... .......... ......C... .......... .......... .......... ..........
FeLV-4314 .......... .......... G........T ..T....... .......... .......... ..........
5461
FeLV-A CCGCCTTTAT CTCCCAGGTA AGTCAGTCTG TGGCCACCCT ACTGGGGATT AATTGGAAGT TACATTGTGC
AY364318 .......... .......... .......... .......... .......... ........A. ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ........A. ..........
5531
FeLV-A ATACCGACCC CAAAGTTCAG GTCAGGTAGA AAGAATGAAT AGATCAATTA AGGAGACTTT AACTAAATTA
204
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
5601
FeLV-A ACGCTAGAAA CTGGCTCTAA GGATTGGGTG CTCCTCCTGC CCCTGGTTTT ATACCGGGTA CGTAACACGC
AY364318 .......... .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... A......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
5671
FeLV-A CAGGCCCCCA CGGGTTAACT CCTTTTGAAA TCCTGTACGG GGCACCCCCA CCTATGGCTC ACTTCTTTGA
AY364318 ....T..... .......... .......... .......... .......... .......... ..........
FeLV-2518 ....T..... T......... .......... ..T....... .......... .......... ..........
FeLV-4314 ....T..... .......... .......... .......... .......... .......... ..........
5741
FeLV-A TACTGATATC TCTAGCTTCG CTACCTCCCC CACTATGCAG GCACATTTAC GCGCCCTGCA GCTGGTCCAA
AY364318 .G....C... ...G.T.... .......... ...C...... .......... .......... ..........
FeLV-2518 .G........ .......... .......... .......... .......... .......... ..........
FeLV-4314 .G.G..C... ...G.T.... .......... ...C...... .......... .......... ..........
5811
FeLV-A GAAGAGATCC AGAGACCTCT AGCGGCGGCC TACCGAGAAA AACTTGAAAC CCCGGTTGTG CCTCACCCCT
AY364318 .......... .......... ......A... .......... .G..C..... .......... ..........
FeLV-2518 .......... .......... .......... ....A..... .G..C..... .......... ..........
FeLV-4314 .......... .......... ......A... .......... .G..C..... .......... ..........
5881
FeLV-A TCAAACCAGG AGACTCCGTC TGGGTTCGGA GACATCAAAC CAAGAACCTC GAGCCACGGT GGAAAGGACC
AY364318 .......... .......... .......... .......... .......... .......... ....G.....
FeLV-2518 .......... .......... .......... .......... ..G....... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ....G.....
5951
FeLV-A ACATATCGTC CTCCTGACCA CCCCCACAGC CTTAAAGGTA GACGGAGTTG CTGCCTGGAT TCACGCCTCT
AY364318 .......... .......... .......G.. ......A... .......... ....T..... C........A
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......G.. ......A... .......... ....T..... C........A
6021
FeLV-A CACGTGAAAG CTGCAGGACC AACCACCAAT CAAGACCTCT CGGACAGCCC CAGCTCAGAC GATCCATCAA
AY364318 ..T..A..G. .......G.. .......... ..G....C.. .A...GA... .......... ........G.
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 ..T..A..G. .......G.. .......... ..G....C.. .A...GA... .......... ........G.
Env Start Codon
FeLV-A GATGGAAAGT CCAACGCACC CAAAACCCTC TAAAGATAAG ACTCTCTCGT GGAACTTAGC GTTTCTGGTG
AY364318 .......G.. .......... .......... .......... ...T...... ..G..C..AT .A........
FeLV-2518 .......... .......... .......... .......... ........A. .......... ..........
FeLV-4314 .......G.. .......... .......... .......... ...T...... ..G..C..AT .A........
FeLV-2518 5’ Recomb. Site
FeLV-A GGGATCTTAT TCACAATAGA CATAGGAATG GCCAATCCTA GTCCACACCA AATATATAAT GTAACTTGGG
AY364318 ...G...... .A.G.C.... .G.G...... .......... ....G..... .G.G...... .........A
FeLV-2518 .......... .......... .......... .......... ....G..... .G.G...... .........A
FeLV-4314 ...G...... .A.G.C.... .G.G...... .......... ....G..... .G.G...... .........A
6231
FeLV-A TAATAACCAA TATGCAAACT AACACCCAAG CTAATGCCAC CTCTATGTTA GGAACCTTAA CCGATGCCTA
AY364318 C......... CC.TGT.... GGA..AA.G. .......... ...C.....G ......C.G. .A..C....T
FeLV-2518 C......... CC.TGT.... GGA..AA.G. .......... ...C.....G ......C.G. .A..C....T
FeLV-4314 C......... CC.TGT.... GGA..AACG. .......... ...C.....G ......C.G. .A..C....T
6301
FeLV-A CCCTACCCTA CATGTTGACC TATGTGACCT AGTGGGAGAC ACCTGGGAAC CTATAGTCCT AGATCCAACC
AY364318 .......A.G T..T.....T .......TA. .A.A...A.T ..A...A.C. ..TC..AT.A G..A...---
FeLV-2518 .......A.G T..T.....T .......TA. .A.A...A.T ..A...A.C. ..TC..AT.A G..A...---
FeLV-4314 .......A.G T..T.....T .......TA. .A.A.ATA.T ..A...A.C. ..TC..AT.A G..A...---
6371
FeLV-A AATGTAAAAC ACGGGGCACG TTACTCCTCC TCAAAGTATG GATGTAAAAC TACAGATAGA AAAAAACAGC
AY364318 ---------- ---------- -------.T. C..GG..... .....G.TCA GC.TATG..G .GGTGG..A.
FeLV-2518 ---------- ---------- -------.T. C..GG..... .....G.TCA GC.TATG..G .GGTGG..A.
FeLV-4314 ---------- ---------- -------.T. C..GG..... .....GGTCA GC.TATG..G .GGTGG..A.
6441
FeLV-A A-ACAAACAT ACCCCTTTTA CGTCTGCCCC GGACATGCCC CCTCGCTGGG GCCAAAGGGA ACACATTGTG
AY364318 .G.G.....C ....-..... T.....T..A .........- ---------- ----..CC.G .AG..A....
205
FeLV-2518 .G.G.....C ....-..... T.....T..A .........- ---------- ----..CC.G .AG..A....
FeLV-4314 .G.G.....C ....-..... T.....T..A .........- ---------- ----..CC.G .AG..A....
6511
FeLV-A GAGGGGCACA AGATGGGTTT TGTGCCGCAT GGGGATGTGA GACCACCGGA GAAGCTTGGT GGAAGCCCTC
AY364318 .G...C.... G........C ..C..T.T.. ....T..C.. .........G ...A.C.AT. ...GA...A.
FeLV-2518 .G...C.... G........C ..C..T.T.. ....T..C.. .........G ...A.C.AT. ...GA...A.
FeLV-4314 .G...C.... G........C ..C..T.T.. ....T..C.. .........G ...A.C.AT. ...GA...A.
6581
FeLV-A CTCCTCATGG GACTATATCA CAGTAAAAAG AGGGAGTAGT CAGG------ ---------- ----------
AY364318 .......... .....C.... .........A ....GT..C. ....GAATAT ATCAATGTAG TGGAGGTGGT
FeLV-2518 .......... .....C.... .........A ....GT..C. ....GAATAT ATCAATGTAG TGGAGGTGGT
FeLV-4314 .......... .....C.... .........A ....GT..C. ....GAATAT ATCAATGTAG TGGAGGTGGT
6651
FeLV-A ---------- ------ACAA TA--GCTGT- ---------- ---------- -------GAG GGAAAATGCA
AY364318 TGGTGTGGGC CCTGTT..G. ..AA.....T CACTCCTCGA AAACGGGAGC TAGTGAA.G. ..CCGG....
FeLV-2518 TGGTGTGGGC CCTGTT..G. ..AA.....T CACTCCTCGA TAACGGGAGC TAGTGAA.G. ..CCGG....
FeLV-4314 TGGTGTGGGC CCTGTT..G. ..AA.....T CACTCCTCGA TAACGGGAGC TAGTGAA.G. ..CCGG....
6721
FeLV-A ACCCCCTGAT TTTGCAGTTC ACCCAGAAGG GAAGACAAGC CTCTTGGGAC GGACCTAAGA TATGGGGATT
AY364318 .....T.... C.....A..T .....A.... ........A. A........T .........T C......GC.
FeLV-2518 .....T.... C.....A..T .....A.... ........A. A........T .........T C......GC.
FeLV-4314 .....T.... C.....A..T .....A.... ........A. A..C.....T .........T C......GC.
6791
FeLV-A GCGACTATAC CGTACAGGAT ATGACCCTAT CGCCTTATTC ACGGTGTCCC GGCAGGTGTC AGCCATTACG
AY364318 A......... ...T...... .......... A...C.G... T....A.... ....A..AAT GA........
FeLV-2518 A......... ...T...... .......... A...C.G... T....A.... ....A..AAT GA........
FeLV-4314 A......... ...T...... .......... A...C.G... T....A.... ....A..AAT GA........
6861
FeLV-A CCGCCTCAGG CAATGGGACC AAACCTAGTC TTACCTGATC AAAAACCCCC ATCCAGACAA TCCCAAACAG
AY364318 .......... .C........ ...T...... C.G....... .......... ......G... ..T....T..
FeLV-2518 .......... .C........ ...T...... C.G....... .......... ......G... ..T....T..
FeLV-4314 .......... .C........ .......... C.G....... .......... ..T.G.G... ..T....T..
6931
FeLV-A GGTCCAAAGT GGCGACCCAG AGGCTCCAAA CGACTGAAAG CGCCCCAAGG ---------- --------TC
AY364318 A....CG... AA.AC.T..C CATTC....G GC.AC.G.G. .A.....G.T ATAACTCTTG TTAATGCC..
FeLV-2518 A....CG... AA.AC.T..C CATTC....G GC.AC.G.G. .A.....G.T ATAACTCTTG TTAATGCC..
FeLV-4314 A....C.... AA.AC.T..C CATTC....G GC.AC.G... .A.....G.T ATAACTCTTG TTAATGCC..
7001
FeLV-A TGTTGCCCC- ---------- ----CACCAC CGTGGGTCCC AAACGGATTG GGACCGGAGA TAGGTTAATA
AY364318 CA.......T CTAAGTACCC CTGT....C. ..CAA..... .....T..A. ....A...A. ..........
FeLV-2518 CA.......T CTAAGTACCC CTGT....C. ..CAA..... .....T..A. ....A...A. ..........
FeLV-4314 CA.......T CTAAGTACCC CTGT....C. ...AA..... .....T..A. ....A...A. ..........
7071
FeLV-A AATTTAGTAC AAGGGACATA CCTAGCCTTA AATGCCACCG ACCCCAACAA AACTAAAGAC TGTTGGCTCT
AY364318 ........G. .G........ T.....T... ....T...TA .......... .......... ..........
FeLV-2518 ........G. .G........ T.....T... ....T...TA .......... .......... ..........
FeLV-4314 ........G. .G........ T.....T... ....T...TA .......... .......... ..........
7141
FeLV-A GCCTGGTTTC TCGACCACCC TATTACGAAG GGATTGCAAT CTTAGGTAAC TACAGCAACC AAACAAACCC
AY364318 .T..A..C.. C.....G... .....T.... .A.....GG. A..G..C..T .......... ....C.....
FeLV-2518 .T..A..C.. C.....G... .....T.... .A.....GG. A..G..C..T .......... ....C.....
FeLV-4314 .T..A..C.. C.....G... .....T.... .A.....GG. A..G..C..T .......... ....C.....
7211
FeLV-A CCCCCCATCC TGCCTATCTA CTCCGCAACA CAAACTGACC ATATCTGAAG TATCAGGGCA AGGACTGTGC
AY364318 .......... ........CG AC..A..... T........T .....A.... .G..C..... ...TT.....
FeLV-2518 .......... ........CG AC..A..... T........T .....A.... .G..C..... ...TT.....
FeLV-4314 .......... ........CG AC..A..... T........T .....A.... .G..C..... ...TT.....
7281
FeLV-A ATAGGGACTG TTCCTAAGAC CCACCAGGCT TTGTGCAATG AGACACAACA GGGACATACA GGGGCGCACT
AY364318 .......... .......... ......A... ........AA ........A. A.......A. ...A.T....
FeLV-2518 .......... .......... ......A... ........AA ........A. A.......A. ...A.T....
FeLV-4314 .......... .......... ......A... ........AA ........A. A.......A. ...A.T....
7351
FeLV-A ATCTAGCCGC CCCCAATGGC GCCTATTGGG CCTGTAACAC TGGACTCACC CCATGCATTT CCATGGCGGT
AY364318 .......A.. ...T.GC..T A....C.... .A..C..... C..G..A... ........C. .......A..
FeLV-2518 .......A.. ...T.GC..T A....C.... .A..C..... C..G..A... ........C. .......A..
FeLV-4314 .......A.. ...T.GC..T A....C.... .A..C..... C..G..A... ........C. .......A..
206
FeLV-2518 3’ Recomb. Site
FeLV-A GCTCAATTGG ACCTCTGATT TTTGTGTCTT AATCGAATTA TGGCCCAGAG TGACTTACCA TCAACCCGAA
AY364318 ......C... .......... ........C. G.....G... .......... .A........ .G.G..T..G
FeLV-2518 ......C... ..T....... .......... .......... .......... .......... ..........
FeLV-4314 ......C... .......... ......C.C. G.....G... .......... .A........ .G.G..T..G
7491 SU/TM Cleavage Site
FeLV-A TATGTGTACA CACATTTTGC CAAAGCTGTC AGGTTCCGAA GAGAACCAAT ATCACTAACT GTTGCCCTCA
AY364318 ...A.C..TT .C..C..C.A A..TAAGCC. C.....AAG. ....T..... C..CT.G..A ..........
FeLV-2518 .........T .......... .......... .......... .......... .......... ........T.
FeLV-4314 ...A.C..TT .C..C..C.A A..TAAGCC. C.....AAG. ....T..... C..CT.G..A ..........
7561
FeLV-A TGTTGGGAGG ACTCACTGTA GGGGGCATAG CCGCGGGGGT CGGAACAGGG ACTAAAGCCC TCCTTGAAAC
AY364318 ..C....... .A........ ........G. ....C..AA. A......... ...GCG.... .T..C..G..
FeLV-2518 .......... .......... .......... .......... .......... .......... ..........
FeLV-4314 ..C....G.. .A........ ........G. ....C..AA. A......... ...GCG.... .T..C..G..
7631
FeLV-A AGCCCAGTTC AGACAACTAC AAATGGCCAT GCACACAGAC ATCCAGGCCC TAGAAGAGTC AATTAGTGCC
AY364318 ......A..T ........G. .......... ......G... ..T......T ....G..... ..........
FeLV-2518 .......... .......... .......... .......... .......... ....G..... ..........
FeLV-4314 ......A..T ........G. .......... ......G... ..T......T ....G..... ..........
FeLV-4314 3’ Recomb. Site
FeLV-A TTAGAAAAGT CCCTGACCTC CCTTTCTGAA GTAGTCTTAC AAAACAGACG GGGCCTAGAT ATTCTATTCT
AY364318 ........A. ..T....T.. .......... .......... .......G.. A......... .....G...C
FeLV-2518 .......... .......... .......... ..G....... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
7771
FeLV-A TACAAGAGGG AGGGCTCTGT GCCGCATTAA AAGAAGAATG TTGCTTCTAT GCGGATCACA CCGGACTCGT
AY364318 ....G..... ......A... ..A..G.... .......... ...T..T... ..A....... .....T.A..
FeLV-2518 .......A.. .......... .......... .......... .......... .......... .......T..
FeLV-4314 .......... .......... .......... .......... .......... ..A....... ..........
7841
FeLV-A CCGAGACAAT ATGGCTAAAT TGAGAGAAAG ACTAAAACAG CGGCAACAAC TGTTTGACTC CCAACAGGGA
AY364318 ......T... .......... .A........ .......... ..A....... .A........ ...G......
FeLV-2518 .......... .......... .A........ .......... .......... .......... ..........
FeLV-4314 .......... .......... .AC....... .......... .......... .......... ..........
7911
FeLV-A TGGTTTGAAG GATGGTTCAA CAAGTCCCCC TGGTTCACAA CCTTAATTTC CTCCATTATG GGCCCCTTAC
AY364318 .......... .G........ .......... ........T. .......A.. ......C... .........A
FeLV-2518 .......... .......... .......... .....T.... ..C....... .......... ..........
FeLV-4314 .......... .......... A......... .....T.... ..C....... .......... ..........
7981
FeLV-A TAATCCTACT CCTAATTCTC CTCTTCGGCC CATGCATCCT TAACAGATTA GTACAATTCG TAAAAGACAG
AY364318 .G.....C.. .......T.A ........A. .T........ ....C.G..G ..G..G..T. .C.....T..
FeLV-2518 .......... .......... .......... .......... ....C..... .......... ..........
FeLV-4314 .......... .......... ..T....... ....GG.... ....C..... .......... ..........
8051
FeLV-A AATATCTGTG GTACAAGCCT TAATTTTAAC CCAACAGTAC CAACAGATAA AGCAATACGA TCCGGACCGA
AY364318 ......C..C ..G..GA.T. ..G.GC.... ...G..AC.. ....GCC.GG G.....G... CT.A....A.
FeLV-2518 .......... ........T. .......G.. .......... .......... .......... ........A.
FeLV-4314 .......... .....G..T. .......... .......... ......G... .......... .......A..
Env Termination Codon, start of 3’U3 Region
FeLV-A CCATGAT-TT CCAATTAAAT GTATGATTCC ATTTAGTCCC C-AGAAAAAG GGGGGAATGA AAGACCCCCT
AY364318 ..G.ATCACC ...GC..... .......... ......G.T. .T.AG..... ....A..... ........T.
FeLV-2518 .......... .......... ...A...... .......... .....G.... .......... ..........
FeLV-4314 ........C. .......... .......... .......... .......... .......... ..........
8191
FeLV-A ACCCCAAAAT TTAGCCAGCT ACTGCAGTGG ---TGCCATT --TCACAAGG CATGGAAAAT TACTCAAGTA
AY364318 -....TTGT. ..GA..CC.. GTCAT.A.AT GCT.AG..A. AG.A..GCCA TT..C..G.C AG.A.C.AG.
FeLV-2518 .......... .....T.... .....T.... .......... .......... T......... ..........
FeLV-4314 .......... .......... .......... .....T...A .......... .......... ..........
8261
FeLV-A TGTTCCCATG AGATACAAGG AAGTTAGAGG CTA------A AACAGGATAT CTGTGGTTAA GCACCTGGGC
AY364318 A....AGGG. TCT..TCCTA .GTCC.CC.T T..GCTGCC. .......... .......C.G C....C..C.
FeLV-2518 .......... .....T.... .......... .A........ .......... .......... ..........
FeLV-4314 .......... .....T.... .......... .G........ .......... .......... ..........
8331
FeLV-A C--------- ---CCGGCTT GAGGCCAAGA ACAGTTAAAC CCCGGATATA GCTGAAACAG C----AGAAG
AY364318 .TAAGATAGC CAC.T...CC T.A.ATGG.. .TG.A-..GT A.T.AC.CC. C.C..T.G.C .CTAG...T.
207
FeLV-2518 .......... .......... .........G .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... .......... ..........
8401
FeLV-A TTTCAAGGCC GCTACCAGCA GTCTCCAGGC TCCCC----- -AGTTGACC- ---------- ----------
AY364318 AGC.T..T.A ..C...CATG T.T.T.CCC. ..ATTCTGGG A.A.C.C..T CAGAAAAGAA AAGAAAAAGA
FeLV-2518 .......... ...G...... .......... .......... .......... .......... ..........
FeLV-4314 .......... A..G.....T .......... .......... .......... .......... ..........
8471
FeLV-A ---------- --AGGGTTCG ACCTTCCGCC TCATTTAAAC TAACCAAT-- --CCCC---- --ACGCCTCT
AY364318 AAAAAAAAAA AA.AAAAAAA .AAAC.A... ........CT GG......AA GA....GTAA CT.T..T...
FeLV-2518 .......... ....A..... .......... .......... .......... .......... ..........
FeLV-4314 .......... ....A..... .......... .......... .......... .......... ..........
8541
FeLV-A CGCTTCTGTG CGCGCGCTTT C--------- -TGCTATAAA ACGAGCCATC AGCCCC-CAA CGGGCGCGCA
AY364318 .........A AC.......C TGCCACTCCA ACC....... .A.TCT.CC. .....AA... GA........
FeLV-2518 .......... .......... .......... .......... .......--- ------.--- ----------
FeLV-4314 .......... .......... .......... .......... .......... ........-- ----------
8611
FeLV-A AGTCTTTGCT GAGACTTGAC CGCCCCGGGT ACCCGTGTAC GAATAAACCT CTTGCTGATT GCATCTGACT
AY364318 .......... .......... .......... .......... .......... .......T.. ..........
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- ----------
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- ----------
8681
FeLV-A CGTGGTCTCG GTGTTCTGTG GGCGCGGGGT CTCATCGCCG AGGAAGACCT AGTTCAGGGG TCTTTCA---
AY364318 .......... ......C... ...A...... .......... .......... ....AG.... .......AGT
FeLV-2518 ---------- ---------- ---------- ---------- ---------- ---------- -------...
FeLV-4314 ---------- ---------- ---------- ---------- ---------- ---------- -------...
(B) Gag-pol polyprotein alignment
1
FeLV-A (Rickard) MSGASSGTAI GAHLFGVSP- --EYRVLIGD EGAGPSKSLS EVSFSVWYRS RAARLVIFCL
enFeLV AY364318 .......... ..R...I.SV LG........ ......R.P. .......... .......L..
FeLV-4314 .....M.... .......... .......... ........P. ........Q. ..........
FeLV-2518 .....M.... .......... .......... ......R... ........Q. ..........
61
FeLV-A (Rickard) VASFLVPCLT FLIAETVMGQ TITTPLSLTL DHWSEVRARA HNQGVEVRKK KWITLCEAEW
enFeLV AY364318 .......... .....A.... .V........ N.....Q... R......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
121
FeLV-A (Rickard) VMMNVGWPRE GTFSLDNISQ VEKKIFAPGP YGHPDQVPYI TTWRSLATDP PSWVRPFLPP
enFeLV AY364318 .......... ...TI..... ..ER...... ......I... .......... .P........
FeLV-4314 .......... ......S... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
181
FeLV-A (Rickard) PK-PPTPLPQ PLSPQPSAPL TSSLYPVLPK SDPPKPPVLP PDPSSPLIDL LTEEPPPYPG
enFeLV AY364318 ..H.R.DP.E .........P I......... P....A.... .N........ ..........
FeLV-4314 .......... .......... .......... PG........ .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
241
FeLV-A (Rickard) GHGP-PPSGP RTPTASPIAS RLRERRENPA EESQALPLRE GPNNRPQYWP FSASDLYNWK
enFeLV AY364318 ....T..... .......... .......... .K........ .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
301
FeLV-A (Rickard) SHNPPFSQDP VALTNLIESI LVTHQPTWDD CQQLLQALLT GEERQRVLLE ARKQVPGEDG
enFeLV AY364318 L......... .......... .......... .......... A......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
361
FeLV-A (Rickard) RPTQLPNVID ETFPLTRPNW DFATPAGREH LRLYRQLLLA GLRGAARRPT NLAQVKQVVQ
enFeLV AY364318 ........V. .A........ .......... .......... .......... ..........
FeLV-4314 .......... .A........ .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... .........P
421
FeLV-A (Rickard) GKEETPAAFL ERLKEAYRMY TPYDPEDPGQ AASVILSFIY QSSPDIRNKL QRLEGLQGFT
208
enFeLV AY364318 .......S.. .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
481
FeLV-A (Rickard) LSDLLKEAEK IYNKRETPEE REERLWQRQE ERDKKRHKEM TKVLATVVAQ NRDKDREESK
enFeLV AY364318 .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
541
FeLV-A (Rickard) LGDQRKIPLG KDQCAYCKEK GHWVRDCPKR PRKKPANSTL LNLGDZESQG QDPPPEPRIT
enFeLV AY364318 .......... .......... .......... ......D... ...E...... ..........
FeLV-4314 .......... .......... .......... .K........ .......... ..........
FeLV-2518 .......... .........R .......... .......... .......... ..........
601
FeLV-A (Rickard) LKIGGQPVTF LVDTGAQHSV LTRPDGPLSD RTALVQGATG SKNYRWTTDR RVQLATGKVT
enFeLV AY364318 ..V....... .......... .......... .S........ .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
661
FeLV-A (Rickard) HSFLYVPECP YPLLGRDLLT KLKAQIHFTG EGANVVGPKG LPLQVLTLQL EEEYRLFEPE
enFeLV AY364318 .......... .......... .......... ........M. .......... ..........
FeLV-4314 .......... .......... .......... ........R. .......... ..........
FeLV-2518 .......... .......... .......... ........R. .......... ..........
721
FeLV-A (Rickard) STQKQEMDIW LKNFPQAWAE TGGMGTAHCQ APVLIQLKAT ATPISIRQYP MPHEAYQGIK
enFeLV AY364318 .EL..G..S. .......... ...I.M.... ..I....... .......... ..........
FeLV-4314 ........T. .......... .....M.... .......... .......... ..........
FeLV-2518 .......... .......... .....M.... ..I....... .......... ..........
781
FeLV-A (Rickard) PHIRRMLDQG ILKPCQSPWN TPLLPVKKPG TEDYRPVQDL REVNKRVEDI HPTVPNPYNL
enFeLV AY364318 .......... .......... .......... .G........ .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
841
FeLV-A (Rickard) LSTLPPSHPW YTVLDLKDAF FCLRLHSESQ LLFAFEWRDP EIGLSGQLTW TRLPQGFKNS
enFeLV AY364318 .......... .......... ......P... .......K.. .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... ......P... .......... .......... ..........
901
FeLV-A (Rickard) PTLFDEALHS DLADFRVRYP ALVLLQYVDD LLLAAATRTE CLEGTKALLE TLGNKGYRAS
enFeLV AY364318 .......... .......... .......... .......K.. .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .A........ .......... .......... .......... .......... ..........
961
FeLV-A (Rickard) AKKAQICLQE VTYLGYSLKD GQRWLTKARK EAILSIPVPK NSRQVREFLG TAGYCRLWIP
enFeLV AY364318 .........K ........E. .......... .......... .P........ ..........
FeLV-4314 .......... .......... .......... .......... .P........ ..........
FeLV-2518 .......... .......... .......... .......... .P........ ..........
1021 FeLV-4314 5’ Recomb. Site
FeLV-A (Rickard) GFAELAAPLY PLTRPGTLFQ WGTEQQLAFE DIKKALLSSP ALGLPDITKP FELFIDENSG
enFeLV AY364318 .......... .......... .......... N......... .......... .......S..
FeLV-4314 .......... .......... .......... N......... .......... .......S..
FeLV-2518 .......... .......... .......... N......... .......... .......S..
1081
FeLV-A (Rickard) FAKGVLVQKL GPWKRPVAYL SKKLDTVASG WPPCLRMVAA IAILVKDAGK LTLGQPLTIL
enFeLV AY364318 .......... .......... .......... .......... .......... ........V.
FeLV-4314 .......... .......... .......... .......... .......... ........V.
FeLV-2518 ......I... .......... .......... .......... .......... ..........
1141
FeLV-A (Rickard) TSHPVEALVR QPPNKWLSNA RMTHYQAMLL DAERVHFGPT VSLNPATLLP LPSGGNHHDC
enFeLV AY364318 .......... .......... .......... .......... .......... ..NE......
FeLV-4314 .......... .......... .......... .......... .......... ..NE......
FeLV-2518 .......... .......... .......... .......... .......... ..........
1201
FeLV-A (Rickard) LQILAETHGT RPDLTDQPLP DADLTWYTDG SSFIRNGERE AGAAVTTESE VIWAAPLPPG
enFeLV AY364318 .......... .......... .......... .........K .......... .....S....
FeLV-4314 .......... .......... .......... .........K .......... .....S....
FeLV-2518 .......... .T........ .......... .........K ..T....... .....S....
209
1261
FeLV-A (Rickard) TSAQRAELIA LTQALKMAEG KKLTVYTDSR YAFATTHVHG EIYRRRGLLT SEGKEIKNKN
enFeLV AY364318 .......... ........K. .......... .....A.... .......... ..........
FeLV-4314 .......... ........K. .......... .....A.... .......... ..........
FeLV-2518 ........V. ........K. .......... .....A.... .......... ..........
1321
FeLV-A (Rickard) EILALLEALF LPKRLSIIHC PGHQKGDSPQ AKGNRLADDT AKKAATETHS SLTVLPTELI
enFeLV AY364318 .......... .......... .......... .......... ........Q. ...I......
FeLV-4314 .......... .......... .......... .......... ........Q. ...I......
FeLV-2518 .......... .......... .......... .......... .......... ..........
1381
FeLV-A (Rickard) EGPKRPPWEY DDSDLDLVQK LEAHYEPKRG TWEYRGKTIM PEKYAKELIS HLHKLTHLSA
enFeLV AY364318 .......... .......... .......... ....Q..... .......... ..........
FeLV-4314 ....K..... N......... .......... ....Q..... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
1441
FeLV-A (Rickard) RKMKTLLERE ETGFYLPNRD LHLRQVTESC RACAQINAGK IKFGPDVRAR GRRPGTHWEV
enFeLV AY364318 .......... .......... .......... .......... .......... .H...I....
FeLV-4314 .......... .......... .......... Q....V.... .......... .H...I....
FeLV-2518 .......... .......K.. .......... .......... .......... ..........
1501
FeLV-A (Rickard) DFTEIKPGMY GYKYLLVFID TFSGWAEAYP AKHETAKVVA KKLLEEIFPR YGIPQVLGSD
enFeLV AY364318 .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
1561
FeLV-A (Rickard) NGPAFISQVS QSVATLLGIN WKLHCAYRPQ SSGQVERMNR SIKETLTKLT LETGSKDWVL
enFeLV AY364318 .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
1621
FeLV-A (Rickard) LLPLVLYRVR NTPGPHGLTP FEILYGAPPP MAHFFDTDIS SFATSPTMQA HLRALQLVQE
enFeLV AY364318 .......... .......... .......... ......A... G......... ..........
FeLV-4314 .......... .......... .......... ......A... G......... ..........
FeLV-2518 .......... .......... .......... ......A... .......... ..........
1681
FeLV-A (Rickard) EIQRPLAAAY REKLETPVVP HPFKPGDSVW VRRHQTKNLE PRWKGPHIVL LTTPTALKVD
enFeLV AY364318 .......... .......... .......... .......... .......... ..........
FeLV-4314 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... Q......... .......... ......R... .......... ..........
1741
FeLV-A (Rickard) GVAAWIHASH VKAAGPTTNQ DLSDSPSSDD PSRWKVQRTQ NPLKIRLSRG TZ
enFeLV AY364318 .......... .......... .P..D..... .......... .......... ..
FeLV-4314 .......... .......... .P..D..... .......... .......... ..
FeLV-2518 .......... .......... .......... .......... ........H. ..
(C) Env protein precursor alignment
FeLV-2518 5’ Recomb. Site Fusion motif
FeLV-A (Rickard) MESPTHPKPS KDKTLSWNLA FLVGILFTID IGMANPSPHQ IYNVTWVITN MQTNTQANAT
FeLV-4314 ..G....... ....F..D.M I...V.LRL. V......... V.....T... LV.G.T....
enFeLV AY364318 ..G....... ....F..D.M I...V.LRL. V......... V.....T... LV.G.K....
FeLV-2518 .......... .......... .......... .......... V.....T... LV.G.K....
FeLV-2518(A) .......... .......... .......... ........P. M......... V.........
61
FeLV-A (Rickard) SMLGTLTDAY PTLHVDLCDL VGDTWEPIVL DPTNVKHGAR YSSSKYGCKT TDRKKQQQTY
FeLV-4314 .........F ..MYF....I IDN..N.SDQ E.F------- ---PG...GQ PM.RW..RNT
enFeLV AY364318 .........F ..MYF....I I.N..N.SDQ E.F------- ---PG...DQ PM.RW..RNT
FeLV-2518 .........F ..MYF....I I.N..N.SDQ E.F------- ---PG...DQ PM.RW..RNT
FeLV-2518(A) .......... .......... .......... N......... ......R... ..........
121
FeLV-A (Rickard) PFYVCPGHAP SLGPKGTHCG GAQDGFCAAW GCETTGEAWW KPSSSWDYIT VKRGSSQDNS
FeLV-4314 .........- ----NRKQ.. .P......V. .......TY. R.T....... ..K.VT.GIY
enFeLV AY364318 .........- ----NRKQ.. .P......V. .......TY. R.T....... ..K.VT.GIY
FeLV-2518 .........- ----NRKQ.. .P......V. .......TY. R.T....... ..K.VT.GIY
FeLV-2518(A) .......... .......... .....Y.... .......... ..T....... ..........
181
210
FeLV-A (Rickard) ---------- C--------- -----EGKCN PLILQFTQKG RQASWDGPKI WGLRLYRTGY
FeLV-4314 QCSGGGWCGP .YDKAVHSSI TGASEG.R.. .......... ..T......S .......S..
enFeLV AY364318 QCSGGGWCGP .YDKAVHSSK TGASEG.R.. .......... ..T......S .......S..
FeLV-2518 QCSGGGWCGP .YDKAVHSSI TGASEG.R.. .......... ..T......S .......S..
FeLV-2518(A) .......... .......... .......R.. ..V....... .......... ..........
241
FeLV-A (Rickard) DPIALFTVSR QVSAITPPQA MGPNLVLPDQ KPPSRQSQTG SKVATQRLQT TESAP-----
FeLV-4314 ......S... ..MT...... .......... ...FG...IE .Q.TPHHS.G NG.T.GITLV
enFeLV AY364318 ......S... ..MT...... .......... ........IE .R.TPHHS.G NGGT.GITLV
FeLV-2518 ......S... ..MT...... .......... ........IE .R.TPHHS.G NGGT.GITLV
FeLV-2518(A) .......... ...T...... .......... .....L...R .......P.. N.........
301
FeLV-A (Rickard) -RSVAP---- -TTVGPKRIG TGDRLINLVQ GTYLALNATD PNKTKDCWLC LVSRPPYYEG
FeLV-4314 NA.I..LSTP V.P.S..... ..N....... .......V.N .......... ..........
enFeLV AY364318 NA.I..LSTP V.PAS..... ..N....... .......V.N .......... ..........
FeLV-2518 NA.I..LSTP V.PAS..... ..N....... .......V.N .......... ..........
FeLV-2518(A) .......... ...I...... .......... XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX
361
FeLV-A (Rickard) IAILGNYSNQ TNPPPSCLST PQHKLTISEV SGQGLCIGTV PKTHQALCNE TQQGHTGAHY
FeLV-4314 ..V....... .........D .......... .......... ........KK ..K..K.T..
enFeLV AY364318 ..V....... .........D .......... .......... ........KK ..K..K.T..
FeLV-2518 ..V....... .........D .......... .......... ........KK ..K..K.T..
FeLV-2518(A) XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX
421 FeLV-2518 3’ Recomb. Site SU/TM Cleavage Site
FeLV-A (Rickard) LAAPNGAYWA CNTGLTPCIS MAVLNWTSDF CVLIELWPRV TYHQPEYVYT HFAKAVRFRR
FeLV-4314 ....S.T... .......... .......... .A........ ...E...I.S ..ENKP..K.
enFeLV AY364318 ....S.T... .......... .......... .......... ...E...I.S ..ENKP..K.
FeLV-2518 ....S.T... .......... .......... .......... .........S ..........
FeLV-2518(A) XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX
481 FeLV-4314 3’ Recomb. Site
FeLV-A (Rickard) EPISLTVALM LGGLTVGGIA AGVGTGTKAL LETAQFRQLQ MAMHTDIQAL EESISALEKS
FeLV-4314 D......... ...I....M. ..I....A.. .......... .......... ..........
enFeLV AY364318 D......... ...I....M. ..I....A.. .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
FeLV-2518(A) XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX
541
FeLV-A (Rickard) LTSLSEVVLQ NRRGLDILFL QEGGLCAALK EE-------C CFYADHTGLV RDNMAKLRER
FeLV-4314 .......... .......... .......... .......... .......... ..........
enFeLV AY364318 .......... .......... .......... .......... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
FeLV-2518(A) XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX
601
FeLV-A (Rickard) LKQRQQLFDS QQGWFEGWFN KSPWFTTLIS SIMGPLLILL LILLFGPCIL NRLVQFVKDR
FeLV-4314 .......... .........K .......... .......... .......WV. ..........
enFeLV AY364318 .......... .......... .......... ......M... .......... ..........
FeLV-2518 .......... .......... .......... .......... .......... ..........
FeLV-2518(A) XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXX... .......--- ----------
661
FeLV-A (Rickard) ISVVQALILT QQYQQIKQYD PDRP----Z
FeLV-4314 .......... .....V.... .........
enFeLV AY364318 .....T.V.. ..H.RLG.C. S.Q.YHPS.
FeLV-2518 .......... .......... ..Q......
FeLV-2518(A) ---------- ---------- ----.....
211
8.5 Predicted secondary structures within FeLV env RNA
FeLV-A env RNA
enFeLV env RNA
212
8.6 Predicted secondary structures within FeLV leader
sequences
FeLV-A Monomeric RNA
enFeLV Monomeric RNA
213
FeLV-A Homodimeric RNA
enFeLV Homodimeric RNA
214
FeLV-A/enFeLV Heterodimeric RNA
215
8.7 Publications arising from this work
Stewart H, Jarrett O, Hosie M, Willett B. (2013). Complete genome sequences of
two feline leukaemia virus subgroup B isolates with novel recombination sites.
Genome Announcements (in press).
Stewart H, Adema K, McMonagle E, Hosie M, Willett B. (2012). Identification of
novel subgroup A variants with enhanced receptor binding and replicative
capacity in primary isolates of anaemogenic strains of feline leukaemia virus.
Retrovirology 9(48).
Stewart H, Jarrett O, Hosie M, Willett B. (2011). Are endogenous feline
leukaemia viruses really endogenous? Journal of Veterinary Immunology and
Immunopathology 143(3-4): 325-331.
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